AU2013200041A1 - Quinazoline derivative and pharmaceutical - Google Patents
Quinazoline derivative and pharmaceutical Download PDFInfo
- Publication number
- AU2013200041A1 AU2013200041A1 AU2013200041A AU2013200041A AU2013200041A1 AU 2013200041 A1 AU2013200041 A1 AU 2013200041A1 AU 2013200041 A AU2013200041 A AU 2013200041A AU 2013200041 A AU2013200041 A AU 2013200041A AU 2013200041 A1 AU2013200041 A1 AU 2013200041A1
- Authority
- AU
- Australia
- Prior art keywords
- amino
- cyclohexyl
- methylquinazolin
- alkoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract description 3
- -1 (4) pyridyl Chemical group 0.000 claims abstract description 77
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 69
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 46
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 40
- 150000002367 halogens Chemical class 0.000 claims abstract description 40
- 239000001257 hydrogen Substances 0.000 claims abstract description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 39
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 15
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 14
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 claims abstract description 10
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 10
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 10
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 10
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 7
- 125000002541 furyl group Chemical group 0.000 claims abstract description 7
- 125000002252 acyl group Chemical group 0.000 claims abstract description 6
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 5
- 150000002431 hydrogen Chemical group 0.000 claims abstract 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 190
- 150000001875 compounds Chemical class 0.000 claims description 132
- AJRDMMJZFJWPIF-RBUKOAKNSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O AJRDMMJZFJWPIF-RBUKOAKNSA-N 0.000 claims description 54
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 43
- 208000003251 Pruritus Diseases 0.000 claims description 28
- 150000003246 quinazolines Chemical class 0.000 claims description 25
- 230000007803 itching Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 16
- ONVWRLNTWBGGDH-MSOLQXFVSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N ONVWRLNTWBGGDH-MSOLQXFVSA-N 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- MVZMTAADYZFHCS-DLBZAZTESA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC MVZMTAADYZFHCS-DLBZAZTESA-N 0.000 claims description 11
- 230000001823 pruritic effect Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000035807 sensation Effects 0.000 claims description 8
- XNERLJAUCHUJFC-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-3-hydroxypropylidene)amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCO XNERLJAUCHUJFC-MOPGFXCFSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- XNOHVHGZLUWVRP-RBUKOAKNSA-N 4-[[(1s,2r)-2-[[amino-(2-methoxyethoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOCCOC XNOHVHGZLUWVRP-RBUKOAKNSA-N 0.000 claims description 4
- IMASAGFSDVNVTF-RBUKOAKNSA-N 4-[[(1s,2r)-2-[[amino-(2-methylsulfanylethoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOCCSC IMASAGFSDVNVTF-RBUKOAKNSA-N 0.000 claims description 4
- IKEUEUVGMCIDLT-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(cyclopropylmethyl)-6-methylquinazoline-2-carboxamide Chemical compound CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC2CC2)=NC2=CC=C(C)C=C12 IKEUEUVGMCIDLT-ZWKOTPCHSA-N 0.000 claims description 4
- FDWPNGKKCCUORT-MSOLQXFVSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N FDWPNGKKCCUORT-MSOLQXFVSA-N 0.000 claims description 3
- VMOILWJSRHMSCV-MOPGFXCFSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N VMOILWJSRHMSCV-MOPGFXCFSA-N 0.000 claims description 3
- ZTUGSGLJTCGWBU-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O ZTUGSGLJTCGWBU-ZWKOTPCHSA-N 0.000 claims description 3
- PVPMAIFREWEKMZ-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC PVPMAIFREWEKMZ-MOPGFXCFSA-N 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- QZEFDHBWKDLPSS-MOPGFXCFSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N QZEFDHBWKDLPSS-MOPGFXCFSA-N 0.000 claims description 2
- YYVMQGWWFMUPJS-RBUKOAKNSA-N 4-[[(1s,2r)-2-[[amino-[methoxy(methyl)amino]methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide Chemical compound CON(C)C(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(C)C=C12 YYVMQGWWFMUPJS-RBUKOAKNSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WQITVLTUWQDZDS-DLBZAZTESA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide Chemical compound CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC(C)C)=NC2=CC=C(C)C=C12 WQITVLTUWQDZDS-DLBZAZTESA-N 0.000 claims 7
- PEDKXQZEUPJPEY-UHFFFAOYSA-N 4-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound COCCC1=NC(=NC2=CC=C(C=C12)C)C(=O)N PEDKXQZEUPJPEY-UHFFFAOYSA-N 0.000 claims 1
- IVDXNIGOBFWKOD-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O IVDXNIGOBFWKOD-ZWKOTPCHSA-N 0.000 claims 1
- DINYHKVWXKITFP-VQTJNVASSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxy-2-methylpropylidene)amino]cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide Chemical compound COC(C)(C)C(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(C)C=C12 DINYHKVWXKITFP-VQTJNVASSA-N 0.000 claims 1
- IGETWQZNQCTPSM-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[[amino-(2-fluoroethoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOCCF IGETWQZNQCTPSM-ZWKOTPCHSA-N 0.000 claims 1
- OJIYGUADAIIEEY-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide Chemical compound CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(C)C=C12 OJIYGUADAIIEEY-ZWKOTPCHSA-N 0.000 claims 1
- YCHUMXMABNULNA-ZWKOTPCHSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC YCHUMXMABNULNA-ZWKOTPCHSA-N 0.000 claims 1
- GVZKUKVYVOCGBF-UHFFFAOYSA-N 6-methyl-N-(2-methylpropyl)quinazoline-2-carboxamide Chemical compound CC(C)CNC(=O)c1ncc2cc(C)ccc2n1 GVZKUKVYVOCGBF-UHFFFAOYSA-N 0.000 claims 1
- QABQWHMWIRFBHZ-UHFFFAOYSA-N C1=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=C21 Chemical compound C1=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=C21 QABQWHMWIRFBHZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- ADADZIWWDWCTBN-UHFFFAOYSA-N n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C1=C(C)C=CC2=NC(C(=O)NCCOC)=NC=C21 ADADZIWWDWCTBN-UHFFFAOYSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 762
- 239000000843 powder Substances 0.000 description 270
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 251
- 150000002500 ions Chemical class 0.000 description 251
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 202
- 238000000921 elemental analysis Methods 0.000 description 198
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 196
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 196
- HIWYISFGWGBTRB-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-3-hydroxypropylidene)amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCO HIWYISFGWGBTRB-MOPGFXCFSA-N 0.000 description 133
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 73
- 239000000203 mixture Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 21
- 230000006399 behavior Effects 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 125000001841 imino group Chemical group [H]N=* 0.000 description 19
- 239000002674 ointment Substances 0.000 description 19
- 238000006748 scratching Methods 0.000 description 18
- 230000002393 scratching effect Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 231100000321 erythema Toxicity 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000008313 sensitization Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 8
- ZEDYICSCPWYWEJ-UXHICEINSA-N 4-[[(1s,2r)-2-[(1-amino-3-methoxypropylidene)amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCOC ZEDYICSCPWYWEJ-UXHICEINSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 231100000475 skin irritation Toxicity 0.000 description 8
- 230000036556 skin irritation Effects 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 235000019615 sensations Nutrition 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- BJQLFRMZQZLUTA-MSOLQXFVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC BJQLFRMZQZLUTA-MSOLQXFVSA-N 0.000 description 3
- DTYSWQGCASSOJL-ZBFHGGJFSA-N 4-[[(1s,2r)-2-aminocyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1N DTYSWQGCASSOJL-ZBFHGGJFSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010048218 Xeroderma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000005456 alcohol based solvent Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000004210 ether based solvent Substances 0.000 description 3
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OWSYOPDVEDWREK-SJORKVTESA-N 4-[[(1s,2r)-2-(cyanoamino)cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC#N OWSYOPDVEDWREK-SJORKVTESA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010067969 Cholestatic liver injury Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010070835 Skin sensitisation Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 231100000370 skin sensitisation Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- IYYYFAYKYBUCQH-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)-2H-quinazoline-2-carboxamide dihydrochloride Chemical compound Cl.Cl.FC(CN1C(N=CC2=CC=CC=C12)C(=O)N)(F)F IYYYFAYKYBUCQH-UHFFFAOYSA-N 0.000 description 1
- ZLSYOZHUUKPDLC-UHFFFAOYSA-N 1-(2-methylsulfanylethyl)-2H-quinazoline-2-carboxamide dihydrochloride Chemical compound Cl.Cl.CSCCN1C(N=CC2=CC=CC=C12)C(=O)N ZLSYOZHUUKPDLC-UHFFFAOYSA-N 0.000 description 1
- MSFGOHZHPUWLSK-UHFFFAOYSA-N 1-(3-methylsulfanylpropyl)-2H-quinazoline-2-carboxamide dihydrochloride Chemical compound Cl.Cl.CSCCCN1C(N=CC2=CC=CC=C12)C(=O)N MSFGOHZHPUWLSK-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- JGSIAOZAXBWRFO-UHFFFAOYSA-N 3-methylsulfanyl-1-phenyl-4,5-dihydrobenzo[g]indazole Chemical compound C1CC2=CC=CC=C2C2=C1C(SC)=NN2C1=CC=CC=C1 JGSIAOZAXBWRFO-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- UXMXNWRQLJYYMB-BLXKPJDKSA-N 4-[[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-N-(2-piperidin-1-ylethyl)quinazoline-2-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NCCN1CCCCC1)C1=NCCC1 UXMXNWRQLJYYMB-BLXKPJDKSA-N 0.000 description 1
- CRNXDWBRPDCPRD-ZFIUDZBFSA-N 4-[[(1S,2R)-2-[(1-amino-2-pyridin-2-ylethylidene)amino]cyclohexyl]amino]-6-chloro-N-cycloheptylquinazoline-2-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)Cl)C(=O)NC1CCCCCC1)C(=N)CC1=CC=CC=N1 CRNXDWBRPDCPRD-ZFIUDZBFSA-N 0.000 description 1
- FKTJQKRJVZTXNC-ZWKKEICBSA-N 4-[[(1S,2R)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-N-(1-methoxy-2-methylpropan-2-yl)-6-methylquinazoline-2-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NC(C)(C)COC)C(=N)C1=CC=CC=N1 FKTJQKRJVZTXNC-ZWKKEICBSA-N 0.000 description 1
- HUTXMLMIQIXOKW-ACBJRQQWSA-N 4-[[(1S,2R)-2-[[amino-[2-(dimethylamino)phenyl]methylidene]amino]cyclohexyl]amino]-N-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide trihydrochloride Chemical compound Cl.Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2C(=CC=CC=2)N(C)C)=C(C=C(C)C=C2)C2=N1 HUTXMLMIQIXOKW-ACBJRQQWSA-N 0.000 description 1
- MVZMTAADYZFHCS-SJORKVTESA-N 4-[[(1r,2s)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@@H]1CCCC[C@@H]1N=C(N)NOC MVZMTAADYZFHCS-SJORKVTESA-N 0.000 description 1
- UZYZKJJHJBVVKA-AAYDIPMQSA-N 4-[[(1s,2r)-2-(1-aminobutylideneamino)cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CCCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCCCOC)=NC2=CC=C(C)C=C12 UZYZKJJHJBVVKA-AAYDIPMQSA-N 0.000 description 1
- CKAJEIAREXZRFQ-KMDCRFISSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCCCCC2)=NC2=CC=C(Cl)C=C12 CKAJEIAREXZRFQ-KMDCRFISSA-N 0.000 description 1
- KYNRUZORXVMFKY-WCRQIBMVSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-fluoroquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(F)C=C12 KYNRUZORXVMFKY-WCRQIBMVSA-N 0.000 description 1
- BOJSPTMWYDIKNS-MOPGFXCFSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide Chemical compound CC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(C)C=C12 BOJSPTMWYDIKNS-MOPGFXCFSA-N 0.000 description 1
- DSELYGAJWDQKFJ-WCRQIBMVSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N DSELYGAJWDQKFJ-WCRQIBMVSA-N 0.000 description 1
- BXICSUJUZMOJQF-QNCHGCKQSA-N 4-[[(1s,2r)-2-(1-aminoethylideneamino)cyclohexyl]amino]-n-butyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCCC)=NC=1N[C@H]1CCCC[C@H]1NC(C)=N BXICSUJUZMOJQF-QNCHGCKQSA-N 0.000 description 1
- QSLCBVNMGIESFH-FJEGXLQFSA-N 4-[[(1s,2r)-2-(1-anilinoethylideneamino)cyclohexyl]amino]-n-butyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C(C)=NC1=CC=CC=C1 QSLCBVNMGIESFH-FJEGXLQFSA-N 0.000 description 1
- BRDZZXVZLMPEPK-QNCHGCKQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-fluoro-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(F)=CC2=1)C(=O)NCC(C)C)C1=NCCC1 BRDZZXVZLMPEPK-QNCHGCKQSA-N 0.000 description 1
- QDNPLZDGMVOJTJ-AAYDIPMQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-fluoro-n-(3-methoxy-2,2-dimethylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(F)=CC2=1)C(=O)NCC(C)(C)COC)C1=NCCC1 QDNPLZDGMVOJTJ-AAYDIPMQSA-N 0.000 description 1
- MVTFTLJMUHQYOA-IQSNUXHRSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-n-(2-methylbutyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)CC)C1=NCCC1 MVTFTLJMUHQYOA-IQSNUXHRSA-N 0.000 description 1
- LZQRVKLBKJAIDA-AAYDIPMQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)C)C1=NCCC1 LZQRVKLBKJAIDA-AAYDIPMQSA-N 0.000 description 1
- XNISUYFGHLKDJL-QNCHGCKQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-n-(2-methylsulfanylethyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCSC)C1=NCCC1 XNISUYFGHLKDJL-QNCHGCKQSA-N 0.000 description 1
- JHOODNITKRNXDD-QNCHGCKQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-n-[(2-methylpropan-2-yl)oxy]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NOC(C)(C)C)C1=NCCC1 JHOODNITKRNXDD-QNCHGCKQSA-N 0.000 description 1
- BKPCIRTXSYJNTM-QNCHGCKQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NC(C)C)C1=NCCC1 BKPCIRTXSYJNTM-QNCHGCKQSA-N 0.000 description 1
- DUOLIINFPBUENB-AAYDIPMQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(1-methoxy-2-methylpropan-2-yl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NC(C)(C)COC)C1=NCCC1 DUOLIINFPBUENB-AAYDIPMQSA-N 0.000 description 1
- JQZQSRBKNNZLDM-ZZYOSWMOSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(2-ethylbutyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(CC)CC)C1=NCCC1 JQZQSRBKNNZLDM-ZZYOSWMOSA-N 0.000 description 1
- DUGDZKUQUZOWDI-QNCHGCKQSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCOC)C1=NCCC1 DUGDZKUQUZOWDI-QNCHGCKQSA-N 0.000 description 1
- LUALGZAJTYAVSH-UXHICEINSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCOC)C1=NCCC1 LUALGZAJTYAVSH-UXHICEINSA-N 0.000 description 1
- JFFSCQLKXYLBHY-PKTZIBPZSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC=2CCCN=2)=C(C=C(C)C=C2)C2=N1 JFFSCQLKXYLBHY-PKTZIBPZSA-N 0.000 description 1
- HHETXIPAJBYUQG-KMDCRFISSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-(furan-2-ylmethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NCC=1OC=CC=1)C1=NCCC1 HHETXIPAJBYUQG-KMDCRFISSA-N 0.000 description 1
- KSERKCHFQMTOAO-LVUUPCAFSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-[(1r,2r)-2-methoxycyclohexyl]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CO[C@@H]1CCCC[C@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC=2CCCN=2)=C(C=C(C)C=C2)C2=N1 KSERKCHFQMTOAO-LVUUPCAFSA-N 0.000 description 1
- SGUJQPTZVQGPHL-NREMKMRBSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-[1-(methoxymethyl)cyclohexyl]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N=1C(N[C@@H]2[C@@H](CCCC2)NC=2CCCN=2)=C2C=C(C)C=CC2=NC=1C(=O)NC1(COC)CCCCC1 SGUJQPTZVQGPHL-NREMKMRBSA-N 0.000 description 1
- LKCQUZVYUWEKLD-WCRQIBMVSA-N 4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-ethyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC)C1=NCCC1 LKCQUZVYUWEKLD-WCRQIBMVSA-N 0.000 description 1
- WVDJOMBYSDOOKX-WCJQCITJSA-N 4-[[(1s,2r)-2-(3h-isoindol-1-ylamino)cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C(C)C=CC2=NC(C(=O)NCC(C)C)=NC(N[C@@H]3[C@@H](CCCC3)NC=3C4=CC=CC=C4CN=3)=C21 WVDJOMBYSDOOKX-WCJQCITJSA-N 0.000 description 1
- WJBKZTFUBBTRAN-SLAHTUFOSA-N 4-[[(1s,2r)-2-(diaminomethylideneamino)cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(N)=N WJBKZTFUBBTRAN-SLAHTUFOSA-N 0.000 description 1
- OMXAYWRBURRLOE-UXHRTOHASA-N 4-[[(1s,2r)-2-(diaminomethylideneamino)cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=N OMXAYWRBURRLOE-UXHRTOHASA-N 0.000 description 1
- IBHAXTLGSYRDKS-UXHRTOHASA-N 4-[[(1s,2r)-2-(diaminomethylideneamino)cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=N IBHAXTLGSYRDKS-UXHRTOHASA-N 0.000 description 1
- FIGVYTMESSGLQS-DPSPSOFVSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O FIGVYTMESSGLQS-DPSPSOFVSA-N 0.000 description 1
- BILMXTUNHXUAFT-OAMYOWMRSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O BILMXTUNHXUAFT-OAMYOWMRSA-N 0.000 description 1
- DXZNTDPBLLPIHL-OAMYOWMRSA-N 4-[[(1s,2r)-2-[(1-amino-2-hydroxy-2-methylpropylidene)amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)O DXZNTDPBLLPIHL-OAMYOWMRSA-N 0.000 description 1
- ZIXAKIFHSHHGLC-DPSPSOFVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxy-2-methylpropylidene)amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)(C)OC ZIXAKIFHSHHGLC-DPSPSOFVSA-N 0.000 description 1
- YIXRSDXUDALLDO-KMDCRFISSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCCCCC2)=NC2=CC=C(Cl)C=C12 YIXRSDXUDALLDO-KMDCRFISSA-N 0.000 description 1
- KZEKFDYZZYKDCT-AMTWEWDESA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-chloro-n-methoxyquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NOC)=NC2=CC=C(Cl)C=C12 KZEKFDYZZYKDCT-AMTWEWDESA-N 0.000 description 1
- CYGJMOCVAFBKHO-BQFBZIMZSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-chloroquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(N)=O)=NC2=CC=C(Cl)C=C12 CYGJMOCVAFBKHO-BQFBZIMZSA-N 0.000 description 1
- WRTQNDUJXZJFIN-WCRQIBMVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-fluoro-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(F)C=C12 WRTQNDUJXZJFIN-WCRQIBMVSA-N 0.000 description 1
- LFKNDZGGDAXNAM-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-fluoro-n-(3-methoxy-2,2-dimethylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)COC)=NC2=CC=C(F)C=C12 LFKNDZGGDAXNAM-QNCHGCKQSA-N 0.000 description 1
- VGSNIHOKMVYESC-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-methoxy-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(OC)C=C12 VGSNIHOKMVYESC-QNCHGCKQSA-N 0.000 description 1
- CBMAEVDAMAJDBQ-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-methyl-n-(2-methylbutan-2-yl)quinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NC(C)(C)CC)=NC=1N[C@H]1CCCC[C@H]1N=C(N)COC CBMAEVDAMAJDBQ-MOPGFXCFSA-N 0.000 description 1
- RWQJWCFWBXXWLP-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(C)C=C12 RWQJWCFWBXXWLP-QNCHGCKQSA-N 0.000 description 1
- RDKWKZYNDZAKHJ-RTWAWAEBSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-methyl-n-(3-propan-2-yloxypropyl)quinazoline-2-carboxamide Chemical compound COCC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCCCOC(C)C)=NC2=CC=C(C)C=C12 RDKWKZYNDZAKHJ-RTWAWAEBSA-N 0.000 description 1
- HEEOICDNNFRHKJ-WCRQIBMVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC(C)C)=NC2=CC=C(C)C=C12 HEEOICDNNFRHKJ-WCRQIBMVSA-N 0.000 description 1
- KRXKYCYJZLWHOL-MSOLQXFVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-fluoroquinazoline-2-carboxamide Chemical compound COCC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(F)C=C12 KRXKYCYJZLWHOL-MSOLQXFVSA-N 0.000 description 1
- RMOHREQZGFDLEO-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide Chemical compound COCC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(C)C=C12 RMOHREQZGFDLEO-MOPGFXCFSA-N 0.000 description 1
- PZZRFJPWSVXLTM-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC PZZRFJPWSVXLTM-QNCHGCKQSA-N 0.000 description 1
- HOPSGWIILXBWIN-AAYDIPMQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2-ethylbutyl)-6-fluoroquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(F)C=CC2=NC(C(=O)NCC(CC)CC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC HOPSGWIILXBWIN-AAYDIPMQSA-N 0.000 description 1
- FLTAFODKFRZXBA-KMDCRFISSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(2-ethylbutyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCC(CC)CC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC FLTAFODKFRZXBA-KMDCRFISSA-N 0.000 description 1
- LVCZJRXALTYSPB-AAYDIPMQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)COC)=NC2=CC=C(C)C=C12 LVCZJRXALTYSPB-AAYDIPMQSA-N 0.000 description 1
- DBZBPDLQZPQJQU-MOPGFXCFSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC DBZBPDLQZPQJQU-MOPGFXCFSA-N 0.000 description 1
- IJYARMMQYLBNBE-WCRQIBMVSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-butyl-6-chloroquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(Cl)C=CC2=NC(C(=O)NCCCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)COC IJYARMMQYLBNBE-WCRQIBMVSA-N 0.000 description 1
- WHYZQSRTOZKFJY-AAYDIPMQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-cyclopentyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCCC2)=NC2=CC=C(C)C=C12 WHYZQSRTOZKFJY-AAYDIPMQSA-N 0.000 description 1
- REOWJUKODINJJZ-AFMFUHLNSA-N 4-[[(1s,2r)-2-[(1-amino-2-methoxyethylidene)amino]cyclohexyl]amino]-n-methoxy-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NOC)=NC2=CC=C(C)C=C12 REOWJUKODINJJZ-AFMFUHLNSA-N 0.000 description 1
- XBMXOJXMOQTYIA-AAYDIPMQSA-N 4-[[(1s,2r)-2-[(1-amino-2-methylpropylidene)amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)C(C)C XBMXOJXMOQTYIA-AAYDIPMQSA-N 0.000 description 1
- CMUMEIXMHAOMSC-IBUTWNQASA-N 4-[[(1s,2r)-2-[(1-amino-2-phenylethylidene)amino]cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)CC=2C=CC=CC=2)=C(C=C(C)C=C2)C2=N1 CMUMEIXMHAOMSC-IBUTWNQASA-N 0.000 description 1
- QSRJVYIHTIQZPH-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-3-hydroxypropylidene)amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCO QSRJVYIHTIQZPH-QNCHGCKQSA-N 0.000 description 1
- RZFSCTUVHCVIFM-YADHBBJMSA-N 4-[[(1s,2r)-2-[(1-amino-3-methoxypropylidene)amino]cyclohexyl]amino]-n-(2-ethylbutyl)-6-methylquinazoline-2-carboxamide Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCC(CC)CC)=NC=1N[C@H]1CCCC[C@H]1N=C(N)CCOC RZFSCTUVHCVIFM-YADHBBJMSA-N 0.000 description 1
- DWNXVFFWMVFAER-QNCHGCKQSA-N 4-[[(1s,2r)-2-[(1-amino-3-methoxypropylidene)amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCOC DWNXVFFWMVFAER-QNCHGCKQSA-N 0.000 description 1
- SBNHORBGWBMEMU-KMDCRFISSA-N 4-[[(1s,2r)-2-[(1-amino-3-methoxypropylidene)amino]cyclohexyl]amino]-n-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.COCCC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)COC)=NC2=CC=C(C)C=C12 SBNHORBGWBMEMU-KMDCRFISSA-N 0.000 description 1
- SPGBHKRIYHEPRT-WCRQIBMVSA-N 4-[[(1s,2r)-2-[(1-amino-3-methoxypropylidene)amino]cyclohexyl]amino]-n-ethyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCC)=NC=1N[C@H]1CCCC[C@H]1NC(=N)CCOC SPGBHKRIYHEPRT-WCRQIBMVSA-N 0.000 description 1
- UMNWSKVHXMYRDW-AAYDIPMQSA-N 4-[[(1s,2r)-2-[(c,n-dimethylcarbonimidoyl)amino]cyclohexyl]amino]-n-(2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CN=C(C)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)(C)C)=NC2=CC=C(C)C=C12 UMNWSKVHXMYRDW-AAYDIPMQSA-N 0.000 description 1
- LKSPNZBHMXCTKR-WCJQCITJSA-N 4-[[(1s,2r)-2-[[1-amino-2-(furan-2-yl)ethylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)Cl)C(=O)NC1CCCCCC1)C(=N)CC1=CC=CO1 LKSPNZBHMXCTKR-WCJQCITJSA-N 0.000 description 1
- MTCNWPJPUUQQJD-FCHUYYIVSA-N 4-[[(1s,2r)-2-[[amino(1,2-oxazolidin-2-yl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide Chemical compound N([C@H]1CCCC[C@H]1N=C(N)N1OCCC1)C(C1=CC(Cl)=CC=C1N=1)=NC=1C(=O)NC1CCCCCC1 MTCNWPJPUUQQJD-FCHUYYIVSA-N 0.000 description 1
- LJNMGOZGKSJFSE-VQTJNVASSA-N 4-[[(1s,2r)-2-[[amino(1,2-oxazolidin-2-yl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide Chemical compound N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)C)=C(N)N1CCCO1 LJNMGOZGKSJFSE-VQTJNVASSA-N 0.000 description 1
- NVOZPQHJEOIGDE-HUQPAIQZSA-N 4-[[(1s,2r)-2-[[amino(1,2-oxazolidin-2-yl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(3-methylsulfanylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCSC)C(=N)N1CCCO1 NVOZPQHJEOIGDE-HUQPAIQZSA-N 0.000 description 1
- PSCBAAUOZBPALA-DDZPGPNZSA-N 4-[[(1s,2r)-2-[[amino(1,2-oxazolidin-2-yl)methylidene]amino]cyclohexyl]amino]-n-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)(C)COC)C(=N)N1CCCO1 PSCBAAUOZBPALA-DDZPGPNZSA-N 0.000 description 1
- CHGMRKALOHEFNF-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(cyclohexyl)methylidene]amino]cyclohexyl]amino]-n-butyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C(=N)C1CCCCC1 CHGMRKALOHEFNF-NREMKMRBSA-N 0.000 description 1
- XCSLADMFIDVILJ-QNCHGCKQSA-N 4-[[(1s,2r)-2-[[amino(furan-2-yl)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCOC)C(=N)C1=CC=CO1 XCSLADMFIDVILJ-QNCHGCKQSA-N 0.000 description 1
- NTNDKDLWGMUKPY-UXHICEINSA-N 4-[[(1s,2r)-2-[[amino(furan-2-yl)methylidene]amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide Chemical compound N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCOC)=C(N)C1=CC=CO1 NTNDKDLWGMUKPY-UXHICEINSA-N 0.000 description 1
- NYJCDGPKJWXHLY-PKTZIBPZSA-N 4-[[(1s,2r)-2-[[amino(furan-2-yl)methylidene]amino]cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)N=C(N)C=2OC=CC=2)=C(C=C(C)C=C2)C2=N1 NYJCDGPKJWXHLY-PKTZIBPZSA-N 0.000 description 1
- XXCMCEBTILPHIL-AAYDIPMQSA-N 4-[[(1s,2r)-2-[[amino(furan-2-yl)methylidene]amino]cyclohexyl]amino]-n-(cyclopropylmethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NCC1CC1)C(=N)C1=CC=CO1 XXCMCEBTILPHIL-AAYDIPMQSA-N 0.000 description 1
- CMOIOEWAPMHWNG-WCRQIBMVSA-N 4-[[(1s,2r)-2-[[amino(furan-2-yl)methylidene]amino]cyclohexyl]amino]-n-ethyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC)C(=N)C1=CC=CO1 CMOIOEWAPMHWNG-WCRQIBMVSA-N 0.000 description 1
- PVRNCWFIIUYGKJ-XZOQPEGZSA-N 4-[[(1s,2r)-2-[[amino(oxazinan-2-yl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide Chemical compound N([C@H]1CCCC[C@H]1N=C(N)N1OCCCC1)C(C1=CC(Cl)=CC=C1N=1)=NC=1C(=O)NC1CCCCCC1 PVRNCWFIIUYGKJ-XZOQPEGZSA-N 0.000 description 1
- SPMCKETZNBNOHS-DDZPGPNZSA-N 4-[[(1s,2r)-2-[[amino(oxazinan-2-yl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)C)C(=N)N1CCCCO1 SPMCKETZNBNOHS-DDZPGPNZSA-N 0.000 description 1
- KZPUFAPEVHFYKR-MOTLJVIHSA-N 4-[[(1s,2r)-2-[[amino(oxazinan-2-yl)methylidene]amino]cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)N2OCCCC2)=C(C=C(C)C=C2)C2=N1 KZPUFAPEVHFYKR-MOTLJVIHSA-N 0.000 description 1
- ISYOZZAXYVPRJM-BJKOFHAPSA-N 4-[[(1s,2r)-2-[[amino(oxazinan-2-yl)methylidene]amino]cyclohexyl]amino]-n-cycloheptyl-6-methylquinazoline-2-carboxamide Chemical compound N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NC1CCCCCC1)=C(N)N1CCCCO1 ISYOZZAXYVPRJM-BJKOFHAPSA-N 0.000 description 1
- GQTYYPJPJQGHBC-FJEGXLQFSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-[(3-fluorophenyl)methyl]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.FC1=CC=CC(CNC(=O)C=2N=C3C=CC(Cl)=CC3=C(N[C@@H]3[C@@H](CCCC3)NC(=N)C=3C=CC=CC=3)N=2)=C1 GQTYYPJPJQGHBC-FJEGXLQFSA-N 0.000 description 1
- FDNGIGGUOVCJFX-FJEGXLQFSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)Cl)C(=O)NC1CCCCCC1)C(=N)C1=CC=CC=C1 FDNGIGGUOVCJFX-FJEGXLQFSA-N 0.000 description 1
- RIKDWEXPVWLUGT-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)C)C(=N)C1=CC=CC=C1 RIKDWEXPVWLUGT-NREMKMRBSA-N 0.000 description 1
- BPVRYSCGYVCMRU-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCOC)C(=N)C1=CC=CC=C1 BPVRYSCGYVCMRU-NREMKMRBSA-N 0.000 description 1
- IHHGJWNXCFFUOZ-JQJBDSOESA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2C=CC=CC=2)=C(C=C(C)C=C2)C2=N1 IHHGJWNXCFFUOZ-JQJBDSOESA-N 0.000 description 1
- SDOCPHXMMIPTQN-ZZYOSWMOSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-butyl-6-chloroquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(Cl)=CC2=1)C(=O)NCCCC)C(=N)C1=CC=CC=C1 SDOCPHXMMIPTQN-ZZYOSWMOSA-N 0.000 description 1
- HVOVWZUMNNXJTA-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-butyl-6-methoxyquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(OC)=CC2=1)C(=O)NCCCC)C(=N)C1=CC=CC=C1 HVOVWZUMNNXJTA-NREMKMRBSA-N 0.000 description 1
- FTVOLJRLSPASTG-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-butyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C(=N)C1=CC=CC=C1 FTVOLJRLSPASTG-NREMKMRBSA-N 0.000 description 1
- JKRZZVKZIQLAAR-JQJBDSOESA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-cycloheptyl-6-methoxyquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)OC)C(=O)NC1CCCCCC1)C(=N)C1=CC=CC=C1 JKRZZVKZIQLAAR-JQJBDSOESA-N 0.000 description 1
- APOWOIRQSDEQRN-JQJBDSOESA-N 4-[[(1s,2r)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-cycloheptyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NC1CCCCCC1)C(=N)C1=CC=CC=C1 APOWOIRQSDEQRN-JQJBDSOESA-N 0.000 description 1
- IXBWHHXAFRIBHM-NREMKMRBSA-N 4-[[(1s,2r)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)Cl)C(=O)NC1CCCCCC1)C(=N)C1=CC=CC=N1 IXBWHHXAFRIBHM-NREMKMRBSA-N 0.000 description 1
- VWNHXCPXNCLLLX-AAYDIPMQSA-N 4-[[(1s,2r)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NC(C)C)C(=N)C1=CC=CC=N1 VWNHXCPXNCLLLX-AAYDIPMQSA-N 0.000 description 1
- BTJZVBGZLCUPJL-ZZYOSWMOSA-N 4-[[(1s,2r)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-n-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)(C)COC)C(=N)C1=CC=CC=N1 BTJZVBGZLCUPJL-ZZYOSWMOSA-N 0.000 description 1
- ZJHISMIDFRFVBG-KMDCRFISSA-N 4-[[(1s,2r)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-n-butyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C(=N)C1=CC=CC=N1 ZJHISMIDFRFVBG-KMDCRFISSA-N 0.000 description 1
- DBGBMLBVEFTRJS-QNCHGCKQSA-N 4-[[(1s,2r)-2-[[amino(pyridin-2-yl)methylidene]amino]cyclohexyl]amino]-n-ethyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC)C(=N)C1=CC=CC=N1 DBGBMLBVEFTRJS-QNCHGCKQSA-N 0.000 description 1
- BNVAXNTUMYAGNN-DPSPSOFVSA-N 4-[[(1s,2r)-2-[[amino-(2-methoxyethoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOCCOC BNVAXNTUMYAGNN-DPSPSOFVSA-N 0.000 description 1
- UAINDNDWGOYENR-FJEGXLQFSA-N 4-[[(1s,2r)-2-[[amino-(3-fluorophenyl)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.FC1=CC=CC(C(=N)N[C@H]2[C@H](CCCC2)NC=2C3=CC(Cl)=CC=C3N=C(N=2)C(=O)NC2CCCCCC2)=C1 UAINDNDWGOYENR-FJEGXLQFSA-N 0.000 description 1
- ABQTVSABBALMFF-WCJQCITJSA-N 4-[[(1s,2r)-2-[[amino-(4-methoxyphenyl)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C(=N)N[C@H]1[C@@H](NC=2C3=CC(C)=CC=C3N=C(N=2)C(=O)NCC(C)C)CCCC1 ABQTVSABBALMFF-WCJQCITJSA-N 0.000 description 1
- FHIPJDXWAJPMGB-OAMYOWMRSA-N 4-[[(1s,2r)-2-[[amino-(ethoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CCON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCCOC)=NC2=CC=C(C)C=C12 FHIPJDXWAJPMGB-OAMYOWMRSA-N 0.000 description 1
- QHKNVTBBVKBFBH-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(hydroxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCC(C)C)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NO QHKNVTBBVKBFBH-UXHRTOHASA-N 0.000 description 1
- COYNEDMBUFCOQW-HUQPAIQZSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-chloro-n-cycloheptylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCCCCC2)=NC2=CC=C(Cl)C=C12 COYNEDMBUFCOQW-HUQPAIQZSA-N 0.000 description 1
- OUEPSACCFKRUCB-FZMMWMHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2,2,2-trifluoroethyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(F)(F)F)=NC2=CC=C(C)C=C12 OUEPSACCFKRUCB-FZMMWMHASA-N 0.000 description 1
- HJGHODGDOAXJCN-OAMYOWMRSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-(2-methylpropyl)quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCC(C)C)=NC2=CC=C(C)C=C12 HJGHODGDOAXJCN-OAMYOWMRSA-N 0.000 description 1
- UFHIZKQOOWKATQ-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-propan-2-ylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC(C)C)=NC2=CC=C(C)C=C12 UFHIZKQOOWKATQ-UXHRTOHASA-N 0.000 description 1
- ZMMDWYARFCTZJN-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methyl-n-propylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC ZMMDWYARFCTZJN-UXHRTOHASA-N 0.000 description 1
- RJHKJVRDPLWEPE-WICJZZOFSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(N)=O)=NC2=CC=C(C)C=C12 RJHKJVRDPLWEPE-WICJZZOFSA-N 0.000 description 1
- BQIKTUHBTOMFOW-OAMYOWMRSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-ethoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOCC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC BQIKTUHBTOMFOW-OAMYOWMRSA-N 0.000 description 1
- FSHWDDZTEAFZEW-JKSUJKDBSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-hydroxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound CONC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCCO)=NC2=CC=C(C)C=C12 FSHWDDZTEAFZEW-JKSUJKDBSA-N 0.000 description 1
- DKAVFDPKDUHABU-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC DKAVFDPKDUHABU-UXHRTOHASA-N 0.000 description 1
- XHFKRUJNPHQRRN-OAMYOWMRSA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-cyclobutyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCC2)=NC2=CC=C(C)C=C12 XHFKRUJNPHQRRN-OAMYOWMRSA-N 0.000 description 1
- VSOSKOGRSCMSBR-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-cyclopropyl-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.CON=C(N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CC2)=NC2=CC=C(C)C=C12 VSOSKOGRSCMSBR-UXHRTOHASA-N 0.000 description 1
- MHKUPWWMUDWQAT-UXHRTOHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-ethyl-n,6-dimethylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)N(C)CC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC MHKUPWWMUDWQAT-UXHRTOHASA-N 0.000 description 1
- ORJBVHOXXQALID-FZMMWMHASA-N 4-[[(1s,2r)-2-[[amino-(methoxyamino)methylidene]amino]cyclohexyl]amino]-n-methoxy-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C=12C=C(C)C=CC2=NC(C(=O)NOC)=NC=1N[C@H]1CCCC[C@H]1NC(N)=NOC ORJBVHOXXQALID-FZMMWMHASA-N 0.000 description 1
- GWTGQZNFNLTSDN-RBUKOAKNSA-N 4-[[(1s,2r)-2-[[amino-(propoxyamino)methylidene]amino]cyclohexyl]amino]-n-(2-methoxyethyl)-6-methylquinazoline-2-carboxamide Chemical compound CCCONC(N)=N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NCCOC)=NC2=CC=C(C)C=C12 GWTGQZNFNLTSDN-RBUKOAKNSA-N 0.000 description 1
- IHHGJWNXCFFUOZ-HWTGJJCHSA-N 4-[[(1s,2s)-2-[[amino(phenyl)methylidene]amino]cyclohexyl]amino]-n-(4-methoxyphenyl)-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@H](CCCC2)NC(=N)C=2C=CC=CC=2)=C(C=C(C)C=C2)C2=N1 IHHGJWNXCFFUOZ-HWTGJJCHSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- KPUFTCLJXVKAQQ-WCRQIBMVSA-N 6-chloro-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-[(2-methylpropan-2-yl)oxy]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(Cl)=CC2=1)C(=O)NOC(C)(C)C)C1=NCCC1 KPUFTCLJXVKAQQ-WCRQIBMVSA-N 0.000 description 1
- GMPNFPWMQDDSQV-AFMFUHLNSA-N 6-chloro-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-n-methoxyquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(Cl)=CC2=1)C(=O)NOC)C1=NCCC1 GMPNFPWMQDDSQV-AFMFUHLNSA-N 0.000 description 1
- LJYNFEQZPTUALB-AMTWEWDESA-N 6-chloro-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(Cl)=CC2=1)C(=O)N)C1=NCCC1 LJYNFEQZPTUALB-AMTWEWDESA-N 0.000 description 1
- XWADZOJYENYPAU-JQJBDSOESA-N 6-chloro-n-cycloheptyl-4-[[(1s,2r)-2-(quinazolin-4-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@@H]2[C@@H](CCCC2)NC=2C3=CC=CC=C3N=CN=2)C2=CC(Cl)=CC=C2N=C1C(=O)NC1CCCCCC1 XWADZOJYENYPAU-JQJBDSOESA-N 0.000 description 1
- OQPXSRCUOXBYHT-KMDCRFISSA-N 6-chloro-n-cycloheptyl-4-[[(1s,2r)-2-[1-(hydroxyamino)ethylideneamino]cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.ON=C(C)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)NC2CCCCCC2)=NC2=CC=C(Cl)C=C12 OQPXSRCUOXBYHT-KMDCRFISSA-N 0.000 description 1
- RZQZGJBKUFMKGZ-KMDCRFISSA-N 6-methyl-n-(2-methylpropyl)-4-[[(1s,2r)-2-(pyridin-2-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCC(C)C)C1=CC=CC=N1 RZQZGJBKUFMKGZ-KMDCRFISSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VFPPMCZFBBBYKW-WMLIAWDTSA-N Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C2=COC=C2)=C(C=C(C)C=C2)C2=N1 Chemical compound Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C2=COC=C2)=C(C=C(C)C=C2)C2=N1 VFPPMCZFBBBYKW-WMLIAWDTSA-N 0.000 description 1
- SYKWQVBCSBXXQD-JIHSWRCFSA-N Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2OC=CC=2)=C(C=C(C)C=C2)C2=N1 Chemical compound Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2OC=CC=2)=C(C=C(C)C=C2)C2=N1 SYKWQVBCSBXXQD-JIHSWRCFSA-N 0.000 description 1
- XHCTVLKBQGVKCR-WSDNCGGVSA-N Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2OC=CC=2)=C(C=C(F)C=C2)C2=N1 Chemical compound Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)C=2OC=CC=2)=C(C=C(F)C=C2)C2=N1 XHCTVLKBQGVKCR-WSDNCGGVSA-N 0.000 description 1
- SVLZQFMMSPKHSJ-VJFZBNOPSA-N Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)N(C)OC)=C(C=C(C)C=C2)C2=N1 Chemical compound Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC(=N)N(C)OC)=C(C=C(C)C=C2)C2=N1 SVLZQFMMSPKHSJ-VJFZBNOPSA-N 0.000 description 1
- AGBQJWWJGGHWLC-JIHSWRCFSA-N Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC=2CCCN=2)=C(C=C(C)C=C2)C2=N1 Chemical compound Cl.Cl.C1C[C@@H](OC)CC[C@@H]1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC=2CCCN=2)=C(C=C(C)C=C2)C2=N1 AGBQJWWJGGHWLC-JIHSWRCFSA-N 0.000 description 1
- SZEDWYZCWUQNGM-YQLOKHOVSA-N Cl.Cl.CC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)N[C@@H]2CC[C@@H](O)CC2)=NC2=CC=C(C)C=C12 Chemical compound Cl.Cl.CC(=N)N[C@@H]1CCCC[C@@H]1NC1=NC(C(=O)N[C@@H]2CC[C@@H](O)CC2)=NC2=CC=C(C)C=C12 SZEDWYZCWUQNGM-YQLOKHOVSA-N 0.000 description 1
- SDHCQEZRSDSQRK-WSDNCGGVSA-N Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)N[C@@H]1CC[C@@H](O)CC1)C1=NCCC1 Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)N[C@@H]1CC[C@@H](O)CC1)C1=NCCC1 SDHCQEZRSDSQRK-WSDNCGGVSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 125000002334 N-hydroxyacetimidoyl group Chemical group [H]C([H])([H])C([*])=NO[H] 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229940099547 Neuronal nitric oxide synthase inhibitor Drugs 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DCBVKFUBKNYWMU-ZWKOTPCHSA-N ethyl 6-methyl-4-[[(1s,2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexyl]amino]quinazoline-2-carboxylate Chemical compound C=12C=C(C)C=CC2=NC(C(=O)OCC)=NC=1N[C@H]1CCCC[C@H]1NC(=O)OC(C)(C)C DCBVKFUBKNYWMU-ZWKOTPCHSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- HSAOMZAKILCTSD-WCJQCITJSA-N n-(4-methoxyphenyl)-6-methyl-4-[[(1s,2r)-2-(pyridin-2-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1NC(=O)C1=NC(N[C@@H]2[C@@H](CCCC2)NC=2N=CC=CC=2)=C(C=C(C)C=C2)C2=N1 HSAOMZAKILCTSD-WCJQCITJSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JOLYDBPZNWACHE-AAYDIPMQSA-N n-butyl-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C1=NCCC1 JOLYDBPZNWACHE-AAYDIPMQSA-N 0.000 description 1
- HQLDULURSCHTKY-WCJQCITJSA-N n-butyl-4-[[(1s,2r)-2-(3h-isoindol-1-ylamino)cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C(C)C=CC2=NC(C(=O)NCCCC)=NC(N[C@@H]3[C@@H](CCCC3)NC=3C4=CC=CC=C4CN=3)=C21 HQLDULURSCHTKY-WCJQCITJSA-N 0.000 description 1
- OBAPMZVRMJARFI-QNCHGCKQSA-N n-butyl-6-chloro-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(Cl)=CC2=1)C(=O)NCCCC)C1=NCCC1 OBAPMZVRMJARFI-QNCHGCKQSA-N 0.000 description 1
- OPBZKXKKLCSTJK-ZZYOSWMOSA-N n-butyl-6-methyl-4-[[(1s,2r)-2-(3,4,5,6-tetrahydro-2h-azepin-7-ylamino)cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C1=NCCCCC1 OPBZKXKKLCSTJK-ZZYOSWMOSA-N 0.000 description 1
- QHYUZWTWYWODQI-WCJQCITJSA-N n-butyl-6-methyl-4-[[(1s,2r)-2-[(n-methyl-c-phenylcarbonimidoyl)amino]cyclohexyl]amino]quinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC=1N=C(N=C2C=CC(C)=CC2=1)C(=O)NCCCC)C(=NC)C1=CC=CC=C1 QHYUZWTWYWODQI-WCJQCITJSA-N 0.000 description 1
- YMZUEPOALKJQID-NREMKMRBSA-N n-cycloheptyl-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NC1CCCCCC1)C1=NCCC1 YMZUEPOALKJQID-NREMKMRBSA-N 0.000 description 1
- TWLOFWLZJBXKLD-IBUTWNQASA-N n-cycloheptyl-4-[[(1s,2r)-2-(3h-isoindol-1-ylamino)cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=C(N[C@@H]2[C@@H](CCCC2)NC=2C3=CC=CC=C3CN=2)C2=CC(C)=CC=C2N=C1C(=O)NC1CCCCCC1 TWLOFWLZJBXKLD-IBUTWNQASA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YXJQFQSDHRAYAF-QNCHGCKQSA-N n-tert-butyl-4-[[(1s,2r)-2-(3,4-dihydro-2h-pyrrol-5-ylamino)cyclohexyl]amino]-6-methylquinazoline-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1CCCC[C@@H]1NC1=NC(=NC2=CC=C(C=C21)C)C(=O)NC(C)(C)C)C1=NCCC1 YXJQFQSDHRAYAF-QNCHGCKQSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940026197 serotonin hydrochloride Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CLYPNYWPVDOGFJ-RBUKOAKNSA-N tert-butyl n-[(1r,2s)-2-[[2-(2-methoxyethylcarbamoyl)-6-methylquinazolin-4-yl]amino]cyclohexyl]carbamate Chemical compound C=12C=C(C)C=CC2=NC(C(=O)NCCOC)=NC=1N[C@H]1CCCC[C@H]1NC(=O)OC(C)(C)C CLYPNYWPVDOGFJ-RBUKOAKNSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract A quinazoline derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: [Chemical 1] R'N [1] wherein RI represents hydrogen or alkyl; R2 represents hydrogen, alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl or alkyl, in which the alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl and alkyl may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) halogen, (3) alkoxyalkyl, (4) hydroxy, (5) alkylthio, (6) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, (7) a 5- to 7-membered saturated aliphatic heterocyclic group which may be substituted with acyl and contains one to three nitrogen atoms, and (8) phenyl which may be substituted with halogen or alkoxy; R3 and R4 are the same or different and each represents hydrogen, alkyl, alkoxy or halogen; R5 is combined with R6 to represent alkylene, or represents hydrogen, hydroxy, alkyl, phenyl or alkoxy, in which the alkylene may be substituted with hydroxy or oxo, and may be condensed with a benzene ring; the alkyl, phenyl and alkoxy represented by R5 may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R represents (1) alkyl, (2) cycloalkyl, (3) phenyl, (4) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in which the alkyl, cycloalkyl, phenyl and aromatic heterocyclic group may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) hydroxy, (3) phenyl, (4) pyridyl, (5) furyl, (6) halogen and (7) N,N-dialkylamino. 04/01/13,gfdksipchx,2
Description
DESCRIPTION QUINAZOLINE DERIVATIVE AND PHARMACEUTICAL Technical Field [0001] The present invention relates to a quinazoline derivative, which is useful as a pharmaceutical, particularly an antipruritic agent, and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising any of them as an active ingredient. Background Art [0002] Itching is a sensation, i.e., pruritic sensation, which takes place at the superficial layer of the skin and the mucosa. The pruritic sensation is a sensation, which senses a parasite or an irritant on the superficial layer of the skin and is for removing an invading substance or an irritant by scratching behavior or anything. Itching can be easily understood as a sensation to cause an impulse to scratch, but its mechanism has not been elucidated completely yet. Diseases accompanied by itching are roughly classified into pruritic dermatosis accompanied by skin lesion (for example, atopic dermatitis, urticaria, psoriasis, xeroderma 1 and tinea) and pruritus cutaneous which is not accompanied by skin lesion but causes itching due to kidney dialysis and visceral diseases [for example, diabetes, blood diseases, cholestatic liver injury (primary biliary liver cirrhosis) and kidney diseases], hyperthyroidism, multiple sclerosis or the like. In addition, as a disease accompanied by severe itching, diseases of cornea and conjunctiva such as allergic conjunctivitis can be exemplified. Recently, any of the diseases has rapidly increased to constitute a large problem in view of QOL (quality of life) . Most itching diseases are common in the fact that vicious circle is caused by scratching the skin. Histamine is known as a typical itching-causing substance and induces itching in the case where it is externally added and is internally released from mastocytes. An antihistaminic agent, an antiallergic agent, a steroid external preparation and the like are used for the treatment of pruritic dermatosis. However, there is no drug that is satisfactory for the treatment of itching due to pruritic dermatosis. Further, it has recently been reported that factors other than histamine take part in itching due to atopic dermatitis. In fact, also in many clinical cases, an antihistaminic agent or an antiallergic agent does not exert a remarkable effect on itching due to atopic dermatitis. In the treatment of pruritus cutaneous, an antihistaminic agent or a steroid external preparation is prescribed in some cases. 2 However, almost no effect is seen, and thus an effective therapy does not exist at present. As described above, there is no satisfactory drug for diseases accompanied by itching and a medicament which effectively suppresses itching regardless of causative diseases has been eagerly desired from a clinical point of view. In order to solve this problem, as a useful compound for an antipruritic agent, a quinazoline derivative (see, for example Patent document 1), a neuronal nitric oxide synthase inhibitor (see, for example, Patent document 2), a cannabinoid receptor agonist (see, for example, Patent document 3), a glutamate receptor inhibitor (see, for example, Patent document 4), a piperidine derivative (see, for example, Patent document 5), a prostaglandin derivative (see, for example, Patent document 6) and the like have been reported. Among these, the quinazoline derivative described in Patent document 1 strongly suppresses scratching behavior spontaneously occurring in a mouse model with disruption of the horny layer barrier and is useful as a drug for effectively suppressing itching regardless of causative disease. The skin of pruritic diseases, especially of atopic dermatitis or the like accompanied by skin lesion develops disruption of the horny layer barrier or hypersensitivity of the sensory nerves in comparison with the normal skin, and the skin is recognized to be sensitive to stimulation. When an 3 external preparation is applied to such pruritic diseases, the external preparation is required to have an extremely low skin irritation. However, when the quinazoline derivative described in Patent document 1 which has a guanidino group in the side chain at the 4-position of the quinazoline skeleton is used as an external preparation for a patient with atopic dermatitis, there is a possibility of causing skin irritation. Patent document 1: WO 03/091224 Patent document 2: JP-A-2002-138052 Patent document 3: JP-A-2003-201250 Patent document 4: JP-A-2004-107209 Patent document 5: JP-A-2005-047909 Patent document 6: JP-A-2005-139194 Non-patent document 1: J. Am. Chem. Soc., 1975, 97, 2512 Non-patent document 2: J. Am. Chem. Soc., 1942, 64, 1827 Non-patent document 3: J. Org. Chem., 1942, 432 Non-patent document 4: J. Chem. Soc. Perkin Trans 2, 2000, 1435 Non-patent document 5: J. Med. Chem., 1997, 40, 2363 Disclosure of the invention 4 [00051 The present invention is directed to a quinazoline derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof (hereinafter referred to as the "inventive compound"). [Chemical 2]
R
5 N H HN R3 N -N R N 0 [1] R' represents hydrogen or alkyl. R2 represents hydrogen, alkoxy, tetrahydropyranyl, 5 phenyl, cycloalkyl, (cycloalkyl)alkyl or alkyl. The alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl and alkyl may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) halogen, (3) alkoxyalkyl, (4) hydroxy, (5) alkylthio, (6) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, (7) a 5- to 7-membered saturated aliphatic heterocyclic group which may be substituted with acyl and contains one to three nitrogen atoms, and (8) phenyl which may be substituted with halogen or alkoxy.
R
3 and R 4 are the same or different and each represents hydrogen, alkyl, alkoxy or halogen.
R
5 is combined with R 6 to represent alkylene, or represents hydrogen, hydroxy, alkyl, phenyl or alkoxy. The alkylene may be substituted with hydroxy or oxo, and may be condensed with a benzene ring. The alkyl, phenyl and alkoxy represented by R5 may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen.
R
6 represents (1) alkyl, (2) cycloalkyl, (3) phenyl, (4) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom or (5) 6 -N (R ) (R ) . The alkyl, cycloalkyl, phenyl and aromatic heterocyclic group may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) hydroxy, (3) phenyl, (4) pyridyl, (5) furyl, (6) halogen and (7) N,N-dialkylamino. R6 is combined with R to represent
-O-(CH
2 )n-, or represents hydrogen or alkyl. R represents hydrogen or alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen. Here, n represents an integer of 3 to 5. Exception is made for a compound wherein R 5 is hydrogen and R 6 is -NH 2 . [00061 A preferred compound in the present invention, may include the following (1) to (29) quinazoline derivatives and pharmaceutically acceptable salts thereof can be exemplified. (1) 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide (2) N-(2,2-dimethylpropyl)-4-({(iS,2R)-2-[(2 methoxy-2-methylpropanimidoyl)amino]cyclohexyl}amino)-6-me thylquinazolin-2-carboxamide (3) 4-({(1S,2R)-2-[(3-methoxypropanimidoyl)amino] cyclohexyl}amino)-N-(3-methoxypropyl)-6-methylquinazolin-2 -carboxamide (4) 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino] cyclohexyl}amino)-N-isopropyl-6-methylquinazolin-2-carboxa 7 mi de (5) 4-({(iS,2R)-2-[(3-hydroxypropanimidoyl)amino] cyclohexyl}amino)-N-(3-methoxypropyl)-6-methylquinazolin-2 -carboxamide (6) 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimid oyl)amino]cyclohexyl}amino)-N-isobutyl-6-methylquinazolin 2-carboxamide (7) N-(2-ethoxyethyl)-4-({(1S,2R)-2-[(3-hydroxy propanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2 -carboxamide (8) 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimid oyl)amino]cyclohexyl}amino)-N-isopropyl-6-methylquinazolin -2-carboxamide (9) 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimid oyl)amino]cyclohexyl}amino)-N-(2-methoxyethyl)-6-methylqui nazolin-2-carboxamide (10) 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino] cyclohexyl}amino)-N-(2-methoxyethyl)-6-methylquinazolin-2 carboxamide (11) 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamid e (12) 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino] cyclohexyl}amino)-N-(3-methoxypropyl)-6-methylquinazolin-2 -carboxamide 8 (13) 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-(2-ethoxyethyl)-6-methylquinazolin-2-carboxamide (14) N-(2-ethoxyethyl)-4-({(1S,2R)-2-[(2-methoxy ethanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2 carboxamide (15) 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-isopropyl-6-methylquinazolin-2-carboxamide (16) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo lin-2-carboxamide (17) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-isobutyl-6-methylquinazolin-2-ca rboxamide (18) 4-[((1S,2R)-2-{[amino(hydroxyimino)methyl] amino}cyclohexyl)amino]-N-isobutyl-6-methylquinazolin-2-ca rboxamide (19) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(cyclopropylmethyl)-6-methylquin azolin-2-carboxamide (20) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-isopropyl-6-methylquinazolin-2-c arboxamide (21) 4-{[(1S,2R)-2-({imino[methoxy(methyl)amino] methyl}amino)cyclohexyl]amino}-N-isobutyl-6-methylquinazol in-2-carboxamide 9 (22) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino)-N-(3-methoxypropyl)-6-methylquinaz olin-2-carboxamide (23) 4-[((1S,2R)-2-{[amino(hydroxyimino)methyl] amino}cyclohexyl)amino]-N-(3-methoxypropyl)-6-methylquinaz olin-2-carboxamide (24) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-ethoxyethyl)-6-methylquinazol in-2-carboxamide (25) 4-[((1S,2R)-2-{[amino(ethoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo lin-2-carboxamide (26) 4-{[(1S,2R)-2-({amino[(2-methoxyethoxy) imino]methyl}amino)cyclohexyl]amino}-N-(2-methoxyethyl)-6 methylquinazolin-2-carboxamide (27) 4-{[(1S,2R)-2-({amino[(2-fluoroethoxy)imino] methyl}amino)cyclohexyl]amino}-N-(2-methoxyethyl)-6-methyl quinazolin-2-carboxamide (28) 4-({(1S,2R)-2-[(amino{[2-(methylthio)ethoxy] imino}methyl)amino]cyclohexyl}amino)-N-(2-methoxyethyl)-6 methylquinazolin-2-carboxamide (29) 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo lin-2-carboxamide [0007] 10 Further, the present invention is also directed to a pharmaceutical composition comprising the inventive compound as an active ingredient, for example, a pharmaceutical composition for suppressing itching, which comprises the inventive compound as an active ingredient. [00081 Hereinafter, the present invention will be described in detail. Examples of the "alkyl" may include a linear or branched alkyl having 1 to 10 carbon atoms, and specific examples thereof may include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, n-nonyl, and n-decyl. Preferred is alkyl having 1 to 8 carbon atoms and more preferred is alkyl having 1 to 6 carbon atoms. Examples of the alkyl moiety of the "alkoxy", "(cycloalkyl)alkyl", "alkoxyalkyl", "alkylthio" and "N,N-dialkylamino" may include the same alkyl as those described above. Examples of the "tetrahydropyranyl" may include 2-tetrahydropyranyl, 3-tetrahydropyranyl and 4-tetrahydropyranyl. Examples of the "cycloalkyl" may include cyclic alkyl having 3 to 10 carbon atoms which is monocyclic to tricyclic, and specific examples thereof may include cyclopropyl, 11 cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecanyl, adamanthyl (1-adamanthyl, 2-adamanthyl, and the like), 2-bicyclo[3.1.l]heptyl and 2-bicyclo[2.2.1]heptyl. Preferred is the cyclic alkyl having 4 to 9 carbon atoms, and more preferred is the cyclic alkyl having 5 to 8 carbon atoms. Examples of the cycloalkyl moiety of the "(cycloalkyl) alkyl" may include the same cycloalkyl as those described above. Examples of the "halogen" may include fluorine, chlorine, bromine and iodine. Examples of the "aromatic heterocyclic group" may include a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and specific examples thereof may include pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (2-pyrazinyl, and the like), pyridazinyl (3-pyridazinyl, 4-pyridazinolyl), pyrrolyl (2-pyrrolyl, and the like), furyl (2-furyl, 3-furyl), thienyl (2-thienyl, 3-thienyl), imidazolyl (1-imidazolyl, 4-imidazolyl, and the like), pyrazolyl (3-pyrazolyl, 5-pyrazolyl, and the like), oxazolyl (4-oxazolyl, 5-oxazolyl, and the like), thiazolyl (1,3-thiazol-2-yl, 1,3-thiazol-5-yl, and the like), isoxazolyl (isoxazol-4-yl, isoxazol-5-yl, and 12 the like), and 1,3,4-thiadiazol-2-yl. Examples of the "acyl" may include acyl having 1 to 11 carbon atoms, and specific examples thereof may include formyl, acetyl, propyonyl, butyryl, isobutyryl, benzoyl, 1-naphthoyl and 2-naphthoyl. Examples of the "saturated aliphatic heterocyclic group" may include a 5- to 7-membered saturated aliphatic heterocyclic group containing one to three nitrogen atoms, and specific examples thereof may include pyrrolidinyl (1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), piperidinyl (1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl), piperazinyl (1-piperazinyl, 2-piperazinyl), homopiperazinyl (1-homopiperazinyl, 2-homopiperazinyl, 3-homopiperazinyl, 6-homopiperazinyl), morpholinyl (2-morpholinyl, 3-morpholinyl, 4-morpholinyl), and thiomorpholinyl (2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl). Examples of the "pyridyl" may include 2-pyridyl, 3-pyridyl and 4-pyridyl. Examples of the "furyl" may include 2-furyl and 3-furyl. Examples of the "alkylene" may include linear or branched alkylene having 1 to 6 carbon atoms, and specific examples thereof may include methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene. Among these, preferred is alkylene having 2 to 5 carbon atoms, and more preferred is alkylene having 3 to 5 carbon atoms. 13 [00091 Examples of the "itching" may include itching accompanying atopic dermatitis, urticaria, psoriasis, xeroderma, tinea, vitiligo, local pruritus cutaneous caused by insect excretion or secretion, nodular prurigo, kidney dialysis, diabetes, blood diseases, cholestatic liver injury (primary biliary liver cirrhosis), liver diseases, kidney diseases, endocrine and metabolic disorders, visceral malignancy, hyperthyroidism, autoimmune diseases, multiple sclerosis, neurological diseases, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or excess use of articles of taste and drugs. Best Mode for Carrying Out the Invention [0010] [Chemical 3]
R
5 N H HN R3 R4- N 0 [1] [0011] The inventive compound [1] can be produced according to, 14 for example, the following method from a known compound or an intermediate which can be easily synthesized. In the production of the inventive compound [1], in the case where a raw material has a substituent which has an influence on a reaction, it is general that the reaction is carried out after the raw material is protected with a suitable protecting group by a known method in advance. It may be easily understood that the protecting group is detached by a known method after the reaction. [0012] Production method 1 The inventive compound [1] can be produced according to, for example, the following reaction step. [Chemical 4] R'N R\ H H2N RN R6 R 6 [3] HN\ R - R 3 - 1 R 'R2 R4 N 2 0 [2] [1] [In the formulae, R' to R 6 have the same meanings as defined above. L represents a leaving group (for example, alkoxy, halogen, pyrazole-1-yl or methylthio).] The inventive compound [1] can be obtained by reacting 15 a compound [2] with one equivalent to an excess amount of a compound [3] in a solvent, for example, an alcohol-based solvent such as methanol or ethanol, a hydrocarbon-based solvent such as benzene or toluene, an ether-based solvent such as dioxane or tetrahydrofuran, a halogen-based solvent such as chloroform or 1,2-dichloroethane, dimethylformamide, or the like in the presence or absence of a base such as triethylamine or N,N-diisopropylethylamine at a temperature of 00C to the boiling point of the solvent employed for several hours to several days. It is preferred that the reaction is carried out in the presence of triethylamine by using ethoxy as the leaving group L of the compound [3] and ethanol as the solvent at 800C for 1 to 48 hours. [0013] The compound [2], which is a raw compound, can be produced by a known method (see, for example, Patent document 1). The compound [3], which is a raw compound, is commercially available, but can also be produced by a known method (see, for example, Non-patent documents 1 and 2). [0014] Production method 2 The inventive compound [la] wherein R 5 is alkoxy, R 6 is -N (R6) (R6) , and R6 and R are both hydrogen, can also be produced according to the following reaction step. [Chemical 5] 16 H R 51 N NC-N/NH uNCHNH [5]
H
2 N ,HN' 'R 51 HN RrR R4N 4 ,R 0 0 [4] [1a] [In the formulae, R' to R 4 have the same meanings as defined above. R5 represents alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen.] [0015] Production method 3 The inventive compound [1b] wherein R 5 is hydrogen and R6 is -N (R6 ) (R62) , can also be produced according to the following reaction step. [Chemical 6] H N
NC-N
/
, R (R62)(61 H 3 HN' HN 1[6] (R 2
(R
61 )N H RN N 2 N NOJY ' N-;Y ' 0 0 [4] [1b] [In the formulae, R to R , R6' and R62 have the same meanings 17 as defined above.] The inventive compound [la] or [1b] can be obtained by reacting a compound [4] with one equivalent to an excess amount of a compound [5] or [6] in a solvent, for example, an alcohol-based solvent such as methanol or ethanol, a hydrocarbon-based solvent such as benzene or toluene, an ether-based solvent such as dioxane or tetrahydrofuran, a halogen-based solvent such as chloroform or 1,2-dichloroethane, dimethylformamide, or the like in the presence or absence of an inorganic base such as sodium carbonate or potassium carbonate, or an organic base such as triethylamine or N,N-diisopropylethylamine at a temperature of 00C to the boiling point of the solvent employed for several hours to several days. It is preferred that the reaction is carried out in the presence of sodium carbonate by using ethanol or dioxane as the solvent at 50'C to 800C for 1 hour to 24 hours. [0016] The compound [4], which is a raw compound, can be produced according to the following reaction step. [Chemical 7] 18 H H2N//. NC-N NBrCN N R 3N BrCNR R 4 N RN RN R 2 RN [2] [4 0 [In the formulae, R' to R 4 have the same meanings as defined above.] The compound [4] can be obtained by reacting the compound [2] with one equivalent to an excess amount of BrCN in a solvent, for example, a hydrocarbon-based solvent such as benzene or toluene, an ether-based solvent such as dioxane or tetrahydrofuran, a halogen-based solvent such as chloroform or 1,2-dichloroethane, dimethylformamide, or the like in the presence of an inorganic base such as sodium carbonate or potassium carbonate, or an organic base such as triethylamine or N,N-diisopropylethylamine at a temperature of -780C to the boiling point of the solvent employed for several minutes to several days. It is preferred that the reaction is carried out in the presence of triethylamine by using tetrahydrofuran as the solvent at -50C to 00C for 10 minutes to 1 hour. [0017] Further, the compound [4], which is a raw compound, can also be produced according to the following reaction step. 19 [Chemical 81 H2H H NC-IQ
H
2 N R3' , KOCN 3 MsCI R3 R4 N N R4 N, pyridine R N R N *R Y Y' N "Y'2 N *R2 0 0 0 [2] [7] [4] A compound [7] can be obtained by reacting the compound [2] with one equivalent to an excess amount of potassium cyanate in a solvent, for example, water, an alcohol-based solvent such as methanol or ethanol, or the like in the presence or absence of an acid such as hydrochloric acid or sulfuric acid, or a base such as triethylamine, N,N-diisopropylethylamine, sodium hydroxide or potassium hydroxide at a temperature of 00C to the boiling point of the solvent employed for several hours to several days. It is preferred that the reaction is carried out in the presence of triethylamine by using hydrous ethanol as the solvent at 500C to 1000C for 1 hour to 5 hours. The compound [4] can be obtained by reacting the compound [7] with methanesulfonyl chloride in pyridine at -100C to 500C for 30 minutes to 5 hours. [0018] The compounds [5] and [6], which are raw compounds, are commercially available, but can also be produced by a known method (see, for example, Non-patent documents 3 to 5). [0019] 20 The quinazoline derivative according to the present invention can be used as a pharmaceutical in the form of a free base itself, or can be used by formulating it in the form of a pharmaceutically acceptable salt by a known method. Examples of such salts include those with a mineral acid such as hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid, these with an organic acid such as acetic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid or methanesulfonic acid, and the like. For example, a hydrochloride salt of the quinazoline derivative according to the present invention can be obtained by dissolving the quinazoline derivative according to the present invention in a suitable solvent and adding an alcohol solution, an ethyl acetate solution or an ether solution of hydrogen chloride thereto, followed by concentration to dryness. [0020] Among the inventive compounds [1], some compounds may have an asymmetric carbon, and all of the optical isomers and mixtures thereof are also included in the present invention. Such an optical isomer can be produced by, for example, starting from a racemate obtained as described above, utilizing the basicity thereof and using an optically active acid (tartaric acid, dibenzoyltartaric acid, mandelic acid, 21 10-camphorsulfonic acid or the like) through a known method for optical resolution, or by using a previously prepared optically active compound as a starting material. In addition to this, it can also be produced by optical resolution or asymmetric synthesis using a chiral column. Further, in the inventive compounds [1], there are also those compounds which may exist in the cis form, trans form, Z form or E form, and each isomer and mixtures thereof are also included in the present invention. [0021] When the inventive compound is administered as a pharmaceutical, the inventive compound is administered to mammals including humans as it is or in a pharmaceutically acceptable non-toxic inert carrier, for example, as a pharmaceutical composition comprising the inventive compound in an amount of 0.001% to 99.5%, preferably 0.1% to 90%. As the carrier, one or more types of auxiliary agents for a formulation such as solid, semi-solid or liquid diluents, fillers and other auxiliary agents for a drug formulation may be used. It is preferred that a pharmaceutical composition according to the present invention is administered in a unit dosage form. The administration of the pharmaceutical composition can be carried out by intra-tissue administration, oral administration, intravenous administration, local administration (transdermal administration, instillation, or 22 the like) or transrectal administration. It may be easily understood that a dosage form suitable for any of these administration routes is employed. For example, oral administration or local administration (transdermal administration or instillation) is preferred. While it is preferred that the dose as an antipruritic agent is adjusted depending on the conditions of the patient such as the age, body weight, nature and degree of the disease as well as the administration route, a daily dose as an active ingredient of the inventive compound in an adult is usually in the range from 0.1 mg to 5 g per adult, preferably from 1 mg to 500 mg per adult in the case of oral administration. In the case of transdermal administration, it is in the range from 0.001% to 5%, preferably from 0.01% to 0.1%. In the case of instillation, it is in the range from 0.0001% to 0.5%, preferably from 0.001% to 0.01%. In some cases, a lower dose may be sufficient or a higher dose may be required. Usually, the dose is given once daily or several times daily as divided portions, or it can be given intravenously and continuously over a period of 1 to 24 hours a day. [0022] Oral administration can be accomplished in a solid or liquid dosage unit such as a bulk powder, a powder, a tablet, a sugar-coated preparation, a capsule, a granule, a suspension, a liquid, a syrup, a drop, a sublingual tablet, a suppository 23 or other dosage forms. Abulkpowder isproducedbypulverizing an active ingredient into a suitable size. Apowder is produced by pulverizing an active ingredient into a suitable size followed by mixing with a pharmaceutical carrier such as an edible carbohydrate including starch or mannitol, which has been pulverized in a similar manner into a suitable size. If necessary, a flavor, a preservative, a dispersing agent, a colorant, a fragrance or other additive may be mixed therein. A capsule is produced by filling a bulk powder or a powder which has previously been pulverized into a powder form as described above or a granule obtained as described in the section of a tablet, for example, in a capsule shell such as a gelatin capsule. It is also possible to perform such a filling operation after mixing a lubricant, a fluidizing agent such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol with the material in a powder form. If a disintegrant or a solubilizing agent such as carboxymethyl cellulose, carboxymethyl cellulose calcium, low substituted hydroxypropyl cellulose, croscarmellose sodium, carboxy starch sodium, calcium carbonate or sodium carbonate is added, the effectiveness of the pharmaceutical taken as a capsule can be enhanced. The finely pulverized powder of the inventive compound can be suspended and dispersed in a vegetable oil, polyethylene glycol, glycerin or a surfactant, and then encapsulated in a 24 gelatin sheet, thereby being prepared as a soft capsule. A tablet is produced by formulating a powder mixture, converting it into a granule or a slug, adding a disintegrant or a lubricant thereto and then compressing it into a tablet. The powder mixture is obtained by mixing an appropriately pulverized material with a diluent or a base described above, and if necessary, a binder (for example, carboxymethyl cellulose sodium, hydroxypropyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, gelatin, polyvinyl pyrrolidone, polyvinyl alcohol or the like), a dissolution retardant (for example, paraffin, wax, hydrogenated castor oil or the like), a resorption promoter (for example, a quaternary salt), or an adsorbent (for example, bentonite, kaolin, calcium diphosphate or the like) may also be mixed together. The powder mixture can be granulated by wetting it with a binder such as syrup, starch glue, gum arabic, a cellulose solution or a polymeric material solution and then passing it forcibly through a sieve. Instead of granulating the powder as described above, the powder can be subjected first to a tabletting machine to obtain an incompletely shaped slug which is then pulverized to obtain a granule. The granule thus obtained can be prevented from adhering to one another by adding a lubricant such as stearic acid, a stearate, talc or mineral oil, or the like. The mixture thus lubricated is then compressed into a tablet. The plane tablet thus obtained can 25 be film-coated or sugar-coated. Further, the inventive compound may also be compressed directly into a tablet after mixing it with a fluidized inert carrier without being subjected to the granulating or slugging process as described above. A transparent or semi-transparent protective film made of a shellac sealing film, a film made of a sugar or a polymeric material and a glossy film made of a wax may also be employed. Other oral dosage forms such as a solution, a syrup and an elixir can also be formulated into a unit dosage form such that a certain amount of the preparation contains a certain amount of the inventive compound. A syrup is produced by dissolving the inventive compound in a suitable flavored aqueous solution, while an elixir is produced by using a non-toxic alcoholic carrier. A suspension is formulated by dispersing the inventive compound in a non-toxic carrier. A solubilizing agent, an emulsifying agent (for example, an ethoxylated isostearyl alcohol or a polyoxyethylene sorbitol ester), a preservative, a flavor-imparting agent (for example, peppermint oil or saccharin), or any other additive may also be added if necessary. A unit dosage formulation for an oral administration may be formulated as a microcapsule if necessary. Such a formulation may be coated or embedded in a polymer, a wax or the like to achieve a prolonged action or a sustained release. 26 [0023] Rectal administration can be accomplished by using a suppository obtained by mixing the inventive compound with a water-soluble or water-insoluble solid having a low melting point such as polyethylene glycol, cocoa butter, a higher ester (for example, myristyl palmitate) and a mixture thereof. [0024] Intra-tissue administration can be accomplished by using a liquid unit dosage form, for example in the form of a solution or a suspension as a subcutaneous, intramuscular, intrabladder or intravenous injection formulation. Any of these formulations can be produced by suspending or dissolving a certain amount of the inventive compound in a non-toxic liquid carrier suitable for the purpose of the injection such as an aqueous or oily vehicle followed by sterilizing the resulting suspension or solution. Alternatively, a certain amount of the inventive compound may be placed in a vial, which is then sterilized together with its content and then sealed. An auxiliary vial and a carrier may be provided in combination with a powdered or lyophilized active ingredient for the purpose of dissolving or mixing just before administration. A non-toxic salt or salt solution may be added for the purpose of making an injection solution isotonic. It is also possible to use a stabilizer, a preservative, an emulsifying agent or the like in combination. 27 [0025] Transdermal administration can be accomplished in a solid or liquid dosage unit such as an aerosol, a liquid, a suspension, an emulsion, an adhesive preparation, an ointment, a cataplasm, a liniment, a lotion or another dosage form. An ointment is produced by, for example, mixing and kneading a certain amount of the inventive compound with a pharmaceutically acceptable solid base suitable for an ointment, for example, a water-soluble base or a lipid-soluble base described in the Japanese pharmacopoeia. It is also possible to use an additive such as a stabilizer, apreservative, an emulsifying agent or a suspending agent. Instillation can be accomplished in a liquid unit dosage form, for example, in the form of a solution or a suspension. Any of these formulations can be produced by suspending or dissolving a certain amount of the inventive compound in a non-toxic liquid carrier suitable for instillation such as an aqueous or oily vehicle followed by sterilizing the resulting suspension or solution. Alternatively, a certain amount of the inventive compound may be placed in a vial, which is then sterilized together with its content and then sealed. An auxiliary vial and a carrier may be provided in combination with a powdered or lyophilized active ingredient for the purpose of dissolving or mixing just before administration. A pharmaceutically acceptable salt or salt solution may be 28 added for the purpose of making an eye drop isotonic. It is also possible to use a stabilizer, a preservative, an emulsifying agent or the like in combination. Examples [0026] Hereinafter, the present invention will be described in more detail with reference to Reference examples, Examples, Test examples and Preparation examples. However, the invention is not limited only to these. Reference example 1 4-{[(1S,2R)-2-aminocyclohexyl]amino}-N-(2-methoxyethyl)-6 methylquinazolin-2-carboxamide Step 1: tert-butyl {(1R,2S)-2-[(2-{[(2-methoxyethyl) amino]carbonyl}-6-methylquinazolin-4-yl)amino]cyclohexyl}c arbamate To a suspension of 15.0 g of ethyl 4-({(1S,2R)-2-[(tert-butoxycarbonyl)amino]cyclohexyl}amino )-6-methylquinazolin-2-carboxylate in 15 ml of methanol, 7.89 g of 2-methoxyethylamine was added, and the mixture was stirred at 500C for 15 hours. After the reaction solution was cooled to room temperature, 45 ml of diisopropyl ether was added thereto, and the mixture was stirred at 00C for 30 minutes. The deposited crystal was collected by filtration, washed with 29 diisopropyl ether and dried under reduced pressure, whereby 12.2 g of a desired compound was obtained as a white powder. Step 2: 4-{[(1S,2R)-2-aminocyclohexyl]amino}-N-(2 methoxyethyl)-6-methylquinazolin-2-carboxamide To a suspension of 2.24 g of tert-butyl {(1R,2S)-2-[(2-{[(2-methoxyethyl)amino]carbonyl}-6-methylq uinazolin-4-yl)amino]cyclohexyl}carbamate in 10 ml of ethyl acetate, 10 ml of a 4 N hydrogen chloride-ethyl acetate solution was added, and the mixture was stirred at room temperature for 48 hours. To the reaction solution, 20 ml of diethyl ether was added, and the mixture was stirred for 30 minutes. Then, the deposited substance was collected by filtration, washed with diethyl ether and dried under reduced pressure. The resulting powder was purified by Fuji Silysia NH silica gel column chromatography (chloroform : methanol = 20 : 1), whereby 1. 61 g of a desired compound was obtained as a colorless powder. [0027] Example 1 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-me thoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Step 1: 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide To a solution of 450 mg of 4-{[(1S,2R)-2 30 aminocyclohexyl]amino}-N-(2-methoxyethyl)-6-methylquinazol in-2-carboxamide and 467 mg of ethylacetoimidate hydrochloride in 10 ml of ethanol, 764 mg of triethylamine was added, and the mixture was stirred at 800C for 8 hours. After the reaction solution was concentrated, the residue was purified by silica gel column chromatography (chloroform : methanol = 20 : 1), whereby 391 mg of a desired compound was obtained as a pale yellow powder. Step 2: 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino}-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride To a solution of 391 mg of 4-{[(1S,2R)-2 (ethanimidoylamino)cyclohexyl]amino}-N-(2-methoxyethyl)-6 methylquinazolin-2-carboxamide in 5 ml of ethyl acetate, 3 ml of a 4 N hydrogen chloride-ethyl acetate solution was added, and the mixture was stirred for 10 minutes. Then, to the reaction solution, 10 ml of diethyl ether was added, and the deposited substance was collected by filtration, washed with diethyl ether and dried under reduced pressure, whereby 405 mg of a desired compound was obtained as a white powder. Elemental analysis value (as C 2 1
H
3 0
N
6 0 2 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 48.84 H: 7.22 N: 16.27 Found (%) C: 48.69 H: 6.83 N: 16.04 Positive ion FAB-MS m/z: 399 [M+H]+ Specific rotation [U]20D =+110.79 (c =0.500 methanol) 31 In the same manner as in Example 1, the following compounds of Examples 2 to 207 were produced. Example 2 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[2-(2-furyl)ethanimi doyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
35
N
6 0 2 Cl / 2HCl / 1.3 H 2 0) Calculated (%) C: 54.29 H: 6.44 N: 13.57 Found (%) C: 54.22 H: 6.37 N: 13.55 Positive ion FAB-MS m/z: 523 [M+H]* Specific rotation []2 D =+108.73 (c =0.504 methanol) Appearance: pale red powder Example 3 6-chloro-N-cycloheptyl-4-({ (1S,2R)-2-[(2-pyridin-2-ylethan imidoyl)amino]cyclohexyl}amino)quinazolin-2-carboxamide trihydrochloride Elemental analysis value (as C 2 9
H
36
N
7 0C1 / 3 HCl / 3.1 H 2 0) Calculated (%) C: 49.81 H: 6.52 N: 14.02 Found (%) C: 49.81 H: 6.46 N: 13.80 Positive ion FAB-MS m/z: 534 [M+H]+ Specific rotation []2 D =+58.40 (c =0.565 methanol) Appearance: pale brown powder 32 Example 4 4-{[(lS,2R)-2-(n-butanimidoylamino)cyclohexyl]amino}-6-chl oro-N-cycloheptylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 7
N
6 OCl / 2 HCl / 1.8 H 2 0) Calculated (%) C: 52.89 H: 7.27 N: 14.23 Found (%) C: 52.90 H: 7.22 N: 13.98 Positive ion FAB-MS m/z: 485 [M+H]+ Specific rotation []2 D =+93.61 (c =0.517 methanol) Appearance: white powder Example 5 N-(2-ethylbutyl)-4-({ (1S,2R)-2-[(2-methoxyethanimidoyl)ami no]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 2 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 55.22 H: 7.75 N: 15.46 Found (%) C: 55.21 H: 7.62 N: 15.44 Positive ion FAB-MS m/z: 387 [M+H]+ Specific rotation []2 D =+96.52 (c =0.518 methanol) Appearance: white powder Example 6 N-(2-ethylbutyl)-4-({ (1S,2R)-2-[(3-methoxypropanimidoyl)am ino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide 33 dihydrochloride Elemental analysis value (as C 2 6
H
4 oN 6 0 2 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 56.17 H: 7.90 N: 15.12 Found (%) C: 56.22 H: 7.84 N: 14.96 Positive ion FAB-MS m/z: 469 [M+H]+ Specific rotation [a]2 D =+94.93 (c =0.533 methanol) Appearance: white powder Example 7 N-(3-methoxy-2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(3-methoxy propanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2 -carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
4 0
N
6 0 3 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 54.60 H: 7.68 N: 14.69 Found (%) C: 54.63 H: 7.59 N: 14.59 Positive ion FAB-MS m/z: 485 [M+H]+ Specific rotation [a]2 D =+84.57 (c =0.525 methanol) Appearance: white powder Example 8 N-(2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(2-methoxyethanimido yl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamid e dihydrochloride Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation [a]2 D =+98.12 (c =0.534 methanol) 34 Appearance: white powder Example 9 N-(2,2-dimethylpropyl)-4-[((iS,2R)-2-{[2-(2-furyl)ethanimi doyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxam ide dihydrochloride Positive ion FAB-MS m/z: 477 [M+H]+ Specific rotation [a] D =+89.57 (c =0.547 methanol) Appearance: red-brown powder Example 10 N-(2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(3-methoxypropanimid oyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxami de dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 2 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 55.22 H: 7.75 N: 15.46 Found (%) C: 55.28 H: 7.52 N: 15.15 Positive ion FAB-MS m/z: 455 [M+H]+ Specific rotation []2 D =+87.07 (c =0.526 methanol) Appearance: white powder [0028] Example 11 4-[((1S,2R)-2-{[3-(dimethylamino)propanimidoyl]amino}cyclo hexyl)amino]-N-(2,2-dimethylpropyl)-6-methylquinazolin-2-c 35 arboxamide trihydrochloride Elemental analysis value (as C 26
H
41
N
7 0 / 3 HCl / 1.8 H 2 0) Calculated (%) C: 51.24 H: 7.87 N: 16.09 Found (%) C: 51.48 H: 7.49 N: 15.68 Positive ion FAB-MS m/z: 468 [M+H]+ Specific rotation []2 D =+57.14 (c =0.469 methanol) Appearance: white powder Example 12 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-6-methyl-N-(2,2,2-trifluoroethyl)quinazolin-2-carboxam ide dihydrochloride Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+116.73 (c =0.514 methanol) Appearance: pale brownish white powder Example 13 N-(trans-4-methoxycyclohexyl)-4-({ (1S,2R)-2-[(2-methoxyeth animidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-car boxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 8
N
6 0 3 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 53.11 H: 7.47 N: 14.29 Found (%) C: 53.24 H: 7.41 N: 13.92 Positive ion FAB-MS m/z: 483 [M+H]+ Specific rotation []2 D =+105.05 (c =0.495 methanol) 36 Appearance: white powder Example 14 N-(2,2-dimethylpropyl)-6-fluoro-4-({(1S,2R)-2-[(2-methoxye thanimidoyl)amino]cyclohexyl}amino)quinazolin-2-carboxamid e dihydrochloride Positive ion FAB-MS m/z: 445 [M+H]+ Specific rotation []2 D =+63.03 (c =0.514 methanol) Appearance: white powder Example 15 N-(2,2-dimethylpropyl)-4-({(1S,2R)-2-[(2-ethoxyethanimidoy 1)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 455 [M+H]+ Specific rotation [a] D =+92.51 (c =0.521 methanol) Appearance: white powder Example 16 N-(2,2-dimethylpropyl)-4-({(1S,2R)-2-[(2-ethoxyethanimidoy 1)amino]cyclohexyl}amino)-6-fluoroquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 24
H
35
N
6 0 2 F / 2 HCl / 0.9 H 2 0) Calculated (%) C: 52.63 H: 7.14 N: 15.34 Found (%) C: 52.76 H: 7.15 N: 15.25 37 Positive ion FAB-MS m/z: 459 [M+H]* Specific rotation []2 D =+55.25 (c =0.514 methanol) Appearance: white powder Example 17 N-(2-ethylbutyl)-6-fluoro-4-({(1S,2R)-2-[(2-methoxyethanim idoyl)amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 5
N
6 0 2 F / 2 HCl / H 2 0) Calculated (%) C: 52.46 H: 7.15 N: 15.29 Found (%) C: 52.65 H: 7.10 N: 15.21 Positive ion FAB-MS m/z: 459 [M+H]+ Specific rotation []2 D =+59.34 (c =0.492 methanol) Appearance: white powder Example 18 6-fluoro-N-(3-methoxy-2,2-dimethylpropyl)-4-({(1S,2R)-2-[( 2-methoxyethanimidoyl)amino]cyclohexyl}amino)quinazolin-2 carboxamide dihydrochloride Positive ion FAB-MS m/z: 475 [M+H]+ Specific rotation [a] D =+54.82 (c =0.518 methanol) Appearance: white powder Example 19 N-(2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(2-methoxy-2-methylp 38 ropanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2 carboxamide dihydrochloride Elemental analysis value (as C 26
H
40
N
6 0 2 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 55.99 H: 7.92 N: 15.07 Found (%) C: 55.94 H: 7.81 N: 15.07 Positive ion FAB-MS m/z: 469 [M+H]+ Specific rotation []2 D =+5.49 (c =0.510 methanol) Appearance: white powder Example 20 6-fluoro-N-isobutyl-4-({ (1S,2R)-2-[(2-methoxyethanimidoyl) amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
31
N
6 0 2 F / 2 HCl / 1.1 H 2 0) Calculated (%) C: 50.50 H: 6.78 N: 16.06 Found (%) C: 50.48 H: 6.69 N: 16.03 Positive ion FAB-MS m/z: 431 [M+H]+ Specific rotation []2 D =+66.42 (c =0.557 methanol) Appearance: white powder [0029] Example 21 N-[(1-hydroxycyclohexyl)methyl]-4-({(1S,2R)-2-[(2-methoxye thanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-c arboxamide dihydrochloride 39 Elemental analysis value (as C 26
H
38
N
6 0 3 / 2 HCl / 2.1 H 2 0) Calculated (%) C: 52.63 H: 7.51 N: 14.16 Found (%) C: 52.57 H: 7.12 N: 14.15 Positive ion FAB-MS m/z: 483 [M+H]+ Specific rotation []2 D =+98.10 (c =0.581 methanol) Appearance: white powder Example 22 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-N-[2-methoxy-1-(methoxymethyl)-1-methylethyl]-6-methyl quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 4 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 50.73 H: 7.42 N: 14.20 Found (%) C: 50.84 H: 7.17 N: 14.46 Positive ion FAB-MS m/z: 487 [M+H]+ Specific rotation []2 D =+99.62 (c =0.532 methanol) Appearance: white powder Example 23 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-N-(2-methoxy-2-methylpropyl)-6-methylquinazolin-2-carb oxamide dihydrochloride Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+99.99 (c =0.542 methanol) Appearance: white powder 40 Example 24 4-{[(lS,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-me thoxy-2-methylpropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 2 / 2 HCl / 3 H 2 0) Calculated (%) C: 49.91 H: 7.65 N: 15.18 Found (%) C: 49.94 H: 7.49 N: 15.09 Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+94.18 (c =0.516 methanol) Appearance: white powder Example 25 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-hy droxy-2-methylpropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 2 / 2 HCl / 3.4 H 2 0) Calculated (%) C: 48.33 H: 7.52 N: 15.37 Found (%) C: 48.27 H: 7.22 N: 15.26 Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+92.24 (c =0.529 methanol) Appearance: white powder Example 26 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-[(1-h 41 ydroxycyclohexyl)methyl]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 6
N
6 0 2 / 2 HCl / 2 H 2 0) Calculated (%) C: 52.63 H: 7.60 N: 14.73 Found (%) C: 52.45 H: 7.41 N: 14.83 Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+84.35 (c =0.569 methanol) Appearance: white powder Example 27 4-({(1S,2R)-2-[(2-methoxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-(2-methoxy-2-methylpropyl)-6-methylquinazo lin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
40
N
6 0 3 / 2 HCl / H 2 0) Calculated (%) C: 54.26 H: 7.71 N: 14.60 Found (%) C: 54.38 H: 7.46 N: 14.24 Positive ion FAB-MS m/z: 485 [M+H]+ Specific rotation []2 D =+5.61 (c =0.534 methanol) Appearance: white powder Example 28 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-[2-me thoxy-1-(methoxymethyl)ethyl]-6-methylquinazolin-2-carboxa mide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / 2.1 H 2 0) 42 Calculated (%) C: 49.93 H: 7.32 N: 15.19 Found (%) C: 49.95 H: 7.19 N: 14.96 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation [a]2D =+106.37 (c =0.549 methanol) Appearance: white powder Example 29 4-[((1S,2R)-2-{[3-(dimethylamino)propanimidoyl]amino}cyclo hexyl)amino]-N-(2-methoxy-2-methylpropyl)-6-methylquinazol in-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 484 [M+H]+ Specific rotation []2 D =+61.43 (c =0.599 methanol) Appearance: white powder Example 30 4-({(1S,2R)-2-[(2-methoxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-(3-methoxypropyl)-6-methylquinazolin-2-car boxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 3 / 2 HCl / H 2 0) Calculated (%) C: 53.47 H: 7.54 N: 14.97 Found (%) C: 53.52 H: 7.24 N: 14.92 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+9.52 (c =0.588 methanol) Appearance: white powder 43 [00301 Example 31 N-(2-methoxy-2-methylpropyl)-4-({(iS,2R)-2-[(3-methoxyprop animidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-car boxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 3 / 2 HCl / 3.3 H 2 0) Calculated (%) C: 49.80 H: 7.79 N: 13.94 Found (%) C: 49.48 H: 7.37 N: 13.75 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+97.21 (c =0.574 methanol) Appearance: white powder Example 32 N-(2-methoxyethyl)-4-({(1S,2R)-2-[(2-methoxy-2-methylpropa nimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 3 / 2 HCl / 2.3 H 2 0) Calculated (%) C: 50.49 H: 7.52 N: 14.72 Found (%) C: 50.59 H: 7.23 N: 14.78 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+21.54 (c =0.557 methanol) Appearance: white powder Example 33 N-isobutyl-4-({ (1S,2R)-2-[(2-methoxy-2-methylpropanimidoyl 44 )amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 2 / 2 HCl / 2.3 H 2 0) Calculated (%) C: 52.77 H: 7.90 N: 14.77 Found (%) C: 52.74 H: 7.53 N: 14.79 Positive ion FAB-MS m/z: 455 [M+H]+ Specific rotation []2 D =+5.92 (c =0.540 methanol) Appearance: white powder Example 34 N-(2-methoxyethyl)-4-({(1S,2R)-2-[(3-methoxypropanimidoyl) amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation [a] D =+113.09 (c =0.527 methanol) Appearance: white powder Example 35 4-({(1S,2R)-2-[(3-methoxypropanimidoyl)amino]cyclohexyl}am ino)-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation [a] D =+107.53(c =0.571 methanol) Appearance: white powder 45 Example 36 N-ethyl-4-({(iS,2R)-2-[(3-methoxypropanimidoyl)amino]cyclo hexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation [a]2D =+122.56 (c =0.545 methanol) Appearance: white powder Example 37 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(4-me thoxyphenyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 0
N
6 0 2 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 54.95 H: 6.46 N: 15.38 Found (%) C: 55.26 H: 6.11 N: 15.31 Positive ion FAB-MS m/z: 447 [M+H]+ Specific rotation []2 D =+28.47 (c =0.576 methanol) Appearance: pale yellow powder Example 38 N-n-butyl-4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amin o}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 53.81 H: 7.47 N: 17.11 Found (%) C: 53.80 H: 7.31 N: 17.22 46 Positive ion FAB-MS m/z: 397 [M+H]* Specific rotation []2 D =+96.42 (c =0.728 methanol) Appearance: white powder Example 39 N-n-butyl-6-methl-4-({(1S,2R)-2-[(2-methylpropanimidoyl)am ino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 56.31 H: 7.80 N: 16.42 Found (%) C: 55.99 H: 7.37 N: 16.54 Positive ion FAB-MS m/z: 425 [M+H]+ Specific rotation []2 D =+1.20 (c =0.662 methanol) Appearance: white powder Example 40 N-n-butyl-4-[((1S,2R)-2-{[cyclohexyl(imino)methyl]amino}cy clohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
4 0
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 57.99 H: 8.00 N: 15.03 Found (%) C: 58.02 H: 7.72 N: 15.14 Positive ion FAB-MS m/z: 465 [M+H]+ Specific rotation []2 D =+1.50 (c =0.665 methanol) Appearance: white powder 47 [0031] Example 41 N-(4-methoxyphenyl)-6-methyl-4-({(iS,2R)-2-[(2-phenylethan imidoyl)amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 3 1
H
3 4
N
6 0 2 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 61.04 H: 6.21 N: 13.78 Found (%) C: 61.07 H: 6.00 N: 13.89 Positive ion FAB-MS m/z: 523 [M+H]+ Specific rotation [a]2 D =+79.81 (c =0.649 methanol) Appearance: pale yellow powder Example 42 N-n-butyl-6-methyl-4-[((1S,2R)-2-{[N-phenylethanimidoyl]am ino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 473 [M+H]+ Appearance: white powder Example 43 N-(2,2-dimethylpropyl)-6-methyl-4-[((1S,2R)-2-{[N-methylet hanimidoyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 / 2 HCl / 0.8 H 2 0) 48 Calculated (%) C: 56.31 H: 7.80 N: 16.42 Found (%) C: 56.44 H: 7.75 N: 16.21 Positive ion FAB-MS m/z: 425 [M+H]+ Specific rotation []2 D =+81.03 (c =0.501 methanol) Appearance: white powder Example 44 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+102.72 (c =0.514 methanol) Appearance: pale yellow powder Example 45 N-(2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(3-hydroxypropanimid oyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxami de dihydrochloride Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+58.24 (c =0.546 methanol) Appearance: pale yellow powder Example 46 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-(trans-4-methoxycyclohexyl)-6-methylquinazolin-2-ca 49 rboxamide dihydrochloride Positive ion FAB-MS m/z: 483 [M+H]+ Specific rotation []2 D =+82.74 (c =0.539 methanol) Appearance: white powder Example 47 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-6-fluor o-N-(trans-4-methoxycyclohexyl)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 3
FN
6 0 2 / 2 HCl / 2 H 2 0) Calculated (%) C: 50.97 H: 6.95 N: 14.86 Found (%) C: 51.07 H: 6.79 N: 15.07 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+48.29 (c =0.468 methanol) Appearance: white powder Example 48 6-fluoro-N-(trans-4-methoxycyclohexyl)-4-({ (1S,2R)-2-[(2-m ethoxyethanimidoyl)amino]cyclohexyl}amino)quinazolin-2-car boxamide dihydrochloride Elemental analysis value (as C 25
H
35
FN
6 0 3 / 2 HCl / 1.7 H 2 0) Calculated (%) C: 50.88 H: 6.90 N: 14.24 Found (%) C: 50.97 H: 6.59 N: 14.20 Positive ion FAB-MS m/z: 487 [M+H]+ Specific rotation []2 D =+69.09 (c =0.605 methanol) 50 Appearance: white powder Example 49 4-{[(lS,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-6-methy 1-N-[2-(methylthio)ethyl]quinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 415 [M+H]+ Specific rotation []2 D =+90.97 (c =0.565 methanol) Appearance: white powder Example 50 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-6-methyl-N-[2-(methylthio)ethyl]quinazolin-2-carboxami de dihydrochloride Positive ion FAB-MS m/z: 445 [M+H]+ Specific rotation [a] D =+105.81 (c =0.550 methanol) Appearance: white powder [0032] Example 51 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-me thoxy-1,1-dimethylethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 2 / 2 HCl / 2 H 2 0) Calculated (%) C: 51.59 H: 7.53 N: 15.69 51 Found (%) C: 51.53 H: 7.23 N: 15.63 Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+90.94 (c =0.530 methanol) Appearance: pale yellow powder Example 52 N-(2-methoxy-1,1-dimethylethyl)-4-({(1S,2R)-2-[(2-methoxye thanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
FN
6 0 3 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 51.30 H: 7.46 N: 14.96 Found (%) C: 51.38 H: 7.18 N: 15.16 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+107.93 (c =0.580 methanol) Appearance: white powder Example 53 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-isobu tyl-6-methoxyquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 2 / 2 HCl / 2.8 H 2 0) Calculated (%) C: 49.31 H: 7.45 N: 15.68 Found (%) C: 49.27 H: 7.10 N: 15.33 Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+123.21 (c =0.560 methanol) Appearance: pale yellow powder 52 Example 54 N-isobutyl-6-methoxy-4-({(iS,2R)-2-[(2-methoxyethanimidoyl )amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation [a]2D =+130.87 (c =0.570 methanol) Appearance: white powder Example 55 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-(2-methoxy-1,1-dimethylethyl)-6-methylquinazolin-2 carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 3 / 2 HCl / 2.4 H 2 0) Calculated (%) C: 50.33 H: 7.53 N: 14.67 Found (%) C: 50.25 H: 7.30 N: 14.74 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+91.69 (c =0.530 methanol) Appearance: pale yellow powder Example 56 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-6-methy 1-[3-(methylthio)propyl]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0S / 2 HCl / 2.2 H 2 0) 53 Calculated (%) C: 48.83 H: 7.15 N: 15.53 Found (%) C: 48.77 H: 6.76 N: 15.23 Positive ion FAB-MS m/z: 429 [M+H]+ Specific rotation [a] D =+81.55 (c =0.645methanol) Appearance: pale yellow powder Example 57 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-6-methyl-N-(2,2,2-trifluoroethyl)quinazolin-2-carboxa mide dihydrochloride Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+109.54 (c =0.555 methanol) Appearance: pale yellow powder Example 58 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-isopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+108.07 (c =0.570 methanol) Appearance: pale yellow powder Example 59 4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide 54 dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / 3.4 H 2 0) Calculated (%) C: 47.90 H: 7.48 N: 14.57 Found (%) C: 48.24 H: 7.34 N: 14.22 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation []2 D =+89.92 (c =0.685 methanol) Appearance: pale yellow powder Example 60 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+27.49 (c =0.560 methanol) Appearance: white powder [00331 Example 61 N-(2-ethoxyethyl)-4-({(1S,2R)-2-[(3-hydroxypropanimidoyl)a mino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / 3.4 H 2 0) Calculated (%) C: 47.90 H: 7.48 N: 14.57 Found (%) C: 48.07 H: 7.13 N: 14.21 Positive ion FAB-MS m/z: 443 [M+H]+ 55 Specific rotation [a] D =+94.54 (c =0.605 methanol) Appearance: pale yellow powder Example 62 4-{[(1S,2R)-2-(n-butanimidoylamino)cyclohexyl]amino}-N-(3 methoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 2 / 2 HCl / 3.4 H 2 0) Calculated (%) C: 50.15 H: 7.86 N: 14.62 Found (%) C: 50.17 H: 7.48 N: 14.60 Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+97.57 (c =0.660 methanol) Appearance: pale yellow powder Example 63 N-(3-methoxypropyl)-6-methyl-4-({(1S,2R)-2-[(2-methylpropa nimidoyl)amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+61.88 (c =0.585 methanol) Appearance: white powder Example 64 4-({ (1R,2S)-2-[(3-hydroxypropanimidoyl)amino]cyclohexyl}am ino)-N-isopropyl-6-methylquinazolin-2-carboxamide 56 dihydrochloride Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation [a]"D =-113.42 (c =0.760 methanol) Appearance: pale yellow powder Example 65 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-isopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+13.23 (c =0.665 methanol) Appearance: pale yellow powder Example 66 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-(3-methoxypropyl)-6-methylquinazolin-2-car boxamide dihydrochloride Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation [a] D =+21.65 (c =0.665 methanol) Appearance: pale yellow powder Example 67 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cycl ohexyl}amino)-N-(2-methoxyethyl)-6-methylquinazolin-2-carb oxamide dihydrochloride 57 Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / H 2 0) Calculated (%) C: 51.78 H: 7.18 N: 15.75 Found (%) C: 51.79 H: 6.86 N: 15.83 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation []2 D =+4.44 (c =0.495 methanol) Appearance: white powder Example 68 6-chloro-N-cycloheptyl-4-{[(1S,2R)-2-(ethanimidoylamino)cy clohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 3 ClN 6 0 / 2 HCl / 2 H 2 0) Calculated (%) C: 50.93 H: 6.95 N: 14.85 Found (%) C: 50.58 H: 6.86 N: 14.48 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+99.35 (c =0.465 methanol) Appearance: white powder Example 69 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[N-hydroxyethanimido yl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 3
N
6 0 2 Cl / 2 HCl / 1.5 H 2 0) Calculated (%) C: 50.31 H: 6.68 N: 14.67 Found (%) C: 50.71 H: 6.85 N: 14.49 Positive ion FAB-MS m/z: 473 [M+H]+ 58 Specific rotation []2 D =+3.99 (c =0.501 methanol) Appearance: white powder Example 70 N-isobutyl-4-({ (1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyc lohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 2 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 50.73 H: 7.59 N: 15.43 Found (%) C: 50.81 H: 7.54 N: 15.59 Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+106.99 (c =0.529 methanol) Appearance: white powder [0034] Example 71 6-chloro-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclo hexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 18
H
2 3
N
6 0 2 Cl / 2 HCl / 3 H 2 0) Calculated (%) C: 41.75 H: 6.03 N: 16.23 Found (%) C: 41.85 H: 5.84 N: 16.22 Positive ion FAB-MS m/z: 391 [M+H]+ Specific rotation [a] D =+154.05 (c =0.518 methanol) Appearance: white powder 59 Example 72 6-chloro-N-methoxy-4-({(lS,2R)-2-[(2-methoxyethanimidoyl)a mino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as CigH 2 5
N
6 0 3 Cl / 2 HCl / 2.5 H 2 0) Calculated (%) C: 42.35 H: 5.99 N: 15.60 Found (%) C: 42.46 H: 6.41 N: 15.36 Positive ion FAB-MS m/z: 421 [M+H]+ Specific rotation []2 D =+21.20 (c =0.547 methanol) Appearance: white powder Example 73 N-n-butyl-6-chloro-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)a mino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 1
N
6 0 2 C1 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 48.31 H: 6.63 N: 15.37 Found (%) C: 48.56 H: 6.49 N: 15.41 Positive ion FAB-MS m/z: 447 [M+H]+ Specific rotation [a] D =+111.52 (c =0.538 methanol) Appearance: white powder Example 74 N-(2,2-dimethylpropyl)-4-{[(1S,2R)-2-(ethanimidoylamino)cy clohexyl]amino}-6-methylquinazolin-2-carboxamide 60 dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 53.92 H: 7.71 N: 16.40 Found (%) C: 54.31 H: 7.55 N: 15.98 Positive ion FAB-MS m/z: 411 [M+H]+ Specific rotation []2 D =+88.65 (c =0.467 methanol) Appearance: white powder Example 75 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-isobu tyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 54.61 H: 7.42 N: 17.37 Found (%) C: 54.85 H: 7.39 N: 17.00 Positive ion FAB-MS m/z: 397 [M+H]+ Specific rotation []2 D =+91.96 (c =0.523 methanol) Appearance: pale brown powder Example 76 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-6-methy 1-N-(2,2,2-trifluoroethyl)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 20
H
25
N
6 0F 3 / 2 HCl / 0.5 H 2 0) Calculated (%) C: 47.63 H: 5.60 N: 16.66 Found (%) C: 47.76 H: 5.74 N: 16.56 61 Positive ion FAB-MS m/z: 423 [M+H]* Specific rotation []2 D =+96.59 (c =0.528 methanol) Appearance: white powder Example 77 N-(cyclopentylmethyl)-4-({(1S,2R)-2-[(2-methoxyethanimidoy 1)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 6
N
6 0 2 / 2 HCl / 0 .7 H 2 0) Calculated (%) C: 55.61 H: 7.39 N: 15.56 Found (%) C: 55.72 H: 7.17 N: 15.58 Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+101.58 (c =0.443 methanol) Appearance: white powder Example 78 N-(cyclopentyl)-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amin o]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 3 / 2 HCl / 0.7 H 2 0) Calculated (%) C: 55.00 H: 7.19 N: 16.04 Found (%) C: 55.14 H: 7.22 N: 15.78 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation []2 D =+110.19 (c =0.559 methanol) Appearance: white powder 62 Example 79 N-(1,1-dimethylpropyl)-4-({ (iS,2R)-2-[(2-methoxyethanimido yl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamid e dihydrochloride Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+96.57 (c =0.497 methanol) Appearance: white powder Example 80 N-(2,2-dimethylpropyl)-4-{[(1S,2R)-2-(2-ethanimidoylamino) cyclohexyl]amino}-6-fluoroquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 1
N
6 0F / 2 HCl / 0.8 H 2 0) Calculated (%) C: 52.65 H: 6.95 N: 16.75 Found (%) C: 52.85 H: 7.13 N: 16.53 Positive ion FAB-MS m/z: 415 [M+H]+ Specific rotation []2 D =+47.88 (c =0.497 methanol) Appearance: white powder [0035] Example 81 4-{[(1S,2R)-2-(2-ethanimidoylamino)cyclohexyl]amino}-6-flu oro-N-(3-methoxy-2,2-dimethylpropyl)quinazolin-2-carboxami de dihydrochloride 63 Positive ion FAB-MS m/z: 445 [M+H]* Specific rotation []2 D =+43.24 (c =0.481 methanol) Appearance: white powder Example 82 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-is opropoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 2 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 52.29 H: 7.48 N: 15.91 Found (%) C: 52.07 H: 7.36 N: 15.89 Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+92.65 (c =0.490 methanol) Appearance: white powder Example 83 4-[((1S,2R)-2-{[N-hydroxyethanimidoyl]amino}cyclohexyl)ami no]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 2 / 2 HCl / H 2 0) Calculated (%) C: 52.48 H: 7.21 N: 16.69 Found (%) C: 52.71 H: 7.31 N: 16.64 Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+3.23 (c =0.556 methanol) Appearance: white powder 64 Example 84 N-(2-isopropoxyethyl)-4-({(lS,2R)-2-[(2-methoxy-2-methylpr opanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 26
H
40
N
6 0 3 / 2 HCl / H 2 0) Calculated (%) C: 54.26 H: 7.71 N: 14.60 Found (%) C: 54.48 H: 7.61 N: 14.71 Positive ion FAB-MS m/z: 485 [M+H]+ Specific rotation []2 D =+10.88 (c =0.551 methanol) Appearance: white powder Example 85 N-(2-isopropoxyethyl)-4-({(1S,2R)-2-[(2-methoxyethanimidoy 1)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 3 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 53.00 H: 7.34 N: 15.45 Found (%) C: 53.05 H: 7.50 N: 15.37 Positive ion FAB-MS m/z: 457 [M+H]+ Specific rotation []2 D =+119.91 (c =0.487 methanol) Appearance: white powder Example 86 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(3-is 65 opropoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 2 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 53.33 H: 7.65 N: 15.55 Found (%) C: 53.46 H: 7.49 N: 15.50 Positive ion FAB-MS m/z: 441 [M+H]* Specific rotation []2 D =+91.49 (c =0.529 methanol) Appearance: white powder Example 87 N-(3-isopropoxypropyl)-4-({ (1S,2R)-2-[(2-methoxyethanimido yl)amino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 3 / 2 HCl / 2 H 2 0) Calculated (%) C: 51.81 H: 7.65 N: 14.50 Found (%) C: 51.47 H: 7.30 N: 14.65 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+100.40 (c =0.500 methanol) Appearance: white powder Example 88 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-metho xy-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 371 [M+H]+ Specific rotation []2 D =+116.79 (c =0.500 methanol) 66 Appearance: white powder Example 89 N-methoxy-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cycl ohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 401 [M+H]+ Specific rotation [a]2D =+105.19 (c =0.500 methanol) Appearance: white powder Example 90 6-chloro-N-cycloheptyl-4-({ (1S,2R)-2-[(2-methoxyethanimido yl)amino]cyclohexyl}amino)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 25
H
35
N
6 0 2 Cl / 2 HCl / 1.4 H 2 0) Calculated (%) C: 51.31 H: 6.86 N: 14.36 Found (%) C: 51.30 H: 6.71 N: 14.20 Positive ion FAB-MS m/z: 487 [M+H]+ Specific rotation [a]2D =+107.38 (c =0.501 methanol) Appearance: white powder [0036] Example 91 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide 67 dihydrochloride Positive ion FAB-MS m/z: 429 [M+H]+ Specific rotation [a]2D =+114.85 (c =0.505 methanol) Appearance: white powder Example 92 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(3-me thoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+96.40 (c =0.500 methanol) Appearance: white powder Example 93 4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cyclohexyl}ami no)-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 49.29 H: 7.37 N: 14.99 Found (%) C: 49.15 H: 7.37 N: 14.93 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation []2 D =+107.57 (c =0.515 methanol) Appearance: white powder Example 94 68 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-et hoxyethyl) -6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 2 / 2 HCl / 2.6 H 2 0) Calculated (%) C: 49.64 H: 7.42 N: 15.79 Found (%) C: 49.27 H: 7.03 N: 15.60 Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation [a]2D =+105.74 (c =0.505 methanol) Appearance: white powder Example 95 N-(2-ethoxyethyl)-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)am ino]cyclohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 4
N
6 0 3 / 2 HCl / 1.3 H 2 0) Calculated (%) C: 51.26 H: 7.22 N: 15.59 Found (%) C: 51.20 H: 7.06 N: 15.55 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation [a]2D =+101.38 (c =0.505 methanol) Appearance: white powder Example 96 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(3-me thoxy-2,2-dimethylpropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 6
N
6 0 2 / 2 HCl / 1.9 H 2 0) 69 Calculated (%) C: 52.63 H: 7.69 N: 15.34 Found (%) C: 52.46 H: 7.39 N: 14.98 Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+83.07 (c =0.520 methanol) Appearance: white powder Example 97 N-(3-methoxy-2,2-dimethylpropyl)-4-({ (1S,2R)-2-[(2-methoxy ethanimidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2 carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 8
N
6 0 3 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 51.02 H: 7.71 N: 14.28 Found (%) C: 50.84 H: 7.32 N: 14.18 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+95.68 (c =0.510 methanol) Appearance: white powder Example 98 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-fu rylmethyl) -6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
2 8
N
6 0 2 / 2 HCl / 3 H 2 0) Calculated (%) C: 50.46 H: 6.63 N: 15.35 Found (%) C: 50.61 H: 6.24 N: 15.36 Positive ion FAB-MS m/z: 421 [M+H]+ Specific rotation []2 D =+100.00 (c =0.510 methanol) 70 Appearance: white powder Example 99 4-{[(lS,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(tran s-4-hydroxycyclohexyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 2 / 2 HCl / 3.6 H 2 0) Calculated (%) C: 50.02 H: 7.55 N: 14.58 Found (%) C: 50.35 H: 7.22 N: 14.21 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation []2 D =+70.58 (c =0.510 methanol) Appearance: white powder Example 100 N-(trans-4-hydroxycyclohexyl)-4-({ (1S,2R)-2-[(2-methoxyeth animidoyl)amino]cyclohexyl}amino)-6-methylquinazolin-2-car boxamide dihydrochloride Positive ion FAB-MS m/z: 469 [M+H]+ Specific rotation []2 D =+103.59 (c =0.500 methanol) Appearance: white powder [0037] Example 101 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-isopr opyl-6-methylquinazolin-2-carboxamide dihydrochloride 71 Positive ion FAB-MS m/z: 383 [M+H]* Specific rotation []2 D =+107.32 (c =0.505 methanol) Appearance: white powder Example 102 N-isopropyl-4-({(1S,2R)-2-[(2-methoxyethanimidoyl)amino]cy clohexyl}amino)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
6 0 2 / 2 HCl / 2 H 2 0) Calculated (%) C: 50.67 H: 7.34 N: 16.12 Found (%) C: 50.94 H: 7.15 N: 16.38 Positive ion FAB-MS m/z: 413 [M+H]+ Specific rotation []2 D =+127.05 (c =0.510 methanol) Appearance: white powder Example 103 4-{[(1S,2R)-2-(ethanimidoylamino)cyclohexyl]amino}-N-(2-fl uoroethyl) -6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 0
H
2 7
N
6 0F / 2 HCl / 2.5 H 2 0) Calculated (%) C: 47.62 H: 6.79 N: 16.66 Found (%) C: 47.59 H: 6.56 N: 16.44 Positive ion FAB-MS m/z: 387 [M+H]+ Specific rotation []2 D =+114.79 (c =0.500 methanol) Appearance: pale brown powder 72 Example 104 4-{[(lS,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 2 / 2 HCl / 1.1 H 2 0) Calculated (%) C: 54.26 H: 7.25 N: 15.82 Found (%) C: 54.27 H: 7.57 N: 15.58 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation []2 D =+83.61 (c =0.476 methanol) Appearance: white powder Example 105 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 425 [M+H]+ Specific rotation []2 D =+79.21 (c =0.510 methanol) Appearance: white powder Example 106 N-(cyclopropylmethyl)-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol -5-ylamino)cyclohexyl]amino}-6-methylquinazolin-2-carboxam ide dihydrochloride Elemental analysis value (as C 2 4
H
3 2
N
6 0 / 2 HCl / 1.4 H 2 0) Calculated (%) C: 55.57 H: 7.15 N: 16.20 73 Found (%) C: 55.53 H: 7.00 N: 16.13 Positive ion FAB-MS m/z: 421 [M+H]* Specific rotation []2 D =+90.67 (c =0.536 methanol) Appearance: white powder Example 107 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-ethylbutyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 57.86 H: 7.81 N: 15.57 Found (%) C: 57.81 H: 7.90 N: 15.34 Positive ion FAB-MS m/z: 451 [M+H]+ Specific rotation []2 D =+81.48 (c =0.540 methanol) Appearance: white powder Example 108 N-(cyclohexylmethyl)-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol 5-ylamino)cyclohexyl]amino}-6-methylquinazolin-2-carboxami de dihydrochloride Elemental analysis value (as C 2 7
H
3 8
N
6 0 / 2 HCl / 1.4 H 2 0) Calculated (%) C: 57.83 H: 7.69 N: 14.99 Found (%) C: 58.09 H: 7.74 N: 14.70 Positive ion FAB-MS m/z: 463 [M+H]+ Specific rotation []2 D =+78.36 (c =0.513 methanol) 74 Appearance: white powder Example 109 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2,2-dimethylpropyl)6-methylquinazolin-2-carboxam ide dihydrochloride Elemental analysis value (as C 2 5
H
3 6
N
6 0 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 55.41 H: 7.74 N: 15.51 Found (%) C: 55.41 H: 7.78 N: 15.51 Positive ion FAB-MS m/z: 437 [M+H]+ Specific rotation []2 D =+75.72 (c =0.486 methanol) Appearance: white powder Example 110 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-[(1R,2R)-2-methoxycyclohexyl]-6-methylquinazolin 2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 8
N
6 0 2 / 2 HCl / 2.1 H 2 0) Calculated (%) C: 55.02 H: 7.56 N: 14.26 Found (%) C: 55.08 H: 7.48 N: 14.23 Positive ion FAB-MS m/z: 479 [M+H]+ Specific rotation []2 D =+61.50 (c =0.517 methanol) Appearance: white powder [0038] 75 Example 111 4-{[(lS,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-ethyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 0
N
6 0 / 2 HCl / 2 H 2 0) Calculated (%) C: 50.32 H: 7.37 N: 16.00 Found (%) C: 50.40 H: 7.14 N: 15.65 Positive ion FAB-MS m/z: 395 [M+H]+ Specific rotation []2 D =+95.73 (c =0.539 methanol) Appearance: white powder Example 112 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-[1-(methoxymethyl)cyclohexyl]-6-methylquinazolin 2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
4 0
N
6 0 2 / 2 HCl / 1.7 H 2 0) Calculated (%) C: 56.41 H: 7.68 N: 14.10 Found (%) C: 56.45 H: 7.65 N: 13.84 Positive ion FAB-MS m/z: 493 [M+H]+ Specific rotation []2 D =+57.51 (c =0.532 methanol) Appearance: white powder Example 113 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-ethylbutyl)-6-methoxyquinazolin-2-carboxamide 76 dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 2 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 54.94 H: 7.66 N: 14.79 Found (%) C: 55.02 H: 7.30 N: 14.58 Positive ion FAB-MS m/z: 467 [M+H]+ Specific rotation [a]2D =+114.98 (c =0.534 methanol) Appearance: white powder Example 114 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-[(1R)-1-(methoxymethyl)-2-methylpropyl]-6-methylq uinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 2 / 2 HCl / 2.3 H 2 0) Calculated (%) C: 53.75 H: 7.74 N: 14.47 Found (%) C: 53.65 H: 7.48 N: 14.52 Positive ion FAB-MS m/z: 467 [M+H]+ Specific rotation []2 D =+75.61 (c =0.529 methanol) Appearance: white powder Example 115 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-ethylpropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 6
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 56.53 H: 7.67 N: 15.82 77 Found (%) C: 56.55 H: 7.62 N: 15.55 Positive ion FAB-MS m/z: 437 [M+H]* Specific rotation []2 D =+91.09 (c =0.494 methanol) Appearance: white powder Example 116 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2,2-dimethylpropyl)-6-fluoroquinazolin-2-carboxa mide dihydrochloride Elemental analysis value (as C 2 4
H
3 3
N
6 0F / 2 HCl / H 2 0) Calculated (%) C: 54.24 H: 7.02 N: 15.81 Found (%) C: 54.47 H: 6.71 N: 15.56 Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+41.26 (c =0.504 methanol) Appearance: white powder Example 117 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-fluoro-N-isobutylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 1
N
6 0F / 2 HCl / 1.3 H 2 0) Calculated (%) C: 52.83 H: 6.86 N: 16.07 Found (%) C: 52.88 H: 6.76 N: 15.74 Positive ion FAB-MS m/z: 427 [M+H]+ Specific rotation []2 D =+48.82 (c =0.512 methanol) 78 Appearance: white powder Example 118 4-{[(lS,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-fluoro-N-(3-methoxy-2,2-dimethylpropyl)quinazolin -2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 5
N
6 0 2 F / 2 HCl / H 2 0) Calculated (%) C: 53.48 H: 7.00 N: 14.97 Found (%) C: 53.59 H: 6.98 N: 14.69 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+33.88 (c =0.543 methanol) Appearance: white powder Example 119 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-[2-methoxy-1-(methoxymethyl)-1-methylethyl]-6-met hylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 3 / 2 HCl / 1.9 H 2 0) Calculated (%) C: 52.95 H: 7.49 N: 14.25 Found (%) C: 52.91 H: 7.36 N: 14.02 Positive ion FAB-MS m/z: 483 [M+H]+ Specific rotation []2 D =+69.64 (c =0.560 methanol) Appearance: white powder Example 120 79 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 7
H
3 2
N
6 0 2 / 2 HCl / 2.7 H 2 0) Calculated (%) C: 54.58 H: 6.68 N: 14.14 Found (%) C: 54.47 H: 7.02 N: 14.25 Positive ion FAB-MS m/z: 473 [M+H]+ Specific rotation []2 D =+34.84 (c =0.683 methanol) Appearance: yellow powder [00391 Example 121 N-n-butyl-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)c yclohexyl]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 24
H
3 4
N
6 0 / 2 HCl / 2 H 2 0) Calculated (%) C: 54.23 H: 7.59 N: 15.81 Found (%) C: 54.36 H: 7.36 N: 15.62 Positive ion FAB-MS m/z: 423 [M+H]+ Specific rotation []2 D =+86.93 (c =0.773 methanol) Appearance: white powder Example 122 N-n-butyl-6-methyl-4-{[(1S,2R)-2-(3,4,5,6-tetrahydropyridi n-2-ylamino)cyclohexyl]amino}quinazolin-2-carboxamide 80 dihydrochloride Elemental analysis value (as C 25
H
36
N
6 0 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 57.12 H: 7.63 N: 15.99 Found (%) C: 57.25 H: 7.64 N: 15.79 Positive ion FAB-MS m/z: 437 [M+H]+ Specific rotation [a]2D =+100.57 (c =0.696 methanol) Appearance: white powder Example 123 N-n-butyl-6-methyl-4-{[(1S,2R)-2-(3,4,5,6-tetrahydro-2H-az epin-7-ylamino)cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 56.54 H: 7.88 N: 15.21 Found (%) C: 56.53 H: 7.60 N: 15.28 Positive ion FAB-MS m/z: 451 [M+H]+ Specific rotation []2 D =+85.02 (c =0.741 methanol) Appearance: white powder Example 124 6-chloro-N-cycloheptyl-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrro 1-5-ylamino)cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
35 ClN 6 0 / 2 HCl / 2 H 2 0) Calculated (%) C: 52.75 H: 6.98 N: 14.20 81 Found (%) C: 52.97 H: 6.86 N: 14.37 Positive ion FAB-MS m/z: 483 [M+H]+ Specific rotation []2 D =+67.28 (c =0.535 methanol) Appearance: white powder Example 125 N-n-butyl-6-chloro-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5 ylamino)cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 1 ClN 6 0 / 2 HCl / H 2 0) Calculated (%) C: 51.84 H: 6.61 N: 15.74 Found (%) C: 51.82 H: 6.74 N: 15.71 Positive ion FAB-MS m/z: 443 [M+H]+ Specific rotation []2 D =+88.64 (c =0.546 methanol) Appearance: white powder Example 126 N-cycloheptyl-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylami no)cyclohexyl]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
38
N
6 0 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 57.64 H: 7.70 N: 14.94 Found (%) C: 57.52 H: 7.78 N: 14.90 Positive ion FAB-MS m/z: 463 [M+H]+ Specific rotation []2 D =+67.56 (c =0.447 methanol) 82 Appearance: white powder Example 127 6-chloro-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cy clohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 1 9
H
2 3 ClN 6 0 / 2 HCl / 1.3 H 2 0) Calculated (%) C: 47.23 H: 5.76 N: 17.39 Found (%) C: 47.21 H: 5.99 N: 17.20 Positive ion FAB-MS m/z: 387 [M+H]+ Specific rotation [a]2D =+104.23 (c =0.520 methanol) Appearance: white powder Example 128 6-chloro-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cy clohexyl]amino}-N-methoxyquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 0
H
2 5 ClN 6 0 2 / 2 HCl / 1.3 H 2 0) Calculated (%) C: 46.80 H: 5.81 N: 16.37 Found (%) C: 46.87 H: 5.55 N: 16.30 Positive ion FAB-MS m/z: 417 [M+H]+ Specific rotation [a] D =+53.81 (c =0.524 methanol) Appearance: white powder Example 129 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] 83 amino}-N-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazolin -2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
38
N
6 0 2 / 2 HCl / H 2 0) Calculated (%) C: 56.01 H: 7.59 N: 15.07 Found (%) C: 55.96 H: 7.85 N: 14.85 Positive ion FAB-MS m/z: 467 [M+H]+ Specific rotation []2 D =+71.08 (c =0.543 methanol) Appearance: white powder Example 130 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 24
H
3 4
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 55.94 H: 7.47 N: 16.31 Found (%) C: 55.89 H: 7.64 N: 16.24 Positive ion FAB-MS m/z: 423 [M+H]+ Specific rotation []2 D =+93.53 (c =0.464 methanol) Appearance: white powder [0040] Example 131 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-isopropoxyethyl)-6-methylquinazolin-2-carboxam ide dihydrochloride 84 Elemental analysis value (as C 2 5
H
3 6
N
6 0 2 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 54.17 H: 7.49 N: 15.16 Found (%) C: 54.27 H: 7.39 N: 15.21 Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+95.25 (c =0.527 methanol) Appearance: white powder Example 132 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-methyl-N-[2-(methylthio)ethyl]quinazolin-2-carbox amide dihydrochloride Elemental analysis value (as C 2 3
H
3 2
N
6 0S / 2 HCl / 1.3 H 2 0) Calculated (%) C: 51.45 H: 6.87 N: 15.65 Found (%) C: 51.52 H: 6.96 N: 15.47 Positive ion FAB-MS m/z: 441 [M+H]+ Specific rotation []2 D =+88.30 (c =0.530 methanol) Appearance: white powder Example 133 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-methoxy-1,1-dimethylethyl)-6-methylquinazolin 2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 453 [M+H]+ Specific rotation []2 D =+64.62 (c =0.489 methanol) Appearance: white powder 85 Example 134 4-{[(lS,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-{[1-(methoxymethyl)cyclohexyl]methyl}-6-methylqui nazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 9
H
4 2
N
6 0 2 / 2 HCl / 1.4 H 2 0) Calculated (%) C: 57.59 H: 7.80 N: 13.89 Found (%) C: 57.64 H: 7.79 N: 13.67 Positive ion FAB-MS m/z: 507 [M+H]+ Specific rotation []2 D =+54.23 (c =0.531 methanol) Appearance: white powder Example 135 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-methyl-N-(2-piperidin-1-ylethyl)quinazolin-2-carb oxamide trihydrochloride Elemental analysis value (as C 2 7
H
3 9
N
7 0 / 3 HCl / 2.1 H 2 0) Calculated (%) C: 51.90 H: 7.45 N: 15.69 Found (%) C: 52.10 H: 7.77 N: 15.40 Positive ion FAB-MS m/z: 478 [M+H]+ Specific rotation []2 D =+111.91 (c =0.470 methanol) Appearance: white powder Example 136 N-cyclopentyl-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylami 86 no)cyclohexyl]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 4
N
6 0 / 2 HCl / 2.4 H 2 0) Calculated (%) C: 54.52 H: 7.47 N: 15.26 Found (%) C: 54.64 H: 7.12 N: 15.07 Positive ion FAB-MS m/z: 435 [M+H]+ Specific rotation []2 D =+86.87 (c =0.541 methanol) Appearance: white powder Example 137 N-tert-butyl-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamin o)cyclohexyl]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 24
H
3 4
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 55.74 H: 7.48 N: 16.25 Found (%) C: 55.81 H: 7.68 N: 16.00 Positive ion FAB-MS m/z: 423 [M+H]+ Specific rotation []2 D =+79.42 (c =0.491 methanol) Appearance: white powder Example 138 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(trans-4-methoxycyclohexyl)-6-methylquinazolin-2 carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 8
N
6 0 2 / 2 HCl / 1.5 H 2 0) 87 Calculated (%) C: 56.05 H: 7.49 N: 14.53 Found (%) C: 56.15 H: 7.56 N: 14.48 Positive ion FAB-MS m/z: 479 [M+H]+ Specific rotation []2 D =+77.12 (c =0.542 methanol) Appearance: white powder Example 139 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-methyl-N-(tetrahydro-2H-pyran-4-yl)quinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 4
N
6 0 2 / 2 HCl / 1.4 H 2 0) Calculated (%) C: 54.72 H: 7.13 N: 15.32 Found (%) C: 55.01 H: 7.10 N: 14.93 Positive ion FAB-MS m/z: 451 [M+H]+ Specific rotation []2 D =+80.15 (c =0.519 methanol) Appearance: white powder Example 140 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-isopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 2
N
6 0 / 2 HCl / 1.3 H 2 0) Calculated (%) C: 54.72 H: 7.31 N: 16.65 Found (%) C: 54.94 H: 7.45 N: 16.29 Positive ion FAB-MS m/z: 409 [M+H]+ 88 Specific rotation []2 D =+96.16 (c =0.547 methanol) Appearance: white powder [0041] Example 141 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(cis-4-methoxycyclohexyl)-6-methylquinazolin-2-ca rboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 8
N
6 0 2 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 54.36 H: 7.60 N: 14.09 Found (%) C: 54.39 H: 7.31 N: 13.99 Positive ion FAB-MS m/z: 479 [M+H]+ Specific rotation []2 D =+68.99 (c =0.516 methanol) Appearance: white powder Example 142 N-[(1-acetylpiperidin-4-yl)methyl]-4-{[(1S,2R)-2-(3,4-dihy dro-2H-pyrrol-5-ylamino)cyclohexyl]amino}-6-methylquinazol in-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 9
N
7 0 2 / 2 HCl / 2.2 H 2 0) Calculated (%) C: 54.40 H: 7.40 N: 15.86 Found (%) C: 54.73 H: 7.48 N: 15.48 Positive ion FAB-MS m/z: 506 [M+H]+ Specific rotation []2 D =+74.33 (c =0.487 methanol) Appearance: white powder 89 Example 143 4-[((lS,2R)-2-{[(3R)-3-hydroxy-3,4-dihydro-2H-pyrrol-5-yl] amino}cyclohexyl)amino]-N-isobutyl-6-methylquinazolin-2-ca rboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 2 / 2 HCl / 0.4 H 2 0) Calculated (%) C: 55.57 H: 7.15 N: 16.20 Found (%) C: 55.66 H: 7.39 N: 16.07 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation [a]2D =+109.62 (c =0.478 methanol) Appearance: pale brown powder Example 144 4-[((1S,2R)-2-{[(3S)-3-hydroxy-3,4-dihydro-2H-pyrrol-5-yl] amino}cyclohexyl)amino]-N-isobutyl-6-methylquinazolin-2-ca rboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 2 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 54.63 H: 7.22 N: 15.93 Found (%) C: 54.90 H: 7.15 N: 15.61 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation []2 D =+51.83 (c =0.710 methanol) Appearance: pale brown powder Example 145 6-chloro-N-cycloheptyl-4-({(1S,2R)-2-[(2-oxo-3,4-dihydro-2 90 H-pyrrol-5-yl)amino]cyclohexyl}amino)quinazolin-2-carboxam ide dihydrochloride Elemental analysis value (as C 2 6
H
3 3
N
6 0 2 Cl / 2 HCl / 1.5 H 2 0) Calculated (%) C: 52.31 H: 6.42 N: 14.08 Found (%) C: 52.38 H: 6.51 N: 14.11 Positive ion FAB-MS m/z: 497 [M+H]+ Specific rotation [a]2D =+133.62 (c =0.464 methanol) Appearance: white powder Example 146 N-(tert-butoxy)-6-chloro-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyr rol-5-ylamino)cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 1
N
6 0 2 C1 / 2 HCl / H 2 0) Calculated (%) C: 50.23 H: 6.42 N: 15.28 Found (%) C: 49.97 H: 6.35 N: 14.99 Positive ion FAB-MS m/z: 459 [M+H]+ Specific rotation []2 D =+74.84 (c =0.473 methanol) Appearance: white powder Example 147 N-(cyclopentylmethyl)-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol -5-ylamino)cyclohexyl]amino}-6-methylquinazolin-2-carboxam ide dihydrochloride Elemental analysis value (as C 26
H
36
N
6 0 / 2 HCl / H 2 0) 91 Calculated (%) C: 55.65 H: 7.62 N: 14.98 Found (%) C: 55.58 H: 7.24 N: 14.84 Positive ion FAB-MS m/z: 449 [M+H]+ Specific rotation []2 D =+51.66 (c =0.542 methanol) Appearance: white powder Example 148 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-methyl-N-[3-(methylthio)propyl]quinazolin-2-carbo xamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0S / 2 HCl / H 2 0) Calculated (%) C: 52.84 H: 7.02 N: 15.40 Found (%) C: 52.83 H: 7.11 N: 15.33 Positive ion FAB-MS m/z: 455 [M+H]+ Specific rotation []2 D =+82.04 (c =0.529 methanol) Appearance: white powder Example 149 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(2-furylmethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 0
N
6 0 2 / 2 HCl / H 2 0) Calculated (%) C: 55.87 H: 6.38 N: 15.64 Found (%) C: 56.09 H: 6.66 N: 15.26 Positive ion FAB-MS m/z: 447 [M+H]+ 92 Specific rotation []2 D =+89.45 (c =0.474 methanol) Appearance: white powder Example 150 N-(tert-butoxy)-4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-yla mino)cyclohexyl]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
6 0 2 / 2 HCl / 0.7 H 2 0) Calculated (%) C: 55.00 H: 7.19 N: 16.04 Found (%) C: 55.00 H: 7.15 N: 15.96 Positive ion FAB-MS m/z: 439 [M+H]+ Specific rotation [a] D =+85.48 (c =0.496 methanol) Appearance: white powder [0042] Example 151 4-{[(1S,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-6-methyl-N-(2,2,2-trifluoroethyl)quinazolin-2-carbo xamide dihydrochloride Elemental analysis value (as C 2 2
H
2 7
N
6 0F 3 / 2 HCl / 0.7 H 2 0) Calculated (%) C: 49.48 H: 5.74 N: 15.74 Found (%) C: 49.37 H: 5.72 N: 15.48 Positive ion FAB-MS m/z: 449 [M+H]+ Specific rotation []2 D =+104.62 (c =0.541 methanol) Appearance: white powder 93 Example 152 4-{[(lS,2R)-2-(3,4-dihydro-2H-pyrrol-5-ylamino)cyclohexyl] amino}-N-(trans-4-hydroxycyclohexyl)-6-methylquinazolin-2 carboxamide dihydrochloride Positive ion FAB-MS m/z: 465 [M+H]+ Specific rotation [a]2 D =+72.65 (c =0.490 methanol) Appearance: white powder Example 153 N-(4-methoxyphenyl)-6-methyl-4-{[(1S,2R)-2-(pyridin-2-ylam ino)cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 0
N
6 0 2 / 2 HCl / H 2 0) Calculated (%) C: 58.64 H: 5.98 N: 14.65 Found (%) C: 58.44 H: 5.90 N: 14.67 Positive ion FAB-MS m/z: 482 [M+H]+ Appearance: pale brown powder Example 154 N-isobutyl-6-methyl-4-{[(1S,2R)-2-(pyridin-2-ylamino)cyclo hexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 2
N
6 0 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 56.39 H: 7.00 N: 15.78 Found (%) C: 56.46 H: 6.74 N: 15.84 94 Positive ion FAB-MS m/z: 432 [M+H]* Appearance: yellow powder Example 155 6-chloro-4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cyclohe xyl)amino]-N-[2-(4-methoxyethyl)ethyl]quinazolin-2-carboxa mide dihydrochloride Elemental analysis value (as C 3 1
H
3 3
N
6 0 2 C1 / 2 HCl / 2.4 H 2 0) Calculated (%) C: 55.30 H: 5.96 N: 12.48 Found (%) C: 55.26 H: 5.72 N: 12.25 Positive ion FAB-MS m/z: 557 [M+H]+ Specific rotation [a] D =+78.95 (c =0.537 methanol) Appearance: pale brown powder Example 156 6-chloro-N-(cyclopentylmethyl)-4-[((1S,2R)-2-{[imino(pheny 1)methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 3
N
6 OCl / 2 HCl / 0.8 H 2 0) Calculated (%) C: 56.77 H: 6.23 N: 14.19 Found (%) C: 56.81 H: 6.14 N: 13.91 Positive ion FAB-MS m/z: 505 [M+H]+ Specific rotation [a] D =+94.71 (c =0.549 methanol) Appearance: white powder 95 Example 157 6-chloro-N-(3,3-dimethylbutyl)-4-[((lS,2R)-2-{[imino(pheny 1)methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 5
N
6 OCl / 2 HCl / 0.8 H 2 0) Calculated (%) C: 56.58 H: 6.55 N: 14.14 Found (%) C: 56.47 H: 6.48 N: 14.26 Positive ion FAB-MS m/z: 507 [M+H]+ Specific rotation [a]2D =+103.51 (c =0.398 methanol) Appearance: white powder Example 158 6-chloro-N-(3-fluorobenzyl)-4-[((1S,2R)-2-{[imino(phenyl)m ethyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 9
H
2 8
N
6 OClF / 2 HCl / 1.5 H 2 0) Calculated (%) C: 55.20 H: 5.28 N: 13.32 Found (%) C: 55.22 H: 5.21 N: 13.00 Positive ion FAB-MS m/z: 531 [M+H]+ Specific rotation []2 D =+91.81 (c =0.501 methanol) Appearance: white powder Example 159 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide 96 dihydrochloride Elemental analysis value (as C 2 5
H
3 2
N
6 0 3 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 54.23 H: 6.52 N: 15.18 Found (%) C: 54.28 H: 6.50 N: 15.15 Positive ion FAB-MS m/z: 465 [M+H]+ Specific rotation [a]2 D =+76.07 (c =0.510 methanol) Appearance: white powder Example 160 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 0
N
6 0 3 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 52.89 H: 6.36 N: 15.42 Found (%) C: 52.94 H: 6.28 N: 15.29 Positive ion FAB-MS m/z: 451 [M+H]+ Specific rotation [a]2 D =+104.31 (c =0.533 methanol) Appearance: white powder [00431 Example 161 N-(cyclohexylmethyl)-4-[((1S,2R)-2-{[imino(pyridin-2-yl)me thyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxam ide dihydrochloride Positive ion FAB-MS m/z: 476 [M+H]+ 97 Specific rotation []2 D =+53.58 (c =0.530 methanol) Appearance: white powder Example 162 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-isopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 446 [M+H]+ Specific rotation [a] D =+93.55 (c =0.543 methanol) Appearance: white powder Example 163 N-(2-ethylbutyl)-4-[((1S,2R)-2-{[2-furyl(imino)methyl]amin olcyclohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 6
N
6 0 2 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 56.25 H: 7.17 N: 14.58 Found (%) C: 56.21 H: 6.96 N: 14.43 Positive ion FAB-MS m/z: 477 [M+H]+ Specific rotation [H] D =+58.41 (c =0.517 methanol) Appearance: white powder Example 164 N-(2-ethylbutyl)-4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl ]amino cyclohexyl)amino]-6-methylquinazolin-2-carboxamide 98 dihydrochloride Elemental analysis value (as C 2 8
H
3 7
N
7 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 57.77 H: 7.17 N: 16.84 Found (%) C: 57.88 H: 7.16 N: 16.54 Positive ion FAB-MS m/z: 488 [M+H]+ Specific rotation []2 D =+57.76 (c =0.554 methanol) Appearance: white powder Example 165 N-(cyclopropylmethyl)-4-[((1S,2R)-2-{[2-furyl(imino)methyl ]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 0
N
6 0 2 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 55.49 H: 6.41 N: 15.53 Found (%) C: 55.44 H: 6.34 N: 15.42 Positive ion FAB-MS m/z: 447 [M+H]+ Specific rotation []2 D =+72.26 (c =0.476 methanol) Appearance: white powder Example 166 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxami de dihydrochloride Positive ion FAB-MS m/z: 476 [M+H]+ Specific rotation [a] D =+72.40 (c =0.511 methanol) 99 Appearance: white powder Example 167 N-(2,2-dimethylpropyl)-4-[((1S,2R)-2-{[2-furyl(imino)methy 1]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 4
N
6 0 2 / 2 HCl / 0.9 H 2 0) Calculated (%) C: 56.60 H: 6.91 N: 15.23 Found (%) C: 56.57 H: 6.74 N: 15.18 Positive ion FAB-MS m/z: 463 [M+H]+ Specific rotation []2 D =+67.63 (c =0.482 methanol) Appearance: white powder Example 168 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 6
N
6 0 3 / 2 HCl / 1.4 H 2 0) Calculated (%) C: 54.90 H: 6.96 N: 14.23 Found (%) C: 55.04 H: 6.90 N: 13.92 Positive ion FAB-MS m/z: 493 [M+H]+ Specific rotation []2 D =+58.92 (c =0.482 methanol) Appearance: white powder Example 169 100 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-[l-(methoxymethyl)cyclohexyl]-6-methylquinazolin-2-ca rboxamide dihydrochloride Elemental analysis value (as C 2 9
H
3 8
N
6 0 3 / 2 HCl / 2 H 2 0) Calculated (%) C: 55.50 H: 7.07 N: 13.39 Found (%) C: 55.53 H: 6.81 N: 13.14 Positive ion FAB-MS m/z: 519 [M+H]+ Specific rotation []2 D =+77.88 (c =0.416 methanol) Appearance: white powder Example 170 N-ethyl-4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohe xyl) amino] -6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
2 8
N
6 0 2 / 2 HCl / 2.7 H 2 0) Calculated (%) C: 50.96 H: 6.58 N: 15.50 Found (%) C: 50.98 H: 6.18 N: 15.15 Positive ion FAB-MS m/z: 421 [M+H]+ Specific rotation []2 D =+86.40 (c =0.537 methanol) Appearance: white powder [0044] Example 171 4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cyclohexyl)amino ]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxamide dihydrochloride 101 Elemental analysis value (as C 3 0
H
3 2
N
6 0 2 / 2 HCl / 2.6 H 2 0) Calculated (%) C: 57.34 H: 6.29 N: 13.37 Found (%) C: 57.34 H: 6.15 N: 13.47 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation []2 D =+12.54 (c =0.606 methanol) Appearance: pale yellow powder Example 172 N-n-butyl-4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cycloh exyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 4
N
6 0 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 57.87 H: 7.05 N: 15.00 Found (%) C: 57.80 H: 7.02 N: 14.82 Positive ion FAB-MS m/z: 459 [M+H]+ Specific rotation []2 D =+75.63 (c =0.788 methanol) Appearance: white powder Example 173 N-n-butyl-6-methyl-4-[((1S,2R)-2-{[(methylimino) (phenyl)me thyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 6
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 59.30 H: 7.18 N: 14.82 Found (%) C: 59.22 H: 6.96 N: 14.94 102 Positive ion FAB-MS m/z: 473 [M+H]* Specific rotation []2 D =+29.53 (c =0.684 methanol) Appearance: white powder Example 174 N-n-butyl-4-{[(iS,2R)-2-(1H-isoindol-3-ylamino)cyclohexyl] amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 4
N
6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 59.51 H: 6.85 N: 14.87 Found (%) C: 59.70 H: 6.76 N: 14.81 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation [a] D =+46.63 (c =0.609 methanol) Appearance: pale yellow powder Example 175 N-n-butyl-4-[((1S,2R)-2-{[(hydroxyimino) (phenyl)methyl]ami nolcyclohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 4
N
6 0 2 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 57.71 H: 6.74 N: 14.96 Found (%) C: 57.77 H: 6.63 N: 15.03 Positive ion FAB-MS m/z: 475 [M+H]+ Specific rotation [H] D =+3.13 (c =0.511 methanol) Appearance: white powder 103 Example 176 4-[((lS,2R)-2-{[[2-(dimethylamino)phenyl] (imino)methyl]ami no}cyclohexyl)amino]-N-(4-methoxyphenyl)-6-methylquinazoli n-2-carboxamide trihydrochloride Elemental analysis value (as C 3 2
H
3 7
N
7 0 2 / 3 HCl / H 2 0) Calculated (%) C: 56.60 H: 6.23 N: 14.44 Found (%) C: 56.78 H: 6.24 N: 14.35 Positive ion FAB-MS m/z: 552 [M+H]* Specific rotation []2 D =+21.93 (c =0.547 methanol) Appearance: pale yellow powder Example 177 4-[((1S,2R)-2-{[(3-fluorophenyl) (imino)methyl]amino}cycloh exyl)amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carbo xamide dihydrochloride Elemental analysis value (as C 3 0
H
3 1
FN
6 0 2 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 58.69 H: 5.68 N: 13.69 Found (%) C: 58.83 H: 5.55 N: 13.42 Positive ion FAB-MS m/z: 527 [M+H]* Specific rotation [a] D =+12.78 (c =0.735 methanol) Appearance: pale yellow powder Example 178 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxamide 104 dihydrochloride Elemental analysis value (as C 2 8
H
3 0
N
6 0 3 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 56.20 H: 5.89 N: 14.04 Found (%) C: 56.22 H: 5.83 N: 13.82 Positive ion FAB-MS m/z: 499 [M+H]+ Specific rotation []2 D =+1.86 (c =0.642 methanol) Appearance: pale yellow powder Example 179 N-n-butyl-6-chloro-4-[((1S,2R)-2-{[imino(phenyl)methyl]ami no}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 26
H
31 ClN 6 0 / 2 HCl / 0.5 H 2 0) Calculated (%) C: 55.67 H: 6.11 N: 14.98 Found (%) C: 55.68 H: 6.17 N: 14.86 Positive ion FAB-MS m/z: 479 [M+H]+ Specific rotation []2 D =+89.76 (c =0.684 methanol) Appearance: white powder Example 180 N-n-butyl-4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cycloh exyl)amino]-6-methoxyquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 4
N
6 0 2 / 2 HCl / 1.25 H 2 0) Calculated (%) C: 56.89 H: 6.81 N: 14.74 105 Found (%) C: 56.82 H: 6.65 N: 14.64 Positive ion FAB-MS m/z: 475 [M+H]+ Specific rotation [a]21D =+108.39 (c =0.679 methanol) Appearance: white powder [0045] Example 181 4-[((1S,2S)-2-{[imino(phenyl)methyl]amino}cyclohexyl)amino ]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 3 0
H
3 2
N
6 0 2 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 59.74 H: 6.08 N: 13.93 Found (%) C: 59.73 H: 5.99 N: 13.94 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation [a]2 D =+40.36 (c =0.654 methanol) Appearance: pale yellow powder Example 182 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[imino(phenyl)methyl ]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 9
H
35 ClN 6 0 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 56.76 H: 6.47 N: 13.70 Found (%) C: 56.84 H: 6.31 N: 13.66 Positive ion FAB-MS m/z: 519 [M+H]+ 106 Specific rotation [a]2D =+100.55 (c =0.537 methanol) Appearance: white powder Example 183 N-cycloheptyl-4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cy clohexyl)amino]-6-methoxyquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 30
H
38
N
6 0 2 / 2 HCl / 1.3 H 2 0) Calculated (%) C: 58.97 H: 7.03 N: 13.75 Found (%) C: 58.95 H: 6.85 N: 13.76 Positive ion FAB-MS m/z: 515 [M+H]+ Specific rotation [a]20D =+109.66 (c =0.538 methanol) Appearance: white powder Example 184 N-cycloheptyl-4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cy clohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 3 0
H
3 8
N
6 0 / 2 HCl / 2 H 2 0) Calculated (%) C: 59.30 H: 7.30 N: 13.83 Found (%) C: 59.12 H: 7.03 N: 13.99 Positive ion FAB-MS m/z: 499 [M+H]+ Specific rotation []2 OD =+85.09 (c =0.463 methanol) Appearance: white powder 107 Example 185 6-chloro-N-cycloheptyl-4-[((lS,2R)-2-{[2-furyl(imino)methy 1]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 3 ClN 6 0 2 / 2 HCl / 2.2 H 2 0) Calculated (%) C: 52.17 H: 6.39 N: 13.52 Found (%) C: 52.17 H: 6.15 N: 13.70 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation [a]2D =+109.94 (c =0.573 methanol) Appearance: white powder Example 186 N-isobutyl-4-{[(1S,2R)-2-(1H-isoindol-3-ylamino)cyclohexyl ]amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 4
N
6 0 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 58.94 H: 6.90 N: 14.73 Found (%) C: 59.14 H: 6.88 N: 14.60 Positive ion FAB-MS m/z: 471 [M+H]+ Specific rotation []2 D =+68.82 (c =0.555 methanol) Appearance: white powder Example 187 N-cycloheptyl-4-{[(1S,2R)-2-(1H-isoindol-3-ylamino)cyclohe xyl] amino}-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 3 1
H
3 8
N
6 0 / 2 HCl / 2 H 2 0) 108 Calculated (%) C: 60.09 H: 7.16 N: 13.56 Found (%) C: 59.88 H: 7.13 N: 13.58 Positive ion FAB-MS m/z: 511 [M+H]+ Specific rotation []2 D =+29.96 (c =0.534 methanol) Appearance: pale yellow powder Example 188 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[imino(pyridin-2-yl) methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 4 ClN 7 0 / 2 HCl / 2.2 H 2 0) Calculated (%) C: 53.16 H: 6.44 N: 15.50 Found (%) C: 53.20 H: 6.59 N: 15.32 Positive ion FAB-MS m/z: 520 [M+H]+ Specific rotation []2 D =+93.92 (c =0.477 methanol) Appearance: white powder Example 189 N-n-butyl-4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino} cyclohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 3
N
7 0 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 54.07 H: 6.98 N: 16.98 Found (%) C: 53.87 H: 7.36 N: 16.73 Positive ion FAB-MS m/z: 460 [M+H]+ 109 Specific rotation []2 D =+75.62 (c =0.521 methanol) Appearance: white powder Example 190 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-(3-methoxy-2,2-dimethylpropyl)-6-methylquinazoli n-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 7
N
7 0 2 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 55.55 H: 7.03 N: 16.20 Found (%) C: 55.76 H: 6.77 N: 15.95 Positive ion FAB-MS m/z: 504 [M+H]+ Specific rotation []2 D =+49.33 (c =0.454 methanol) Appearance: white powder [0046] Example 191 N-ethyl-4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cy clohexyl)amino]-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 24
H
29
N
7 0 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 54.24 H: 6.45 N: 18.45 Found (%) C: 54.14 H: 6.49 N: 18.28 Positive ion FAB-MS m/z: 432 [M+H]+ Specific rotation [a] D =+93.78 (c =0.499 methanol) Appearance: white powder 110 Example 192 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-(2-methoxy-1,1-dimethylethyl)-6-methylquinazolin -2-carboxamide trihydrochloride Elemental analysis value (as C 2 7
H
3 5
N
7 0 2 / 3 HCl / 1.4 H 2 0) Calculated (%) C: 51.95 H: 6.59 N: 15.71 Found (%) C: 52.10 H: 6.62 N: 15.42 Positive ion FAB-MS m/z: 490 [M+H]+ Specific rotation []2 D =+88.29 (c =0.564 methanol) Appearance: white powder Example 193 4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(trans-4-methoxycyclohexyl)-6-methylquinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 6
N
6 0 3 / 2 HCl / H 2 0) Calculated (%) C: 56.47 H: 6.77 N: 14.11 Found (%) C: 56.46 H: 6.88 N: 14.11 Positive ion FAB-MS m/z: 505 [M+H]+ Specific rotation []2 D =+78.74 (c =0.508 methanol) Appearance: white powder Example 194 N-(2,2-dimethylpropyl)-4-[((1S,2R)-2-{[imino(1H-pyrrol-2-y 111 1)methyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 26
H
35
N
7 0 / 2 HCl / 0.75 H 2 0) Calculated (%) C: 56.98 H: 7.08 N: 17.89 Found (%) C: 57.19 H: 6.85 N: 17.70 Positive ion FAB-MS m/z: 462 [M+H]+ Specific rotation []2 D =-25.62 (c =0.484 methanol) Appearance: white powder Example 195 6-fluoro-4-[((1S,2R)-2-{[2-furyl(imino)methyl]amino}cycloh exyl)amino]-N-(trans-4-methoxycyclohexyl)quinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 3
FN
6 0 3 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 52.82 H: 6.34 N: 13.69 Found (%) C: 52.94 H: 6.23 N: 13.72 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation []2 D =+36.36 (c =0.495 methanol) Appearance: white powder Example 196 4-[((1S,2R)-2-{[3-furyl(imino)methyl]amino}cyclohexyl)amin o]-N-(trans-4-methoxycyclohexyl)-6-methylquinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 6
N
6 0 3 / 2 HCl / 1.4 H 2 0) 112 Calculated (%) C: 55.79 H: 6.82 N: 13.94 Found (%) C: 55.94 H: 6.73 N: 13.69 Positive ion FAB-MS m/z: 505 [M+H]+ Specific rotation [a] D =+88.09 (c =0.563 methanol) Appearance: white powder Example 197 N-(4,4-difluorocyclohexyl)-4-[((1S,2R)-2-{[2-furyl(imino)m ethyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxa mide dihydrochloride Positive ion FAB-MS m/z: 511 [M+H]+ Specific rotation []2 D =+79.24 (c =0.530 methanol) Appearance: white powder Example 198 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxami de trihydrochloride Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation [H] D =-4.42 (c =0.995 methanol) Appearance: golden yellow powder Example 199 4-[((1S,2R)-2-{[imino(pyridin-3-yl)methyl]amino}cyclohexyl )amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxami 113 de trihydrochloride Elemental analysis value (as C 2 9
H
3 1
N
7 0 2 / 3 HCl / 1.5 H 2 0) Calculated (%) C: 53.92 H: 5.77 N: 15.18 Found (%) C: 53.89 H: 5.80 N: 15.14 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation []2 D =-23.50 (c =0.570 methanol) Appearance: yellow powder Example 200 4-[((1S,2R)-2-{[imino(pyridin-4-yl)methyl]amino}cyclohexyl )amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxami de trihydrochloride Elemental analysis value (as C 2 9
H
3 1
N
7 0 2 / 3 HCl / 0.3 H 2 0) Calculated (%) C: 55.78 H: 5.59 N: 15.70 Found (%) C: 55.76 H: 5.77 N: 15.74 Positive ion FAB-MS m/z: 509 [M+H]+ Specific rotation []2 D =-9.04 (c =1.105 methanol) Appearance: yellow powder [0047] Example 201 6-chloro-N-cycloheptyl-4-{[(1S,2R)-2-(quinazolin-4-ylamino )cyclohexyl]amino}quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 3 0
H
3 4
N
7 0Cl / 2 HCl / 0.8 H 2 0) Calculated (%) C: 57.07 H: 6.00 N: 15.53 114 Found (%) C: 57.06 H: 5.94 N: 15.32 Positive ion FAB-MS m/z: 544 [M+H]+ Specific rotation []2 D =+7.06 (c =0.764 methanol) Appearance: white powder Example 202 4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cyclohexyl)amino ]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
34
N
6 0 / 2 HCl / 2.2 H 2 0) Calculated (%) C: 56.78 H: 7.13 N: 14.71 Found (%) C: 56.71 H: 6.82 N: 14.62 Positive ion FAB-MS m/z: 459 [M+H]+ Specific rotation []2 D =+72.00 (c =0.500 methanol) Appearance: white powder Example 203 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[(3-fluorophenyl) (im ino)methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 9
H
3 4
N
6 OClF / 2 HCl / 2.5 H 2 0) Calculated (%) C: 53.18 H: 6.31 N: 12.83 Found (%) C: 53.40 H: 6.14 N: 12.70 Positive ion FAB-MS m/z: 537 [M+H]+ Specific rotation []2 D =+82.28 (c =0.559 methanol) 115 Appearance: white powder Example 204 4-[((lS,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-N-(2-isopropoxyethyl)-6-methylquinazolin-2-carboxa mide dihydrochloride Positive ion FAB-MS m/z: 490 [M+H]+ Specific rotation [a]2D =+107.86 (c =0.534 methanol) Appearance: white powder Example 205 4-[((1S,2R)-2-{[imino(pyridin-2-yl)methyl]amino}cyclohexyl )amino]-6-methyl-N-[2-(methylthio)ethyl]quinazolin-2-carbo xamide dihydrochloride Positive ion FAB-MS m/z: 478 [M+H]+ Specific rotation [a] D =+74.85 (c =0.521 methanol) Appearance: white powder Example 206 4-[((1S,2R)-2-{[imino(4-methoxyphenyl)methyl]amino}cyclohe xyl)amino]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 6
N
6 0 2 / 2 HCl / H 2 0) Calculated (%) C: 58.03 H: 6.96 N: 14.50 Found (%) C: 58.05 H: 6.91 N: 14.59 116 Positive ion FAB-MS m/z: 489 [M+H]* Specific rotation []2 D =+55.88 (c =0.476 methanol) Appearance: white powder Example 207 4-[((1S,2R)-2-{[imino(phenyl)methyl]amino}cyclohexyl)amino ]-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 4
N
6 0 2 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 54.73 H: 6.97 N: 14.18 Found (%) C: 54.71 H: 6.60 N: 14.21 Positive ion FAB-MS m/z: 475 [M+H]+ Specific rotation []2 D =+73.66 (c =0.505 methanol) Appearance: pale brown powder Example 208 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamid e dihydrochloride Step 1: 4-{[(1S,2R)-2-(cyanoamino)cyclohexyl]amino} N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide In an argon atmosphere, to a solution of 3.30 g of 4-{[(1S,2R)-2-aminocyclohexyl]amino}-N-(2-methoxyethyl)-6 methylquinazolin-2-carboxamide in 80 ml of tetrahydrofuran, 1.54 ml of triethylamine and 978 mg of cyanogen bromide were 117 sequentially added at -20'C, and the mixture was stirred at the same temperature for 0.5 hour. Water was added to the reaction solution, and the mixture was subjected to an extraction with ethyl acetate. The organic layer was washed with water and saturated brine and dried over magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (chloroform : methanol = 50 : 1), whereby 1.96 g of a desired compound was obtained as a pale yellow crystal. Step 2: 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo lin-2-carboxamide To a solution of 1.96 g of 4-{[(1S,2R)-2 (cyanoamino)cyclohexyl]amino}-N-(2-methoxyethyl)-6-methylq uinazolin-2-carboxamide and 8.56 g of methoxyamine hydrochloride in 80 ml of ethanol, 10.86 g of sodium carbonate was added and the mixture was heated at reflux for 1 hour. The reaction solution was added to 400 ml of ice water, and the deposited substance was collected by filtration. After the collected deposited substance was washed with water, it was dried under reduced pressure. The obtained powder was washed with a mixed solution of (chloroform : diisopropyl alcohol = 1 : 1), whereby 1.71 g of a desired compound was obtained as a white powder. Elemental analysis value (as C 2 1
H
3 1
N
7 0 3 ) 118 Calculated (%) C: 58.72 H: 7.27 N: 22.83 Found (%) C: 58.48 H: 7.17 N: 22.76 Positive ion FAB-MS m/z: 430 [M+H]+ Appearance: white powder Step 3: 4-[((1S,2R)-2-{[amino(methoxyimino)methyl] amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo lin-2-carboxamide dihydrochloride 1.71 g of 4-[((1S,2R)-2-{[amino(methoxyimino) methyl]amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methyl quinazolin-2-carboxamide was suspended in 20 ml of ethyl acetate, and 5 ml of a 4 N hydrogen chloride-ethyl acetate solution was added thereto, and the mixture was stirred for 15 minutes. To the reaction solution, 40 ml of diethyl ether was added, and the resulting deposited substance was collected by filtration, washed with diethyl ether and dried under reduced pressure, whereby 2.01 g of a desired compound was obtained as a white powder. Positive ion FAB-MS m/z: 430 [M+H]+ Specific rotation [a] D =+56.80 (c =0.500 methanol) In the same manner as in Example 208, the following compounds of Examples 209 to 247, 249 and 250 were produced. Example 209 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl 119 )amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxami de dihydrochloride Elemental analysis value (as C 2 5
H
3 1
N
7 0 3 / 2 HCl / 0.6 H 2 0) Calculated (%) C: 53.50 H: 6.14 N: 17.48 Found (%) C: 53.81 H: 6.11 N: 17.14 Positive ion FAB-MS m/z: 478 [M+H]+ Specific rotation []2 D =-20.23 (c =0.771 methanol) Appearance: yellow powder Example 210 4-[((1S,2R)-2-{[amino(hydroxyimino)methyl]amino}cyclohexyl )amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carboxami de dihydrochloride Elemental analysis value (as C 2 4
H
2 9
N
7 0 3 / 2 HCl / H 2 0) Calculated (%) C: 51.99 H: 6.00 N: 17.68 Found (%) C: 52.23 H: 6.07 N: 17.55 Positive ion FAB-MS m/z: 464 [M+H]+ Specific rotation [a] D =-34.15 (c =0.650 methanol) Appearance: pale yellow powder [0048] Example 211 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride 120 Elemental analysis value (as C 2 2
H
3 3
N
7 0 2 / 2 HCl / 2.5 H 2 0) Calculated (%) C: 48.44 H: 7.39 N: 17.97 Found (%) C: 48.59 H: 7.05 N: 17.88 Positive ion FAB-MS m/z: 428 [M+H]+ Specific rotation []2 D =+45.71 (c =0.525 methanol) Appearance: white powder Example 212 4-[((1S,2R)-2-{[amino(hydroxyimino)methyl]amino}cyclohexyl )amino]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 414 [M+H]+ Specific rotation []2 D =+33.55 (c =0.590 methanol) Appearance: white powder Example 213 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-6-methyl-N-(n-propyl)quinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 1
H
3 1
N
7 0 2 / 2 HCl / 1.8 H 2 0) Calculated (%) C: 48.61 H: 7.11 N: 18.90 Found (%) C: 48.32 H: 6.71 N: 18.60 Positive ion FAB-MS m/z: 414 [M+H]+ Specific rotation [a] D =+48.84 (c =0.520 methanol) Appearance: white powder 121 Example 214 4-[((lS,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(cyclopropylmethyl)-6-methylquinazolin-2-carboxa mide dihydrochloride Positive ion FAB-MS m/z: 426 [M+H]+ Specific rotation []2 D =+46.72 (c =0.535 methanol) Appearance: white powder Example 215 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-hydroxyethyl)-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 0
H
2 9
N
7 0 3 / 2 HCl / 3 H 2 0) Calculated (%) C: 44.28 H: 6.87 N: 18.07 Found (%) C: 44.59 H: 6.48 N: 18.14 Positive ion FAB-MS m/z: 416 [M+H]+ Specific rotation [a] D =+56.32 (c =0.625 methanol) Appearance: white powder Example 216 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-isopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 1
H
3 1
N
7 0 2 / 2 HCl / 2 H 2 0) 122 Calculated (%) C: 48.28 H: 7.14 N: 18.77 Found (%) C: 48.52 H: 6.79 N: 18.72 Positive ion FAB-MS m/z: 414 [M+H]+ Specific rotation []2 D =+43.61 (c =0.720 methanol) Appearance: white powder Example 217 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-cyclopropyl-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 412 [M+H]+ Specific rotation []2 D =+49.39 (c =0.575 methanol) Appearance: white powder Example 218 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-cyclobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 1
N
7 0 2 / 2 HCl / 1.6 H 2 0) Calculated (%) C: 50.11 H: 6.92 N: 18.59 Found (%) C: 50.19 H: 6.69 N: 18.55 Positive ion FAB-MS m/z: 426 [M+H]+ Specific rotation [a] D =+35.10 (c =0.490 methanol) Appearance: white powder 123 Example 219 4-[((lS,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-6-methyl-N-(2,2,2-trifluoroethyl)quinazolin-2-carb oxamide dihydrochloride Positive ion FAB-MS m/z: 454 [M+H]+ Specific rotation []2 D =+56.92 (c =0.520 methanol) Appearance: white powder Example 220 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-ethyl-N,6-dimethylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 1
H
3 1
N
7 0 2 / 2 HCl / 2.3 H 2 0) Calculated (%) C: 47.78 H: 7.18 N: 18.57 Found (%) C: 47.80 H: 6.74 N: 18.53 Positive ion FAB-MS m/z: 414 [M+H]+ Specific rotation [a] D =+37.14 (c =0.490 methanol) Appearance: white powder [0049] Example 221 4-[((1S,2R)-2-{[imino(1,2-oxazinan-2-yl)methyl]amino}cyclo hexyl)amino]-N-(4-methoxyphenyl)-6-methylquinazolin-2-carb oxamide dihydrochloride Elemental analysis value (as C 2 8
H
3 5
N
7 0 3 / 2 HCl / 0.8 H 2 0) 124 Calculated (%) C: 55.59 H: 6.43 N: 16.21 Found (%) C: 55.89 H: 6.66 N: 15.87 Positive ion FAB-MS m/z: 518 [M+H]+ Specific rotation []2 D =-14.90 (c =0.510 methanol) Appearance: yellow powder Example 222 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[imino(1,2-oxazinan 2-yl)methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 7
H
3 8
N
7 0 2 Cl / 2 HCl / 2.2 H 2 0) Calculated (%) C: 50.62 H: 6.99 N: 15.30 Found (%) C: 50.45 H: 6.59 N: 15.19 Positive ion FAB-MS m/z: 528 [M+H]+ Specific rotation []2 D =+57.73 (c =0.485 methanol) Appearance: white powder Example 223 4-[((1S,2R)-2-{[imino(1,2-oxazinan-2-yl)methyl]amino}cyclo hexyl)amino]-N-isobutyl-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 7
N
7 0 2 / 2 HCl / H 2 0) Calculated (%) C: 53.76 H: 7.40 N: 17.55 Found (%) C: 53.51 H: 7.20 N: 17.26 Positive ion FAB-MS m/z: 468 [M+H]+ 125 Specific rotation []2 D =+56.76 (c =0.532 methanol) Appearance: white powder Example 224 N-cycloheptyl-4-[((1S,2R)-2-{[imino(1,2-oxazinan-2-yl)meth yl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 8
H
4 1
N
7 0 2 / 2 HCl / 1.5 H 2 0) Calculated (%) C: 55.35 H: 7.63 N: 16.14 Found (%) C: 55.67 H: 7.73 N: 15.92 Positive ion FAB-MS m/z: 508 [M+H]+ Specific rotation []2 D =+52.47 (c =0.404 methanol) Appearance: white powder Example 225 6-chloro-N-cycloheptyl-4-[((1S,2R)-2-{[imino(isoxazolidin 2-yl)methyl]amino}cyclohexyl)amino]quinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 6
H
3 6
N
7 0 2 Cl / 2 HCl / 2.5 H 2 0) Calculated (%) C: 49.41 H: 6.86 N: 15.51 Found (%) C: 49.18 H: 6.86 N: 15.41 Positive ion FAB-MS m/z: 514 [M+H]+ Specific rotation []2 D =+76.82 (c =0.492 methanol) Appearance: white powder 126 Example 226 4-[((lS,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-6-chloro-N-cycloheptylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 4
N
7 0 2 Cl / 2 HCl / H 2 0) Calculated (%) C: 49.79 H: 6.62 N: 16.93 Found (%) C: 49.66 H: 6.54 N: 17.12 Positive ion FAB-MS m/z: 488 [M+H]* Specific rotation []2 D =+54.20 (c =0.424 methanol) Appearance: white powder Example 227 6-chloro-N-cycloheptyl-4-{[(1S,2R)-2-({imino[methoxy(methy 1)amino]methyl}amino)cyclohexyl]amino}quinazolin-2-carboxa mide dihydrochloride Elemental analysis value (as C 2 5
H
3 6
N
7 0 2 Cl / 2 HCl / 2.5 H 2 0) Calculated (%) C: 48.43 H: 6.99 N: 15.81 Found (%) C: 48.28 H: 6.60 N: 15.97 Positive ion FAB-MS m/z: 502 [M+H]+ Specific rotation []2 D =+78.83 (c =0.515 methanol) Appearance: white powder Example 228 N-(2,2-dimethylpropyl)-4-[((1S,2R)-2-{[imino(isoxazolidin 2-yl)methyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-c 127 arboxamide dihydrochloride Positive ion FAB-MS m/z: 468 [M+H]+ Specific rotation []2 D =+50.28 (c =0.533 methanol) Appearance: white powder Example 229 4-[((1S,2R)-2-{[imino(isoxazolidin-2-yl)methyl]amino}cyclo hexyl)amino]-6-methyl-N-[3-(methylthio)propyl]quinazolin-2 -carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 5
N
7 0 2 S / 2 HCl / H 2 0) Calculated (%) C: 49.99 H: 6.82 N: 17.00 Found (%) C: 50.05 H: 6.72 N: 16.87 Positive ion FAB-MS m/z: 486 [M+H]+ Specific rotation []2 D =+56.42 (c =0.514 methanol) Appearance: white powder Example 230 4-[((1S,2R)-2-{[imino(isoxazolidin-2-yl)methyl]amino}cyclo hexyl)amino]-N-(3-methoxy-2,2-dimethylpropyl)-6-methylquin azolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 9
N
7 0 3 / 2 HCl / H 2 0) Calculated (%) C: 53.06 H: 7.36 N: 16.66 Found (%) C: 53.44 H: 7.13 N: 16.52 Positive ion FAB-MS m/z: 498 [M+H]+ Specific rotation [a] D =+48.19 (c =0.527 methanol) 128 Appearance: pale yellow powder [00501 Example 231 4-[((lS,2R)-2-{[imino(isoxazolidin-2-yl)methyl]amino}cyclo hexyl)amino]-6-methyl-N-(tetrahydro-2H-pyran-4-yl)quinazol in-2-carboxamide dihydrochloride Elemental analysis value (as C 2 5
H
3 5
N
7 0 3 / 2 HCl / 2.4 H 2 0) Calculated (%) C: 50.23 H: 7.05 N: 16.40 Found (%) C: 50.29 H: 6.88 N: 16.39 Positive ion FAB-MS m/z: 482 [M+H]+ Specific rotation []2 D =+62.18 (c =0.550 methanol) Appearance: white powder Example 232 4-[((1S,2R)-2-{[imino(isoxazolidin-2-yl)methyl]amino}cyclo hexyl)amino]-N-(trans-4-methoxycyclohexyl)-6-methylquinazo lin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 7
H
3 9
N
7 0 3 / 2 HCl / 2 H 2 0) Calculated (%) C: 52.42 H: 7.33 N: 15.85 Found (%) C: 52.13 H: 7.19 N: 15.69 Positive ion FAB-MS m/z: 510 [M+H]+ Specific rotation []2 D =+61.67 (c =0.548 methanol) Appearance: white powder 129 Example 233 N-(2-ethylbutyl)-4-[((lS,2R)-2-{[imino(isoxazolidin-2-yl)m ethyl]amino}cyclohexyl)amino]-6-methylquinazolin-2-carboxa mide dihydrochloride Elemental analysis value (as C 2 6
H
3 9
N
7 0 2 / 2 HCl / H 2 0) Calculated (%) C: 54.54 H: 7.57 N: 17.12 Found (%) C: 54.49 H: 7.38 N: 16.91 Positive ion FAB-MS m/z: 482 [M+H]* Specific rotation []2 D =+52.57 (c =0.563 methanol) Appearance: white powder Example 234 N-(2,2-dimethylpropyl)-4-{[(1S,2R)-2-({imino[methoxy(methy 1)amino]methyl}amino)cyclohexyl]amino}-6-methylquinazolin 2-carboxamide dihydrochloride Elemental analysis value (as C 2 4
H
3 7
N
7 0 2 / 2 HCl / 0.5 H 2 0) Calculated (%) C: 53.63 H: 7.50 N: 18.24 Found (%) C: 53.63 H: 7.56 N: 17.89 Positive ion FAB-MS m/z: 456 [M+H]+ Specific rotation []2 D =+64.07 (c =0.518 methanol) Appearance: white powder Example 235 4-[((1S,2R)-2-{[imino(isoxazolidin-2-yl)methyl]amino}cyclo hexyl)amino]-N-isobutyl-6-methylquinazolin-2-carboxamide 130 dihydrochloride Elemental analysis value (as C 2 4
H
3 5
N
7 0 2 / 2 HCl / 1.2 H 2 0) Calculated (%) C: 52.59 H: 7.25 N: 17.89 Found (%) C: 52.55 H: 7.13 N: 17.59 Positive ion FAB-MS m/z: 454 [M+H]+ Specific rotation []2 D =+59.96 (c =0.507 methanol) Appearance: white powder Example 236 4-{[(1S,2R)-2-({imino[methoxy(methyl)amino]methyl}amino)cy clohexyl]amino}-N-isobutyl-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 3
H
3 5
N
7 0 2 / 2 HCl / 0.7 H 2 0) Calculated (%) C: 52.41 H: 7.34 N: 18.60 Found (%) C: 52.44 H: 7.22 N: 18.26 Positive ion FAB-MS m/z: 442 [M+H]+ Specific rotation []2 D =+73.00 (c =0.526 methanol) Appearance: white powder Example 237 4-{[(1S,2R)-2-({imino[methoxy(methyl)amino]methyl}amino)cy clohexyl]amino}-N-(trans-4-methoxycyclohexyl)-6-methylquin azolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 6
H
3 9
N
7 0 3 / 2 HCl / H 2 0) Calculated (%) C: 53.06 H: 7.36 N: 16.66 131 Found (%) C: 53.34 H: 7.17 N: 16.40 Positive ion FAB-MS m/z: 498 [M+H]+ Specific rotation []2 D =+70.16 (c =0.496 methanol) Appearance: white powder Example 238 4-{[(1S,2R)-2-({imino[methoxy(methyl)amino]methyl}amino)cy clohexyl]amino}-N-(3-methoxypropyl)-6-methylquinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 5
N
7 0 3 / 2 HCl / 2 H 2 0) Calculated (%) C: 48.76 H: 7.29 N: 17.31 Found (%) C: 48.38 H: 6.89 N: 17.14 Positive ion FAB-MS m/z: 458 [M+H]+ Specific rotation []2 D =+66.80 (c =0.500 methanol) Appearance: white powder Example 239 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxami de dihydrochloride Elemental analysis value (as C 2 2
H
3 3
N
7 0 3 / 2 HCl / 2.2 H 2 0) Calculated (%) C: 47.36 H: 7.15 N: 17.57 Found (%) C: 47.19 H: 6.76 N: 17.50 Positive ion FAB-MS m/z: 444 [M+H]+ Specific rotation []2 D =+47.45 (c =0.510 methanol) 132 Appearance: white powder Example 240 4-[((lS,2R)-2-{[amino(hydroxyimino)methyl]amino}cyclohexyl )amino]-N-(3-methoxypropyl)-6-methylquinazolin-2-carboxami de dihydrochloride Positive ion FAB-MS m/z: 430 [M+H]+ Specific rotation []2 D =+31.28 (c =0.505 methanol) Appearance: white powder [0051] Example 241 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-ethoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 3
N
7 0 3 / 2 HCl / 2 H 2 0) Calculated (%) C: 47.83 H: 7.11 N: 17.75 Found (%) C: 47.59 H: 6.94 N: 17.72 Positive ion FAB-MS m/z: 444 [M+H]+ Specific rotation [a] D =+57.20 (c =0.500 methanol) Appearance: white powder Example 242 4-[((1R,2S)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamid 133 e dihydrochloride Positive ion FAB-MS m/z: 430 [M+H]+ Specific rotation []2 D =-53.09 (c =0.550 methanol) Appearance: white powder Example 243 4-[((1S,2R)-2-{[amino(ethoxyimino)methyl]amino}cyclohexyl) amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 444 [M+H]+ Specific rotation []2 D =+55.04 (c =0.505 methanol) Appearance: white powder Example 244 4-[((1S,2R)-2-{[amino(propoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamid e dihydrochloride Elemental analysis value (as C 2 3
H
3 5
N
7 0 3 / 2 HCl / 3.3 H 2 0) Calculated (%) C: 49.23 H: 7.26 N: 17.47 Found (%) C: 48.97 H: 6.88 N: 17.48 Positive ion FAB-MS m/z: 458 [M+H]+ Specific rotation [a] D =+50.29 (c =0.505 methanol) Appearance: white powder Example 245 134 4-{[(1S,2R)-2-({amino[(2-methoxyethoxy)imino]methyl}amino) cyclohexyl]amino}-N-(2-methoxyethyl)-6-methylquinazolin-2 carboxamide dihydrochloride Elemental analysis value (as C 2 3
H
3 5
N
7 0 4 / 2 HCl / 2.4 H 2 0) Calculated (%) C: 46.84 H: 7.14 N: 16.63 Found (%) C: 46.82 H: 6.82 N: 16.50 Positive ion FAB-MS m/z: 474 [M+H]+ Specific rotation []2 D =+48.40 (c =0.500 methanol) Appearance: white powder Example 246 4-{[(1S,2R)-2-({amino[(2-fluoroethoxy)imino]methyl}amino)c yclohexyl]amino}-N-(2-methoxyethyl)-6-methylquinazolin-2-c arboxamide dihydrochloride Elemental analysis value (as C 2 2
H
3 2
N
7 0 3 F / 2 HCl / 2 H 2 0) Calculated (%) C: 46.32 H: 6.71 N: 17.19 Found (%) C: 46.32 H: 6.36 N: 17.09 Positive ion FAB-MS m/z: 462 [M+H]+ Specific rotation []2 D =+47.76 (c =0.515 methanol) Appearance: white powder Example 247 4-({(1S,2R)-2-[(amino{[2-(methylthio)ethoxy]imino}methyl)a mino]cyclohexyl}amino)-N-(2-methoxyethyl)-6-methylquinazol in-2-carboxamide dihydrochloride 135 Elemental analysis value (as C 2 3
H
3 5
N
7 0 3 S / 2 HCl / 2 H 2 0) Calculated (%) C: 46.15 H: 6.90 N: 16.38 Found (%) C: 46.05 H: 6.73 N: 16.26 Positive ion FAB-MS m/z: 490 [M+H]+ Specific rotation [a]2 D =+39.19 (c =0.500 methanol) Appearance: white powder Example 248 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamid e 1/2 sulfate 300 mg of 4-[((1S,2R)-2-{[amino(methoxyimino) methyl]amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methyl quinazolin-2-carboxamide was suspended in 9 ml of methanol, and 35.4 mg of concentrated sulfuric acid was added thereto. After the mixture was stirred for 15 minutes, 75 ml of diisopropyl ether was added thereto. The deposited substance was collected by filtration, washed with diisopropyl ether and dried under reduced pressure, whereby 314 mg of a desired compound was obtained as a white powder. Elemental analysis value (as C 2 1
H
3 1
N
7 0 3 / 0.5 H 2
SO
4 / 1.5 H 2 0) Calculated (%) C: 49.89 H: 6.98 N: 19.39 Found (%) C: 49.78 H: 6.61 N: 19.18 Positive ion FAB-MS m/z: 430 [M+H]+ Specific rotation []2 OD =-27.63 (c =0.550 methanol) 136 Example 249 4-[((lS,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-6-methylquinazolin-2-carboxamide dihydrochloride Positive ion FAB-MS m/z: 372 [M+H]* Specific rotation []2 D =+57.20 (c =0.465 methanol) Appearance: white powder Example 250 4-[((1S,2R)-2-{[amino(methoxyimino)methyl]amino}cyclohexyl )amino]-N-methoxy-6-methylquinazolin-2-carboxamide dihydrochloride Elemental analysis value (as C 1 9
H
2 7
N
7 0 3 / 2 HCl / 0.8 H 2 0) Calculated (%) C: 46.69 H: 6.31 N: 20.06 Found (%) C: 46.95 H: 6.27 N: 19.87 Positive ion FAB-MS m/z: 402 [M+H]+ Specific rotation [a] D =+8.80 (c =0.500 methanol) Appearance: white powder [0052] Test example 1: Test for skin sensitization in guinea pigs (adjuvant and patch test method) The dorsal area of male Hartley guinea pigs (n = 5) at the age of 7 weeks was shaved with an electric shaver, and on the following day, primary sensitization was initiated. In 137 the primary sensitization, emulsified complete Freund's adjuvant was intradermally administered at a dose of 0.1 ml only at the initial time, and an adhesive plaster for a patch test spread with 0. 1 g of an ointment containing a test compound at 1%, was applied in an occluded state to the site where the adjuvant was intradermally administered. As a base of the ointment, petrolatum containing sorbitan sesquioleate (a surfactant) at 1% was used. At 24 hours after the adhesive plaster for a patch test was applied, the adhesive plaster was removed, and the application site was cleaned by wiping. The procedure of this primary sensitization was performed once daily and continued for a total of 3 days. On 7 days after the initial application of the primary sensitization, secondary sensitization was performed. The site subjected to the primary sensitization was shaved, and an ointment containing sodium lauryl sulfate at 10% was applied thereto in an open state. After 24 hours, the application site was cleaned by wiping, and a lint cloth spread with 0.2 g of the ointment containing a test compound at 1% was applied, thereto in an occluded state. At 48 hours after the lint cloth was applied, the cloth was removed, and the application site was cleaned by wiping. Challenge was performed on 13 days after initiation of the secondary sensitization. The dorsal area and flank area were shaved, and 0.01 g of the ointment containing a test compound at 1% was applied to the challenge 138 site and left for about 24 hours. At about 24 hours and 48 hours after the challenge, observation of the skin surface was performed, and the presence or absence of sensitizing was determined. The determination was carried out by scoring according to the evaluation criteria (see Table 1) of the Draize method (1959). In this connection, as a positive control, 1-chloro 2,4-dinitrobenzene (DNCB) (sensitization: 1%, challenge: 0.1%) was used. As the test compound, the compounds of Example 58 and Example 248 were used. As a comparative control, 4-[((1S,2R)-2-{[amino(imino)methyl]amino} cyclohexyl)amino]-N-isobutyl-6-methylquinazoline-2-carboxa mide dihydrochloride described in Example 383 in Patent document 1 (sensitization: 0.1%, induction: 1%) was used. [00531 [Table 1] Erythema Edema 0 No erythema 0 No edema 1 Very slight erythema (barely perceptible) 1 Very slight edema (barely perceptible) 2 Well-defined erythema 2 Slight edema (edges of area well defined by definite raising) 3 Moderate to severe erythema 3 Moderate edema (raised approximately 1 mm) 4 Severe erythema to slight eschar 4 Severe edema (raised 1 mm or more and formation (injuries in depth) extending beyond the area of exposure) [0054] As a result, sensitizing was not observed in the test compounds. However, in the positive control of DNCB, severe erythema (score 3 in 3/5 cases, score 2 in 1/5 cases, and score 139 1 in 1/5 cases) and slight edema (score 1 in 3/5 cases, and score 0 in 2/5 cases) were observed. Further, in the comparative control compound, edema was not observed in all the cases, while well-defined erythema (score 2) was observed in 2/5 cases. Accordingly, it is evident that the inventive compounds which do not show sensitizing are very useful not only for external preparations but also for medicaments of other dosage forms. [00551 Test example 2: Test for primary skin irritation in rabbits The dorsal area of female Kbs: JW rabbits (n = 3 to 32) at the age of 20 weeks was shaved with an electric shaver, and on the following day, an adhesive plaster for a patch test spread with 0.1 g of an ointment containing a test compound was applied (administered) to the dorsal skin. As a base of the ointment, petrolatum containing sorbitan sesquioleate (a surfactant) at 5% was used. At 24 hours after administration, the adhesive plaster for a patch test was removed, and the application site was cleaned by wiping. Then, erythema and edema formation at the application site was observed. The determination of irritation was carried out by scoring according to the evaluation criteria (Table 1) of the Draize method (1959) used in Test example 1. The mean value of the sum of erythema and edema scores was used as a simple primary 140 skin irritation index. As comparative control compounds, the following compounds which are structurally similar to the inventive compound were used: 4-[((1S,2R)-2-{[amino(imino) methyl]amino}cyclohexyl)amino]-N-isobutyl-6-methylquinazol ine-2-carboxamide dihydrochloride (hereinafter referred to as Comparative control A) described in Example 383 in Patent document 1; 4-[((1S,2R)-2-{[amino (imino)methyl]amino}cyclohexyl)amino]-6-methyl-N-neopentyl quinazoline-2-carboxamide dihydrochloride (hereinafter referred to as Comparative control B) described in Example 29 in Patent document 1; 4-[((1S,2R) 2-{[amino(imino)methyl]amino}cyclohexyl)amino]-N-(2-ethoxy ethyl)-6-methylquinazoline-2-carboxamide dihydrochloride (hereinafter referred to as Comparative control C) described in Example 372 in Patent document 1; 4-[((1S,2R)-2-{[amino(imino)methyl]amino}cyclohexyl)amino] -N-(3-methoxypropyl)-6-methylquinazoline-2-carboxamide dihydrochloride (hereinafter referred to as Comparative control D) described in Example 346 in Patent document 1; 4-[((1S,2R)-2-{[amino(imino)methyl]amino} cyclohexyl)amino]-N-isopropyl-6-methylquinazoline-2-carbox amide dihydrochloride (hereinafter referred to as Comparative control E) described in Example 388 in Patent document 1; and 4-[((1S,2R)-2-{[amino(imino)methyl] 141 amino}cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazo line-2-carboxamide dihydrochloride (hereinafter referred to as Comparative control F) described in Example 48 in Patent document 1. To be more specific, the compound of Comparative control A is different from the compounds of Examples 211, 212, 236 and 60 according to the present invention only in the substituent at the 4-position; the compound of Comparative control B is different from the compound of Example 19 according to the present invention only in the substituent at the 4-position; the compound of Comparative control C is different from the compounds of Examples 94, 95 and 61 according to the present invention only in the substituent at the 4-position; the compound of Comparative control D is different from the compounds of Examples 239, 240, 92, 59, 35 and 93 according to the present invention only in the substituent at the 4-position; the compound of Comparative control E is different from the compounds of Examples 101 and 58 according to the present invention only in the substituent at the 4-position; the compound of Comparative control F is different from the compounds of Examples 208, 1 and 91 according to the present invention only in the substituent at the 4-position; and all other moieties have the same structures. The results are shown in Table 2. 142 [ 0 0 5 6 ] [Table 2] comparatie cntrIncompound Concentration (%) Simple primary skin irritation index Comparative control A 3.0 1.8 Example 211 3.0 1.5 Example 212 3.0 0.8 Example 236 3.0 1.6 Example 60 3.0 1.0 Comparative control B 3.0 2.4 Example 19 3.0 0.4 Comparative control C 3.0 2.3 Example 94 3.0 1.0 Example 95 3.0 0.7 Example 61 3.0 0.4 Comparative control D 3.0 2.0 Example 239 3.0 1.0 Example 240 3.0 1.0 Example 92 3.0 0.0 Example 59 3.0 0.2 Example 35 3.0 1.5 Example 93 3.0 0.2 Comparative control E 3.0 3.6 Example 101 3.0 2.6 Example 58 3.0 0.4 Comparative control F 3.0 2.2 Example 208 3.0 0.2 Example 248 3.0 0.8 Example 1 3.0 0.3 Example 91 3.0 0.5 As shown in Table 2, substitution of the guanidino group in the side chain at the 4-position of a quinazoline derivative with such substituents as those in the inventive compounds markedly reduced the primary skin irritation. Accordingly, it is evident that the inventive compounds are extremely useful as an external preparation with less skin irritation. [0057] Test example 3: Effect on scratching behavior induced by serotonin application in mice 143 To the cervical and dorsal area of male ICR mice (n = 3 to 6) at the age of 4 to 6 weeks, 100 pl of a solution obtained by dissolving serotonin hydrochloride in ethanol at 0.1% (hereinafter referred to as serotonin) was applied, and the number of scratching behavior at the application site with the hind legs occurring immediately after the application was counted for 15 minutes after administration with a counter. Administration of a test compound was carried out by skin application, intravenous administration or oral administration. In the case of skin application, the test compound that was dissolved in ethanol was applied in an amount of 100 pl concurrently with serotonin. In the case of intravenous administration, the test compound that was dissolved in physiological saline was administered at a dose of 10 ml/kg at 5 minutes prior to the serotonin application. In the case of oral administration, the test compound that was dissolved in distilled water was administered at a dose of 10 ml/kg at 20 minutes prior to the serotonin application. The control group of each administration route was given the respective solvent, and the values of scratching behavior were compared between the control group and the test compound group. The results obtained by skin application of the test compound are shown in Table 3; the results obtained by intravenous administration of the test compound are shown in Table 4; and the results obtained by oral administration of 144 the test compound are shown in Table 5. [00581 [Table 31 Concentration Average number Standard error Average number of Testcomoun N crathin beavir Stndad eror scratching behavior in control group Example 211 0.1 73.0 9.7 134.8 Example 212 0.1 49.8 7.8 180.3 Example 19 0.1 69.2 9.8 164.6 Example 239 0.1 55.8 13.9 134.8 Example 240 0.1 65.3 7.1 111.3 Example 92 0.1 76.3 11.7 138.3 Example 59 0.1 57.8 9.3 131.0 Example 35 0.1 69.0 5.3 168.8 Example 101 0.1 56.8 7.5 137.0 Example 58 0.1 55.5 6.8 131.0 Example 208 0.1 81.0 15.2 211.2 Example 1 0.1 57.8 6.6 101.8 Example 91 0.1 70.5 11.6 166.5 [00591 [Table 41 Average number of Average number of Test compound Dose mg/kg scratching behavior Standard error scratching behavior in control group Example 60 3 64.0 8.5 156.3 Example 208 3 53.8 14.3 158.8 [00601 [Table 51 Average number of Average number of Test compound Dose mg/kg scratching behavior Standard error scratching behavior in control group Example 239 30 88.6 9.6 148.8 Example 240 30 95.2 6.2 229.2 Example 92 30 141.0 12.4 229.2 As shown in Tables 3 to 5, the inventive compounds significantly suppressed scratching behavior at the cervical and dorsal area induced by serotonin application. From these results, it is evident that the use of inventive compounds as an external preparation, a preparation for intravenous 145 administration or a preparation for oral administration are useful for itching caused by various pruritic diseases. [0061] Test Example 4: Effect on spontaneous scratching behavior induced by disruption of the horny layer barrier in mice The cervical and dorsal area of male ICR mice at the age of 5 weeks was shaved under ether anesthesia, and the horny layer barrier was disrupted by applying a solution mixture of acetone and ether in a ratio of 1 : 1 to the shaved site and then applying distilled water twice a day for consecutive days (for 10 days) . Spontaneous scratching behavior at the vicinity of the shaved site induced by disruption of the horny layer barrier was observed before and after the application of a test drug each for 30 minutes using a video system under an unmanned condition and a change (%) in the number of scratching behavior was measured. As the test drug, an ointment containing a test compound was used, and 50 mg in terms of the ointment was applied to the area around the shaved site. In this connection, in a control group, a petrolatum ointment containing sorbitan sesquioleate (a surfactant) used as a base of the ointment in an amount of 1% was used. The results are shown in Table 6. 146 [0062] [Table 61 Test compound Concentration (%) Ratio of change (%) Standard error Control group - 100.9 16.9 Example 60 0.1 55.2 5.7 Example 94 0.1 43.9 10.2 Example 61 0.1 51.7 14.8 Example 239 0.1 47.9 11.3 Example 240 0.1 54.5 11.7 Example 92 1.0 55.9 12.4 Example 35 0.1 60.4 8.0 Example 58 0.1 67.7 15.5 Example 208 0.1 41.6 10.7 As shown in Table 6, the inventive compounds significantly suppressed spontaneous scratching behavior induced by disruption of the horny layer barrier. From these results, it is evident that the use of inventive compounds as an ointment external preparation is also effective in the treatment of itching caused by xeroderma or atopic dermatitis, itching accompanying dialysis and other itching. [00631 Test example 5: Acute toxicity test in mice Male ICR mice at the age of 4 to 6 weeks were used. The inventive compound was intravenously administered at a dose of 10 ml/kg from the tail vein, and then, the behavior thereof was observed for 2 hours. The results are shown in Table 7. 147 [0064] [Table 7] Test compound Concentration (mg/kg) Change in behavior Example 211 10 No obvious change Example 212 10 No obvious change Example 60 5 No obvious change Example 239 10 No obvious change Example 240 10 No obvious change Example 92 10 No obvious change Example 101 10 No obvious change Example 58 10 No obvious change Example 208 20 No obvious change Example 1 10 No obvious change As shown in Table 7, changes in symptoms such as sedation were not observed at all in mice to which the test compound was administered. Accordingly, the toxicity of the inventive compound is extremely low, and the compound can be used safely as a pharmaceutical. [0065] Preparation example 1 100 g of the inventive compound of Example 1, 292 g of D-mannitol, 120 g of corn starch and 28 g of low-substituted hydroxypropyl cellulose are placed in a fluidized bed granulation dryer (STREA; manufactured by PAUREC) and granulated with spraying a certain amount of an aqueous 5% hydroxypropyl cellulose solution. After drying and then milling with a grinding/milling machine (COMIL; manufactured by PAULEC), a certain amount of magnesium stearate is mixed therewith in a mixer (BOHRE container mixer Model MC20; manufactured by KOTOBUKI-GIKEN), and the mixture is molded into 148 tablets with a diameter of 7 mm and a weight of 140 mg per tablet with a rotary tablet compacting machine (CORRECT 12HUK; manufactured by KIKUSUI), whereby a tablet containing 25 mg of the inventive compound is obtained. Preparation example 2 75 g of the inventive compound of Example 1, 180 g of lactose, 75 g of corn starch and 18 g of carmellose calcium are placed in a stirring granulator (vertical granulator model VG-01), and a certain amount of an aqueous 5% hydroxypropylmethyl cellulose solution is added thereto and the mixture is granulated and dried by a fluidized bed granulation dryer (STREA; manufactured by PAUREC) and then milled by a grinding/milling machine (COMIL; manufactured by PAULEC) . 120 mg of the milled material is filled into a No. 3 capsule using a capsule filling machine (capsule filler; SHIONOGI QUALICAPS), whereby a capsule containing 25 mg of the inventive compound is obtained. Preparation example 3 2.5 g of the inventive compound of Example 1 and 4.5 g of sodium chloride are weighed, and 450 ml of water for injection is added thereto and the mixture is stirred and dissolved, and then adjusted to pH 6.5 with 0.1 mol/l hydrochloric acid or 0.1 mol/l sodium hydroxide. Then water 149 for injection is added to make the total volume 500 ml. The solution thus prepared is filtered under pressure through a membrane filter (pore size: 0.22 pm) . Then 5.3 ml of the filtrate is aseptically filled into a sterilized 5 ml brown ampoule, whereby an injection formulation containing 25 mg of the inventive compound is obtained. The procedure from the preparation through the filling is performed in an aseptic manner. Preparation example 4 99.75 g of WITEPSOL H-15 (manufactured by HIRTH) is dissolved at 4500 and 0.25 g of the inventive compound of Example 1 is added thereto and dispersed therein by stirring. The resulting dispersion is infused into a 1 g suppository mold while paying attention to preventing deposition at a high temperature, solidified and taken out from the mold, whereby a suppository containing 25 mg of the inventive compound is obtained. Preparation example 5 0.5 g of the inventive compound of Example 1, 5.2 g of sodium dihydrogen phosphate, 11.9 g of sodium monohydrogen phosphate, 2.5 g of sodium chloride and 0.3 g of benzalkonium chloride are weighed, and 950 ml of purified water is added thereto, and the mixture is stirred and dissolved. Then 150 purified water is added to make the total volume 1000 ml. The solution thus prepared is filtered under pressure through a membrane filter (pore size: 0.2 pm) . Then, 5 ml of the filtrate is filled aseptically to a sterilized 5 ml eye drop bottle, whereby an eye drop (5 ml) containing 0.5 mg/ml of the inventive compound is obtained. The procedure from the preparation through the filling is performed in an aseptic manner. [00661 Preparation example 6 80 g of olive oil, 15 g of cetyl alcohol and 15 g of stearyl alcohol are weighed, and the mixture is stirred and dissolved while heating to 700C on a water bath (oil phase) . Separately, 1 g of the inventive compound of Example 1, 10 g of Polysolvate 80, 5 g of sodium lauryl sulfate, 0.25 g of methyl parahydroxybenzoate, 0.15 g of propyl parahydroxybenzoate and 880 g of purified water are weighed, and the mixture is stirred and dissolved while heating to 70'C on a water bath (aqueous phase) . The oil phase and the aqueous phase are placed in a vacuum emulsifying apparatus and then the mixture is emulsified while stirring at a high speed in a homomixer at 70'C under vacuum. Then, the resulting emulsion is water-cooled to 350C while stirring at a low speed. Then 50 ml of the resulting emulsion is filled into a 50 ml container for lotion, whereby a lotion (50 ml) containing 1.0 mg/ml of the inventive compound is obtained. 151 Preparation example 7 250 g of white petrolatum, 250 g of stearyl alcohol and 40 g of polyoxyethylene hydrogenated castor oil 60 are weighed, and the mixture is stirred and dissolved while heating to 700C on a water bath (oil phase). Separately, 1 g of the inventive compound of Example 1, 120 g of propylene glycol, 0.25 g of methyl parahydroxybenzoate, 0.15 g of propyl parahydroxybenzoate and 340 g of purified water are weighed, and the mixture is stirred and dissolved while heating to 70'C on a water bath (aqueous phase) . The oil phase and the aqueous phase are placed in a vacuum stirring and mixing apparatus and then the mixture is emulsified while stirring at 70'C under vacuum. An ointment obtained by cooling the resulting emulsion and slowly stirring until the emulsion is solidified is filled into a 10 g ointment bottle or a 10 g ointment tube, whereby an ointment containing 1.0 mg/g of the inventive compound is obtained. Preparation example 8 110 g of gelatin, 25 g of polyvinyl alcohol and 10 g of methylcellulose are weighed and mixed to obtain a mixed powder. Then, 13 g of glycerin is added thereto, and the powder is dispersed therein using a small-sized mixer. Then, 100 g of purified water is added thereto, and the mixture is dissolved 152 therein while heating to 600C. Further, 85 g of kaolin is added thereto and dispersed therein at 600C. A dispersion separately obtained by mixing 20 g of glycerin with 5 g of sodium polyacrylate is added thereto, and dissolved and dispersed therein at 600C. Then 15 g of polybutene is added thereto and dispersed therein at 600C. To the dispersion, 0.5 g of the inventive compound of Example 1 is added and dispersed therein at 500C thereby obtaining a paste. Then, the paste is spread over a support (nonwoven fabric) (100 g/700 cm2), and then the coated support is covered with a liner made of a polyethylene film (50 pm) and cut, whereby an adhesive preparation is obtained. The inventive compound is contained in an amount of 1 mg in 7 cm2 of the adhesive preparation. Industrial Applicability [0067] As described above, the inventive compound has an action of strongly suppressing scratching behavior, less skin irritation and no skin sensitization, and hence, it is extremely useful as an external preparation. Further, the inventive compound has an action of suppressing scratching behavior not only by application to the skin, but also by intravenous administration, subcutaneous administration and oral administration, and therefore, it is extremely useful as a medicament in another dosage form. 153 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form or suggestion that the prior art forms part of the common general knowledge. 154
Claims (15)
1. A quinazoline derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: [Chemical 1] R5N R 6 HN R3 R 4N RI R-I I N NR2 0 [1] wherein RI represents hydrogen or alkyl; R2 represents hydrogen, alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl or alkyl, in which the alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl and alkyl may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) halogen, (3) alkoxyalkyl, (4) hydroxy, (5) alkylthio, (6) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, (7) a 5- to 7-membered saturated aliphatic heterocyclic group which may be substituted with acyl and contains one to three nitrogen atoms, and (8) phenyl which may be substituted with halogen or alkoxy; R 3 and R 4 are the same or different and each represents hydrogen, alkyl, alkoxy or halogen; R 5 is combined with R 6 to represent alkylene, or represents hydrogen, hydroxy, alkyl, phenyl or alkoxy, in which the alkylene may be substituted with hydroxy or oxo, and may be condensed with a benzene ring; the alkyl, phenyl and alkoxy represented by R 5 may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R represents (1) alkyl, (2) cycloalkyl, (3) phenyl, (4) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the 04/01/13,gbmvaabwpq,155 - 156 group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in which the alkyl, cycloalkyl, phenyl and aromatic heterocyclic group may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) hydroxy, (3) phenyl, (4) pyridyl, (5) furyl, (6) halogen and (7) N,N-dialkylamino.
2. A quinazoline derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: [Chemical 1] R 5 N R 6 HN R3 N , N 0 [1] wherein RI represents hydrogen or alkyl; R2 represents hydrogen, alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl or alkyl, in which the alkoxy, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl and alkyl may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) halogen, (3) alkoxyalkyl, (4) hydroxy, (5) alkylthio, (6) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, (7) a 5- to 7-membered saturated aliphatic heterocyclic group which may be substituted with acyl and contains one to three nitrogen atoms, and (8) phenyl which may be substituted with halogen or alkoxy; R 3 and R 4 are the same or different and each represents hydrogen, alkyl, alkoxy or halogen; R and R6 represent any of groups of the following (i) and (ii). 04/01/13,gbmvaabwpq,156 - 157 (i) R 5 represents hydrogen, alkyl or phenyl, in which the alkyl and phenyl represented by R 5 may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R represents -N(R 6 ) (R 6); R is combined with R62 to represent -0 (CH 2 )n-, or represents hydrogen or alkyl; R62 represents hydrogen or alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; (ii) R 5 represents hydroxy or alkoxy, in which alkoxy represented by R 5 may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R represents -N(R 6 ) (R 62), in which R 6 1 is combined with R62 to represent O-(CH2)n-, or represents hydrogen or alkyl; R62 represents alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; n represents an integer of 3 to 5;
3. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 5 is combined with R 6 to represent alkylene or is hydrogen, alkyl, phenyl or alkoxy, in which the alkylene may be substituted with hydroxy or oxo, and may be condensed with a benzene ring; and R is (1) alkyl, (2) cycloalkyl, (3) phenyl, or (4) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in which the alkyl, cycloalkyl, phenyl and aromatic heterocyclic group may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) hydroxy, (3) phenyl, (4) pyridyl, (5) furyl, (6) halogen and (7) N,N-dialkylamino.
4. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein 04/01/13,gbmvaabwpq,157 - 158 R 2 is hydrogen, tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl or alkyl, in which the tetrahydropyranyl, phenyl, cycloalkyl, (cycloalkyl)alkyl and alkyl may be substituted with one to three groups selected from the group consisting of (1) alkoxy, (2) halogen, (3) hydroxy, and (4) alkylthio; R 3 and R 4 are the same or different and each is hydrogen, alkyl or halogen; R and R6 represent any of groups of the following (i) and (ii). (i) R 5 is hydrogen; and R 6 is -N(R 6 1 )(R 62 ), in which R 61 is combined with R 62 to form -O-(CH 2 )n-, in which n represents an integer of 3 to 5, or is hydrogen or alkyl; R62 is alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; (ii) R 5 is hydroxy or alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R 6 is -N(R 6 1 )(R 62 ), in which R 61 is combined with R 62 to form -O-(CH 2 )n-, in which n represents an integer of 3 to 5, or is hydrogen or alkyl; R62 is hydrogen or alkoxy which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen;
5. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 2 is (1) hydrogen, (2) alkoxy, (3) tetrahydropyranyl, (4) phenyl which may be substituted with alkoxy, (5) cycloalkyl which may be substituted with one to three groups selected from the group consisting of halogen, alkoxy, alkoxyalkyl and hydroxy, (6) (cycloalkyl)alkyl which may be substituted with one to three groups selected from the group consisting of alkoxyalkyl and hydroxy or (7) alkyl; R 5 is combined with R 6 to represent alkylene or is hydrogen, alkyl, phenyl or hydroxy, in which the alkylene may be substituted with hydroxy or oxo, and may be condensed with a benzene ring; and R represents (1) alkyl which may be substituted with one to three groups selected from the group consisting of alkoxy, hydroxy, N,N-dialkylamino, phenyl, pyridyl and furyl, (2) cycloalkyl, (3) phenyl which may be substituted with one to 04/01/13,gbmvaabwpq,158 - 159 three groups selected from the group consisting of alkoxy, halogen and N,N dialkylamino or (4) a 5- to 10-membered aromatic heterocyclic group containing one to three heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom.
6. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 2, wherein R 2 is (1) hydrogen, (2) tetrahydropyranyl, (3) phenyl which may be substituted with alkoxy, (4) cycloalkyl which may be substituted with alkoxy, (5) (cycloalkyl)alkyl or (6) alkyl which may be substituted with one to three groups selected from the group consisting of halogen, hydroxy, alkoxy and alkylthio; R 3 and R 4 are the same or different and each is hydrogen, alkyl or halogen; R and R6 represent and of groups of the following (i) and (ii). (i) R 5 is (1) hydrogen or (2) alkyl which may be substituted with one to three groups selected from the group consisting of alkoxy, alkylthio and halogen; and R 6 is -N(R 6 1 )(R 62 ), in which R 61 is combined with R 62 to form -O-(CH 2 )n-, in which n is an integer of 3 to 5, or is hydrogen or alkyl; R62 is alkoxy; (ii) R 5 is alkoxy; and R 6 is -N(R 6 1 )(R 62 ), in which R 61 is combined with R 62 to form -O-(CH 2 )n-, in which n is an integer of 3 to 5, or is hydrogen or alkyl; R62 is hydrogen or alkoxy.
7. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 1, which is selected from the group consisting of the following (1) to (15) compounds: (1) 4-{ [(1 S,2R)-2-(ethanimidoylamino)cyclohexyl] amino } -N-(2 methoxyethyl)-6-methylquinazolin-2-carboxamide, (2) N-(2,2-dimethylpropyl)-4-({ (IS,2R)-2-[(2- methoxy-2 methylpropanimidoyl)amino] cyclohexyl} amino)-6-methylquinazolin-2 carboxamide, 04/01/13,gbmvaabwpq,159 - 160 (3) 4-({(iS,2R)-2-[(3-methoxypropanimidoyl)amino] cyclohexyl}amino)-N (3-methoxypropyl)-6-methylquinazolin-2-carboxamide, (4) 4-({(iS,2R)-2-[(3-hydroxypropanimidoyl)amino] cyclohexyl}amino)-N isopropyl-6-methylquinazolin-2-carboxamide, (5) 4-({(iS,2R)-2-[(3-hydroxypropanimidoyl)amino] cyclohexyl}amino)-N (3-methoxypropyl)-6-methylquinazolin-2-carboxamide, (6) 4-({(iS,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cyclohexyl} amino)-N-isobutyl-6-methylquinazolin-2-carboxamide, (7) N-(2-ethoxyethyl)-4-({ (IS,2R)-2- [(3 -hydroxypropanimidoyl)amino] cyclohexyl} amino)-6-methylquinazolin-2-carboxamide, (8) 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cyclohexyl} amino)-N-isopropyl-6-methylquinazolin-2-carboxamide, (9) 4-({(1S,2R)-2-[(2-hydroxy-2-methylpropanimidoyl)amino]cyclohexyl} amino)-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide, (10) 4-({ (1S,2R)-2-[(2-methoxyethanimidoyl)amino] cyclohexyl}amino)-N (2-methoxyethyl)-6-methylquinazolin-2-carboxamide, (11) 4-{ [(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino } -N-(3 methoxypropyl)-6-methylquinazolin-2-carboxamide, (12) 4-({ (1S,2R)-2-[(2-methoxyethanimidoyl)amino] cyclohexyl}amino)-N (3-methoxypropyl)-6-methylquinazolin-2-carboxamide, (13) 4-{ [(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino } -N-(2 ethoxyethyl)-6-methylquinazolin-2-carboxamide, (14) N-(2-ethoxyethyl)-4-({ (1S,2R)-2- [(2-methoxyethanimidoyl)amino] cyclohexyl}amino)-6-methylquinazolin-2-carboxamide, and (15) 4-{ [(1S,2R)-2-(ethanimidoylamino)cyclohexyl] amino } -N-isopropyl-6 methylquinazolin-2-carboxamide.
8. The quinazoline derivative or a pharmaceutically acceptable salt thereof according to claim 2, which is selected from the group consisting of the following (1) to (14) compounds: (1) 4-[((1 S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide, 04/01/13,gbmvaabwpq,160 - 161 (2) 4-[((1 S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-isobutyl-6-methylquinazolin-2-carboxamide, (3) 4-[((iS,2R)-2-{[amino(hydroxyimino)methyl] amino } cyclohexyl)amino] N-isobutyl-6-methylquinazolin-2-carboxamide, (4) 4-[((1 S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-(cyclopropylmethyl)-6-methylquinazolin-2 carboxamide, (5) 4-[((1 S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-isopropyl-6-methylquinazolin-2-carboxamide, (6) 4-{ [(1S,2R)-2-({ imino [methoxy(methyl)amino] methyl} amino)cyclohexyl] amino } -N-isobutyl-6-methylquinazolin-2-carboxamide, (7) 4-[((1S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino)-N-(3 -methoxypropyl)-6-methylquinazolin-2 carboxamide, (8) 4-[((1S,2R)-2-{[amino(hydroxyimino)methyl] amino } cyclohexyl)amino] N-(3-methoxypropyl)-6-methylquinazolin-2-carboxamide, (9) 4-[((1S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-(2-ethoxyethyl)-6-methylquinazolin-2-carboxamide, (10) 4-[((1S,2R)-2-{[amino(ethoxyimino)methyl] amino } cyclohexyl)amino] N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide, (11) 4-{ [(1S,2R)-2-({ amino [(2-methoxyethoxy) imino]methyl} amino)cyclohexyl] amino } -N-(2-methoxyethyl)-6-methylquinazolin-2 carboxamide, (12) 4-{ [(1S,2R)-2-({ amino [(2-fluoroethoxy)imino] methyl} amino)cyclohexyl] amino } -N-(2-methoxyethyl)-6-methylquinazolin-2 carboxamide, (13) 4-({ (IS,2R)-2-[(amino { [2-(methylthio)ethoxy] imino } methyl)amino]cyclohexyl} amino)-N-(2-methoxyethyl)-6-methylquinazolin-2 carboxamide, and (14) 4-[((1S,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino]-N-(2-methoxyethyl)-6-methylquinazolin-2-carboxamide. 04/01/13,gbmvaabwpq,161 - 162 9. 4-[((iS,2R)-2-{ [amino(methoxyimino)methyl] amino } cyclohexyl)amino] N(2-methoxyethyl)-6-methylquinazolin-2-carboxamide 12 sulphate.
10. A pharmaceutical composition comprising the quinazoline derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 as an active ingredient.
11. The pharmaceutical composition according to claim 10, when used to suppress itching.
12. A method for reducing pruritic sensation in a patient by the administration of a quinazoline derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10 to the patient.
13. A method for controlling itching by a patient by the administration of a quinazoline derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10 to the patient.
14. Use of a quinazoline derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in the treatment of itching or to reduce pruritic sensation.
15. Use of a quinazoline derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of pruritic sensation or itching of a patient.
16. A quinazoline derivative or pharmaceutically acceptable salt thereof as defined in claim 1 substantially as hereinbefore described with reference to the Examples. 04/01/13,gbmvaabwpq,162 - 163 17. A quinazoline derivative or pharmaceutically acceptable salt thereof as defined in claim 2 substantially as hereinbefore described with reference to the Examples. 04/01/13,gbmvaabwpq,163
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013200041A AU2013200041B2 (en) | 2005-10-03 | 2013-01-04 | Quinazoline derivative and pharmaceutical |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-290416 | 2005-10-03 | ||
AU2006298073A AU2006298073A1 (en) | 2005-10-03 | 2006-10-03 | Quinazoline derivative and pharmaceutical |
AU2013200041A AU2013200041B2 (en) | 2005-10-03 | 2013-01-04 | Quinazoline derivative and pharmaceutical |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006298073A Division AU2006298073A1 (en) | 2005-10-03 | 2006-10-03 | Quinazoline derivative and pharmaceutical |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013200041A1 true AU2013200041A1 (en) | 2013-01-24 |
AU2013200041B2 AU2013200041B2 (en) | 2016-11-03 |
Family
ID=47560915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013200041A Ceased AU2013200041B2 (en) | 2005-10-03 | 2013-01-04 | Quinazoline derivative and pharmaceutical |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2013200041B2 (en) |
-
2013
- 2013-01-04 AU AU2013200041A patent/AU2013200041B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2013200041B2 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60017898T2 (en) | NOVEL HETEROCYCLIC CARBOXAMIDE DERIVATIVES | |
RU2642777C2 (en) | 2-aminopyrasine derivatives as csf-1r kinase inhibitors | |
CN102548983B (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
JP4513566B2 (en) | Quinazoline derivatives and pharmaceuticals | |
JP2003012653A (en) | Quinazoline derivative | |
AU2016317806A1 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
PL208711B1 (en) | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | |
JP2014015452A (en) | Medicine containing pyrazole derivative | |
EP3696176B1 (en) | Novel phenylpyridine derivative and pharmaceutical composition containing same | |
US8835446B2 (en) | Quinazoline derivatives and pharmaceutical compositions thereof | |
WO2019054430A1 (en) | Amide compound having aromatic heterocycle | |
AU2013200041B2 (en) | Quinazoline derivative and pharmaceutical | |
MXPA06011827A (en) | 2-aminopyridine derivative. | |
EP3778586A1 (en) | Quinazoline compound serving as egfr triple mutation inhibitor and applications thereof | |
KR101916773B1 (en) | Diaminopyrimidine derivatives for kinase inhibitors | |
WO2013051159A1 (en) | Nop receptor antagonist | |
EP3544685B1 (en) | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | |
KR102409595B1 (en) | Novel purinone derivatives as protein kinase CSF-1R inhibitor | |
KR20180122493A (en) | Novel TYRO 3 inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating TYRO 3 relating diseases containing the same as an active ingredient | |
WO2008118092A1 (en) | Maleate salt of 3-bromo-n-{ (2s) -2- (4-f luorophenyl) -4- [3- (4-acetylpiperazin-1-yl) azetidin-1-yl] butyl} -methyl-5- (trifluoromethyl)benzamide for the treatment of gastrointestinal disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 03 OCT 2013 TO 03 JUL 2014 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED . |
|
NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 03 JUL 2014 . |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 03 OCT 2015 TO 03 NOV 2016 IN WHICH TO PAY A CONTINUATION FEE AND GAIN ACCEPTANCE HAS BEEN FILED . |
|
NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE AND GAIN ACCEPTANCE HAS BEEN EXTENDED TO 03 NOV 2016 |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |